<SEC-DOCUMENT>0001279569-18-001166.txt : 20180525
<SEC-HEADER>0001279569-18-001166.hdr.sgml : 20180525
<ACCEPTANCE-DATETIME>20180524190325
ACCESSION NUMBER:		0001279569-18-001166
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20180524
FILED AS OF DATE:		20180525
DATE AS OF CHANGE:		20180524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		18859253

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of May 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F &#9746;; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>



<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following exhibits included herein were filed by the Registrant
with the Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval on the dates noted
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Exhibit 99.1: January 15, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. Exhibit 99.2: January 19, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. Exhibit 99.3: February 5, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Exhibit 99.4: February 27, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0">The Registrant inadvertently did not furnish these documents to the Securities and Exchange Commission. This
report on Form 6-K is furnished solely to correct this oversight and to incorporate by reference Exhibits 99.1, 99.2 and 99.3 into
the Registrant's registration statements on Form&nbsp;F-3 (File No.&nbsp;333-222654) and Form S-8 (File No. 333-225056) that have
been filed with the Securities and Exchange Commission.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBITS INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 89%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">Material Change Report, dated January 15, 2016</A><A HREF="ex991.htm"></A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex992.htm">99.2</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex992.htm">Material Change Report, dated January 19, 2018</A><A HREF="ex992.htm"></A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex993.htm">99.3</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex993.htm">Material Change Report, dated February 5, 2018</A><A HREF="ex993.htm"></A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex994.htm">99.4</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex994.htm">Management Information Circular, dated February 23, 2018</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: May 24, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>MCR DATED JANUARY 15, 2016
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin: 0"><B>FORM 51-102F3</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin: 0"><B><I>MATERIAL CHANGE REPORT</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 1:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name and Address of Company</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70.9pt">ESSA Pharma Inc. (&ldquo;ESSA&rdquo; or the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70.9pt">Suite 720, 999 West Broadway</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70.9pt">Vancouver, British Columbia, Canada V5Z 1K5</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 2:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date of Material Change</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">January 7, 2016.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 3:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;News Release</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 1.55pt 0 70.9pt; text-align: justify">A news release announcing the
material change was issued on January 7, 2016 through Canada NewsWire and a copy was filed on SEDAR on January 7, 2016.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 4:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Material Change</B></P>

<P STYLE="font-size: 12pt; text-align: justify; margin: 0 0 0 13.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 70.9pt; text-align: justify">&nbsp;ESSA announced that Dr. David
Parkinson had been appointed as the company&rsquo;s President &nbsp;and Chief Executive Officer effective immediately, replacing Mr.
Bob Rieder who had &nbsp;announced his departure from the company and resignation from the Board of Directors.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 5:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Full Description of Material Change</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>5.1 &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Full Description of Material Change</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 70.9pt; text-align: justify">&nbsp;ESSA announced that Dr. David
Parkinson had been appointed as the company&rsquo;s President &nbsp;and Chief Executive Officer effective immediately, replacing Mr.
Bob Rieder who had &nbsp;announced his departure from the company and resignation from the Board of Directors. &nbsp;Prior to January 7, 2016,
Dr. Parkinson had been serving as a Director of the Company and he &nbsp;will continue acting in that capacity.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>5.2 &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure for Restructuring Transactions</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 70.9pt">Not applicable.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 6:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reliance on subsection 7.1(2) of National Instrument
51-102</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 70.9pt">Not applicable.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 7: &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Omitted Information</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 70.9pt">Not applicable.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B></B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 8:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Officer</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70.9pt">For further information, please contact David Wood, CFO
of the Company at 778-331-0962.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><B>Item 9:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date of Report</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70.9pt; text-indent: 1in"><BR>
January 15, 2016.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 70; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font-size: 12pt; margin: 0">&nbsp;</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR><TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -58.5pt">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992.htm
<DESCRIPTION>MCR DATED JANUARY 19, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.2</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>FORM 51-102F3</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B><I>MATERIAL CHANGE REPORT</I></B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 1:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name and Address of Company</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">ESSA Pharma Inc. (&ldquo;ESSA&rdquo; or the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">Suite 720, 999 West Broadway</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">Vancouver, British Columbia, Canada V5Z 1K5</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 2:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date of Material Change</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">January 9, 2018 and January 16, 2018</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 3:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;News Release</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">News releases announcing the material
changes referred to in this report were issued on January 9, 2018 and January 16, 2018 through Canada NewsWire and copies have
been filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 4:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Material Change</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">On January 9, 2018 ESSA announced
that it has closed an initial US$20,325,000 brokered equity offering (the &ldquo;<B>Offering</B>&rdquo;) and a concurrent US$675,000
non-brokered private placement (the &ldquo;<B>Concurrent Private Placement</B>&rdquo;) for aggregate gross proceeds of US$21 million.
Pursuant to the Offering, ESSA issued 68,545,000 common shares of the Company (&ldquo;<B>Common Shares</B>&rdquo;) and 33,080,000
pre-funded common share purchase warrants of the Company (&ldquo;<B>Warrants</B>&rdquo;, and together with the Common Shares, the
&ldquo;<B>Securities</B>&rdquo;) each at a price of US$0.20 per Security (the &ldquo;<B>Offering Price</B>&rdquo;).</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Pursuant to the Concurrent Private
Placement, the Company issued 3,375,000 Common Shares at the Offering Price to certain directors of the Company. Bloom Burton Securities
Inc. (the &ldquo;<B>Agent</B>&rdquo;) acted as the Company&rsquo;s sole agent for the Offering in Canada, with H.C. Wainwright
&amp; Co., LLC acting as exclusive U.S. placement agent (the &ldquo;<B>U.S. Agent</B>&rdquo; and, collectively, the &ldquo;<B>Selling
Group</B>&rdquo;).</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">On January 16, 2018 ESSA announced
that it has closed the second tranche of its brokered equity offering, raising an additional US$4 million from a fund managed by
Omega Fund Management, LLC (&ldquo;<B>Omega</B>&rdquo;) as well as the partial exercise by the Agent of its over-allotment option
for additional proceeds of approximately US$1 million, with aggregate gross proceeds increasing from $21 million to $26 million
(collectively, the &ldquo;<B>Second Offering</B>&rdquo;). Pursuant to the Second Offering, 14,500,000 Common Shares were issued,
of which Omega acquired 9,300,000, representing approximately 8% of the issued and outstanding Common Shares, and Omega acquired
10,700,000 Warrants all at the Offering Price.</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 0; text-align: justify"><B>Item 5:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Full Description
of Material Change</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify"><B>5.1 Full Description of Material
Change</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">On January 9, 2018 ESSA announced
that, further to its previously announced offering of equity securities, it has closed an initial US$20,325,000 Offering and a
US$675,000 Concurrent Private Placement for aggregate gross proceeds of US$21 million. On January 16, 2018 ESSA announced that
it has closed the Second Offering of its brokered equity offering, raising an additional US$4 million from a fund managed by Omega
as well as the partial exercise by the Canadian agent of its over-allotment option for additional proceeds of approximately US$1
million, with aggregate gross proceeds increasing from $21 million to $26 million.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Pursuant to the Offering, ESSA
issued 68,545,000 Common Shares and 33,080,000 Warrants each at the Offering Price of US$0.20 per Security for aggregate gross
proceeds of US$20,325,000. Each Warrant entitles the holder thereof to acquire, for a nominal exercise price, one common share
in the capital of the Company (each, a &ldquo;<B>Warrant Share</B>&rdquo;) until 4:30 p.m. (Toronto time) on the date that is 60
months following its date of issuance.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Pursuant to the Concurrent Private
Placement, the Company issued 3,375,000 Common Shares at the Offering Price to certain directors of the Company for additional
aggregate gross proceeds of US$675,000. All securities issued in connection with the Concurrent Private Placement are subject to
a prescribed four month plus one day hold period from the date of issuance, and no finders&rsquo; fee or commission was paid in
respect of the Common Shares issued under the Concurrent Private Placement.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Pursuant to the Second Offering,
14,500,000 Common Shares were issued, of which Omega acquired 9,300,000, representing approximately 8% of the issued and outstanding
Common Shares, and Omega acquired 10,700,000 Warrants. Assuming the exercise in full of the 10,700,000 Warrants and certain common
share purchase warrants held by Omega prior to the Second Offering, Omega would own 22,303,029 Common Shares, representing approximately
17.6% of the issued and outstanding Common Shares, on a partially-diluted basis.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Effective on the closing of
the Second Offering, Hugo Beekman of Omega Fund Management, LLC, was appointed to the board of directors of the Company pursuant
to the terms of a nomination rights agreement between ESSA and Omega. Under the terms of the nomination rights agreement, Omega
is entitled to nominate one director to the board of directors of ESSA, who must meet ESSA&rsquo;s general criteria for directors,
for so long as Omega holds at least 9.99% of the issued and outstanding Common Shares.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">The Securities were issued pursuant
to the terms and conditions of a second amended and restated agency agreement dated January 5, 2018 between the Company and the
Agent as the Company&rsquo;s sole agent for the Offering in Canada, with an exclusive U.S. placement agent being part of the Selling
Group. The U.S. Agent acted as exclusive U.S. placement agent. The Selling Group was: (a) paid a cash commission equal to 7.0%
of the gross proceeds of the Offering (except in respect of Common Shares and Warrants issued in certain circumstances to specified
purchasers, in which case the cash commission was reduced to 3.5%); and (b) issued broker warrants (the &ldquo;<B>Broker Warrants</B>&rdquo;)
representing 5.0% of the aggregate number of Common Shares and Warrants issued and sold under the Offering. No Broker Warrants
were issuable with respect to any Common Shares or Warrants purchased under the Offering in certain circumstances to specified
purchasers. Each Broker Warrant entitles the holder thereof to acquire one common share of the Company (a &ldquo;<B>Broker Warrant
Share</B>&rdquo;) at the Offering Price for a period of 60 months following its date of issuance.</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="width: 34%; font: 8pt Arial, Helvetica, Sans-Serif; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">The Company intends to use the
net proceeds of the Offering, Concurrent Private Placement and Second Offering primarily to advance the preclinical and clinical
development of the Company&rsquo;s next-generation Aniten compounds. The net proceeds will also be used for the interest and principal
payments on the Company&rsquo;s outstanding debt and for working capital and general corporate purposes.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">The Offering and Second Offering
were completed in each of the provinces of British Columbia, Alberta and Ontario by way of a second amended and restated prospectus
supplement dated January 5, 2018 to ESSA&rsquo;s base shelf prospectus dated December 22, 2015 and elsewhere on a private placement
basis.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">The issuance of the Common Shares
under the Concurrent Private Placement constitutes a related-party transaction under Multilateral Instrument 61-101 - <I>Protection
of Minority Security Holders in Special Transactions</I> (&ldquo;<B>MI 61-101</B>&rdquo;). These transactions are exempt from the
formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101
as neither the fair market value of any securities issued to nor the consideration paid by such persons would exceed 25.0% of the
Company&rsquo;s market capitalization.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">The securities described herein
have not been registered under the United States Securities Act of 1933, as amended (the &ldquo;<B>U.S. Securities Act</B>&rdquo;),
or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the
United States or &ldquo;U.S. persons,&rdquo; as such term is defined in Regulation S promulgated under the U.S. Securities Act
(&ldquo;<B>U.S. Persons</B>&rdquo;), except in compliance with the registration requirements of the U.S. Securities Act and applicable
state securities requirements or pursuant to exemptions therefrom. This material change report does not constitute an offer to
sell or a solicitation of an offer to buy any of the Company&rsquo;s securities to, or for the account of benefit of, persons in
the United States or U.S. Persons.</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="width: 34%; font: 8pt Arial, Helvetica, Sans-Serif; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify"><B>5.2 Disclosure of Restructuring
Transactions</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Not applicable.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 6:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reliance on subsection 7.1(2) of National Instrument
51-102</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">Not applicable.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 7:&#9; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Omitted Information</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in">Not applicable.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 8:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Officer</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">For further information, please contact David Wood, Chief
Financial Officer of the Company at 778-331-0962.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Item 9:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date of Report</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 1in"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January 19, 2018</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>This material change
report contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about the intended use of proceeds
of the Offering and the Concurrent Private Placement and the expected closing date of an additional US$4 million worth of Securities
under the Offering.</I></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>Forward-looking statements
and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA
to control or predict, and which may cause ESSA&rsquo;s actual results, performance or achievements to be materially different
from those expressed or implied thereby. Such statements reflect ESSA&rsquo;s current views with respect to future events, are
subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered
reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic,
competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various
material assumptions, including but not limited to (i) the accuracy of ESSA&rsquo;s financial projections; (ii) obtaining positive
results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.
 </I></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="width: 34%; font: 8pt Arial, Helvetica, Sans-Serif; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>Forward-looking information
is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA&rsquo;s Annual Report
on Form 20-F dated December 11, 2017 under the heading &ldquo;Risk Factors&rdquo;, a copy of which is available on ESSA&rsquo;s
profile on the SEDAR website at www.sedar.com, ESSA&rsquo;s profile on EDGAR at www.sec.gov, and as otherwise disclosed from time
to time on ESSA&rsquo;s SEDAR profile. Forward-looking statements are made based on management's beliefs, estimates and opinions
on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates
and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities
laws. Readers are cautioned against attributing undue certainty to forward-looking statements.</I></P>



<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; width: 33%">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0F0F0F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0F0F0F">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993.htm
<DESCRIPTION>MCR DATED FEBRUARY 5, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.3</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>FORM 51-102F3</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B><I>MATERIAL CHANGE REPORT</I></B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 1:</B></TD><TD><B>Name and Address of Company</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">ESSA Pharma Inc. (&ldquo;ESSA&rdquo; or the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-indent: 0">Suite 720, 999 West Broadway</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">Vancouver, British Columbia, Canada V5Z 1K5</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 2:</B></TD><TD><B>Date of Material Change</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-indent: 0">January 25, 2018</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 3:</B></TD><TD><B>News Release</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">A news release announcing the material
change referred to in this report was issued on January 26, 2018 through Canada NewsWire and a copy has been filed on SEDAR at
www.sedar.com and EDGAR at www.sec.gov.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 4:</B></TD><TD><B>Summary of Material Change</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 13.5pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">On January 25, 2018, ESSA announced
that Frank Perabo, M.D., Ph.D., will depart ESSA as the Company&rsquo;s Chief Medical Officer to pursue other opportunities, effective
January 31, 2018. Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA&rsquo;s medical
advisory committee.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 5:</B></TD><TD STYLE="text-align: justify; padding-right: 1.55pt"><B>Full Description of Material Change</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify"><B>5.1 Full Description of Material
Change</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">On January 25, 2018, ESSA announced
that Frank Perabo, M.D., Ph.D., will depart ESSA as the Company&rsquo;s Chief Medical Officer to pursue other opportunities, effective
January 31, 2018. Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA&rsquo;s medical
advisory committee.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">ESSA announced in September 2017, its
intention to cease clinical development of EPI-506 and utilize the results from the successfully completed Phase 1 proof of concept
trial to expand the preclinical development program around more potent next-generation aniten molecules. Within the next-generation
program, the Company expects to file an Investigational New Drug filing and initiate a Phase 1 clinical trial of the selected next-generation
molecule in the first quarter of 2019. ESSA recently announced the completion of an approximately US$26 million financing to fund
preclinical and clinical development within its next-generation Aniten program.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify"><B>5.2 Disclosure of Restructuring
Transactions</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">Not applicable.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 1.55pt 12pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 6:</B></TD><TD><B>Reliance on subsection 7.1(2) of National Instrument 51-102</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">Not applicable.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 7:</B></TD><TD><B>Omitted Information</B></TD></TR>
</TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-indent: 0">Not applicable.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8:</B></TD><TD><B>Executive Officer</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">For further information, please contact David Wood, Chief
Financial Officer of the Company at 778-331-0962.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9:</B></TD><TD><B>Date of Report</B></TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-indent: 0"><BR>
February 5, 2018</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>This material change
report contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about Dr. Perabo&rsquo;s departure
from the Company as Chief Medical Officer and continuing involvement with the Company in an advisory capacity and as a member of
the Company&rsquo;s medical advisory committee, the acceleration of ESSA&rsquo;s next-generation NTD-inhibitor Aniten compounds,
the anticipated timing of the IND filing for the Aniten program and the initiation of the Phase 1 clinical trial for such program,
and the anticipated sufficiency of the Company&rsquo;s financial resources.</I></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>Forward-looking statements
and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA
to control or predict, and which may cause ESSA&rsquo;s actual results, performance or achievements to be materially different
from those expressed or implied thereby. Such statements reflect ESSA&rsquo;s current views with respect to future events, are
subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered
reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic,
competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various
material assumptions, including but not limited to (i) the accuracy of ESSA&rsquo;s financial projections; (ii) obtaining positive
results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.</I></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>Forward-looking information
is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA&rsquo;s Annual Report
on Form 20-F dated December 11, 2017 under the heading &ldquo;Risk Factors&rdquo;, a copy of which is available on ESSA&rsquo;s
profile on the SEDAR website at www.sedar.com, ESSA&rsquo;s profile on EDGAR at www.sec.gov, and as otherwise disclosed from time
to time on ESSA&rsquo;s SEDAR profile. Forward-looking statements are made based on management's beliefs, estimates and opinions
on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates
and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities
laws. Readers are cautioned against attributing undue certainty to forward-looking statements.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0F0F0F">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994.htm
<DESCRIPTION>MANAGEMENT INFORMATION CIRCULAR
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.4</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><IMG SRC="image_logo.jpg" ALT=""></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>ESSA
PHARMA INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">NOTICE OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">ANNUAL GENERAL
AND SPECIAL MEETING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">OF SHAREHOLDERS
OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">ESSA PHARMA INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">TO BE HELD ON
MARCH 28, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>MANAGEMENT
INFORMATION CIRCULAR</B></FONT></P>

<P STYLE="font: 10pt Cambria, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>DATED:
FEBRUARY 23, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>ESSA
PHARMA INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Suite
720, 999 West Broadway</B><BR>
<B>Vancouver, British Columbia</B><BR>
<B>Canada V5Z 1K5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B><U>NOTICE
OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>NOTICE
IS HEREBY GIVEN </B>that the annual general and special meeting (the &ldquo;<B>Meeting</B>&rdquo;) of the shareholders of ESSA
Pharma Inc. (the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>ESSA</B>&rdquo;) will be held at the offices of Blake, Cassels &amp;
Graydon, LLP at Suite 2600, 595 Burrard St., Vancouver, British Columbia, V7X 1L3, on March 28, 2018 at 2:00 p.m. (Vancouver time)
for the following purposes:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to receive
                                         and consider the audited financial statements of the Company for the year ended September
                                         30, 2017 together with the auditor&rsquo;s report thereon;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to set
                                         the number of directors for the ensuing year at eight;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to elect
                                         directors for the ensuing year;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to appoint
                                         an auditor for the ensuing year and authorize the directors to approve the remuneration
                                         to be paid to the auditor;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to consider,
                                         and if thought fit, pass with or without amendment, an ordinary resolution to ratify,
                                         confirm and approve the Company&rsquo;s stock option plan as set out in Schedule A to
                                         the accompanying Management Information Circular (the &ldquo;<B>Circular</B>&rdquo;),
                                         and to reserve common shares from treasury for issuance under the stock option plan,
                                         the full text of which resolution is set out in the accompanying Circular under the heading
                                         &ldquo;<I>Approval of Stock Option Plan</I>&rdquo;;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to consider,
                                         and if thought fit, pass with or without amendment, an ordinary resolution to ratify,
                                         confirm and approve the re-grant and repricing, and the extension of the expiry dates
                                         of certain of the outstanding stock options granted to certain directors, officers, employees
                                         and consultants of the Company, the full text of which resolution is set out in the accompanying
                                         Circular under the heading &ldquo;<I>Approval of Stock Option Re-Grant and Repricing,
                                         and Extension of Expiry Dates</I>&rdquo;;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to consider,
                                         and if thought fit, pass with or without amendment, an ordinary resolution to ratify,
                                         confirm and approve previous grants of stock options exercisable for an aggregate of
                                         up to 14,523,000 common shares of the Company, to certain directors, officers, employees
                                         and consultants of the Company, as previously approved by the board of directors, as
                                         more particularity described under the heading &ldquo;<I>Ratification of Stock Option
                                         Grants</I>&rdquo; in the Circular;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">8.
to consider, and if thought fit, pass with or without amendment, a special resolution to approve the consolidation of the Company&rsquo;s
common shares, the full text of which resolution is set out in the accompanying Circular under the heading &ldquo;<I>Approval
of Common Share Consolidation</I>&rdquo;;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to consider,
                                         and if thought fit, pass with or without amendment, an ordinary resolution to ratify,
                                         confirm and approve the Company&rsquo;s restricted share unit plan, as set out in Schedule
                                         B to the accompanying Circular, and to reserve common shares from treasury for issuance
                                         under the restricted share unit plan, the full text of which resolution is set out in
                                         the accompanying Circular under the heading &ldquo;<I>Approval of RSU Plan</I>&rdquo;;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to transact
                                         such other business as may properly come before the meeting.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The board
of directors has fixed February 21, 2018 as the record date for determining the shareholders entitled to receive notice of and
vote at the Meeting. Shareholders unable to attend the meeting in person are requested to read the enclosed Circular and proxy
(or Voting Instruction Form, a &ldquo;<B>VIF</B>&rdquo;) and complete and deposit the proxy or VIF in accordance with its instructions.
Unregistered shareholders must deliver their complete proxy or VIF in accordance with the instructions given by their financial
institution or other intermediary that forwarded the proxy to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">If you
are unable to attend the meeting in person, you may also listen to a live webcast, which will be available on ESSA&rsquo;s website
at www.essapharma.com commencing at 2:00 p.m. (Vancouver time) on Wednesday, March 28, 2018; however you will not be able to vote
or otherwise participate in the meeting via the webcast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>DATED
</B>at Vancouver, British Columbia this 23rd day of February, 2018.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt 2in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 11pt"><B>ON
BEHALF OF THE BOARD OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">&#9;<U>Signed:
<I>David R. Parkinson&#9;</I></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-size: 11pt">David
R. Parkinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-size: 11pt">President,
Chief Executive Officer and Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>These
securityholder materials are being sent to both registered and non-registered owners of the securities. If you are a non-registered
owner, and the issuer or its agent has sent these materials directly to you, your name and address and information about your
holdings of securities, have been obtained in accordance with applicable securities regulatory requirements from the intermediary
holding on your behalf. By choosing to send these materials to you directly, the Company (and not the intermediary holding on
your behalf) has assumed responsibility for (i) delivering these materials to you, and (ii) executing your proper voting instructions.
Please return your voting instructions as specified in the request for voting instructions.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>ESSA
PHARMA INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Suite
720, 999 West Broadway</B><BR>
<B>Vancouver, British Columbia</B><BR>
<B>Canada V5Z 1K5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>MANAGEMENT
INFORMATION CIRCULAR</B><BR>
as at February 23, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>This
Management Information Circular (the &ldquo;Circular&rdquo;) is furnished in connection with the solicitation of proxies by the
management of ESSA Pharma Inc. for use at the annual general and special meeting (the &ldquo;Meeting&rdquo;) of its shareholders
to be held on March 28, 2018 at the time and place and for the purposes set forth in the accompanying notice of the Meeting. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In this
Circular, references to the &ldquo;<B>Company</B>&rdquo;, &ldquo;<B>ESSA</B>&rdquo;, &ldquo;<B>we</B>&rdquo; and &ldquo;<B>our</B>&rdquo;
refer to ESSA Pharma Inc. &ldquo;<B>Common Shares</B>&rdquo; means common shares without par value in the capital of the Company.
&ldquo;<B>Beneficial Shareholders</B>&rdquo; means shareholders who do not hold Common Shares in their own name and &ldquo;<B>intermediaries</B>&rdquo;
refers to brokers, investment firms, clearing houses and similar entities that own securities on behalf of Beneficial Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">All amounts
are in United States dollars (&ldquo;$&rdquo; or &ldquo;US$&rdquo;), unless otherwise stated. Canadian dollars are presented as
&ldquo;C$&rdquo;, where indicated</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">GENERAL
PROXY INFORMATION</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Solicitation
of Proxies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The solicitation
of proxies will be primarily by mail, but proxies may be solicited personally or by telephone by directors, executive officers
and regular employees of the Company. The Company will bear all costs of this solicitation. We have arranged for intermediaries
to forward the meeting materials to beneficial owners of Common Shares held as of record by those intermediaries and we may reimburse
the intermediaries for their reasonable fees and disbursements in that regard.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Appointment
of Proxyholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The individuals
named in the accompanying form of proxy (the &ldquo;<B>Proxy</B>&rdquo;) are executive officers and/or directors of the Company<B>.
If you are a shareholder entitled to vote at the Meeting, you have the right to appoint a person or company other than either
of the persons designated in the Proxy, who need not be a shareholder, to attend and act for you on your behalf at the Meeting.
You may do so either by inserting the name of that other person in the blank space provided in the Proxy or by completing and
delivering another suitable form of proxy.</B></FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Voting
by Proxyholder</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The persons
named in the Proxy will vote or withhold from voting the Common Shares represented thereby in accordance with your instructions
on any ballot that may be called for. If you specify a choice with respect to any matter to be acted upon, your Common Shares
will be voted accordingly. The Proxy confers discretionary authority on persons named therein with respect to:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">each
                                         matter or group of matters identified therein for which a choice is not specified, other
                                         than the appointment of an auditor and the election of directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">any
amendment to or variation of any matter identified therein; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"></FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;any
other matter that properly comes before the Meeting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>In
respect of a matter for which a choice is not specified in the Proxy, the management appointee acting as a proxyholder will vote
in favour of each matter identified on the Proxy and, if applicable, for the nominees of management for directors and auditors
as identified in the Proxy.</B></FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Registered
Shareholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Registered
shareholders may wish to vote by proxy whether or not they are able to attend the Meeting in person. Registered shareholders electing
to submit a proxy may do so by:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">completing,
                                         dating and signing the enclosed form of proxy and returning it to the Company&rsquo;s
                                         transfer agent, Computershare Investor Services Inc. (&ldquo;<B>Computershare</B>&rdquo;),
                                         by fax within North America at 1-866-249-7775, outside North America at (416) 263-9524,
                                         or by mail to the 8th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1 or by hand
                                         delivery at 3nd Floor, 510 Burrard Street, Vancouver, British Columbia, V6C 3B9;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">using
                                         a touch-tone phone to transmit voting choices to a toll free number. Registered shareholders
                                         must follow the instructions of the voice response system and refer to the enclosed proxy
                                         form for the toll free number, the holder&rsquo;s account number and the proxy access
                                         number; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">logging
                                         on to the internet through Computershare&rsquo;s website at <U>www.investorvote.com</U>.
                                         Registered shareholders must follow the instructions that appear on the screen and refer
                                         to the enclosed proxy form for the holder&rsquo;s account number and the proxy access
                                         number;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">in all
cases ensuring that the proxy is received at least 48 hours (excluding Saturdays, Sundays and holidays) before the Meeting or
the adjournment thereof at which the proxy is to be used.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Beneficial
Shareholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>The
following information is of significant importance to shareholders who do not hold Common Shares in their own name.</B> Beneficial
Shareholders should note that the only proxies that can be recognized and acted upon at the Meeting are those deposited by registered
shareholders (those whose names appear on the records of the Company as the registered holders of Common Shares) or as set out
in the following disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">If Common
Shares are listed in an account statement provided to a shareholder by a broker, then in almost all cases those Common Shares
will not be registered in the shareholder&rsquo;s name on the records of the Company. Such Common Shares will more likely be registered
under the names of intermediaries. In Canada, the vast majority of such Common Shares are registered under the name of CDS &amp;
Co. (the registration name for The Canadian Depository for Securities Limited, which acts as nominee for many Canadian brokerage
firms).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Intermediaries
are required to seek voting instructions from Beneficial Shareholders in advance of meetings of shareholders. Every intermediary
has its own mailing procedures and provides its own return instructions to clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">There
are two kinds of Beneficial Shareholders: (i) those who object to their name being made known to the issuers of securities which
they own (called &ldquo;<B>OBOs</B>&rdquo; for Objecting Beneficial Owners); and (ii) those who do not object to the issuers of
the securities they own knowing who they are (called &ldquo;<B>NOBOs</B>&rdquo; for Non-Objecting Beneficial Owners).</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Company
is taking advantage of the provisions of National Instrument 54-101 <I>Communication with Beneficial Owners of Securities of a
Reporting Issuer</I> that permit it to deliver proxy-related materials directly to its NOBOs. As a result NOBOs can expect to
receive a scannable Voting Instruction Form (&ldquo;<B>VIF</B>&rdquo;) from our transfer agent, Computershare. The VIF is to be
completed and returned to Computershare as set out in the instructions provided on the VIF. Computershare will tabulate the results
of the VIFs received from NOBOs and will provide appropriate instructions at the Meeting with respect to the shares represented
by the VIFs they receive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">These
securityholder materials are being sent to both registered and non-registered owners of the securities of the Company. If you
are a non-registered owner, and the Company or its agent has sent these materials directly to you, your name, address and information
about your holdings of securities, were obtained in accordance with applicable securities regulatory requirements from the intermediary
holding securities on your behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">By choosing
to send these materials to you directly, the Company (and not the intermediary holding securities on your behalf) has assumed
responsibility for (i) delivering these materials to you, and (ii) executing your proper voting instructions. Please return your
VIF as specified in the request for voting instructions that was sent to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Beneficial
Shareholders who are OBOs should follow the instructions of their intermediary carefully to ensure that their Common Shares are
voted at the Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The form
of proxy supplied to you by your broker will be similar to the proxy provided to registered shareholders by the Company. However,
its purpose is limited to instructing the intermediary on how to vote your Common Shares on your behalf. Most brokers delegate
responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc. (&ldquo;<B>Broadridge</B>&rdquo;)
in the United States and in Canada. Broadridge mails a VIF in lieu of a proxy provided by the Company. The VIF will name the same
persons as the Company&rsquo;s Proxy to represent your Common Shares at the Meeting. You have the right to appoint a person (who
need not be a Beneficial Shareholder of the Company), other than any of the persons designated in the VIF, to represent your Common
Shares at the Meeting and that person may be you. To exercise this right, insert the name of the desired representative (which
may be you) in the blank space provided in the VIF. The completed VIF must then be returned to Broadridge by mail or facsimile
or given to Broadridge by phone or over the internet, in accordance with Broadridge&rsquo;s instructions. Broadridge then tabulates
the results of all instructions received and provides appropriate instructions respecting the voting of Common Shares to be represented
at the Meeting and the appointment of any shareholder&rsquo;s representative<B>. If you receive a VIF from Broadridge, the VIF
must be completed and returned to Broadridge, in accordance with its instructions, well in advance of the Meeting in order to
have your Common Shares voted or to have an alternate representative duly appointed to attend the Meeting and vote your Common
Shares at the Meeting.</B></FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Notice
to Shareholders in the United States</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The solicitation
of proxies and the matters to be voted on, as contemplated in this Circular, involve securities of an issuer located in Canada
and are being effected in accordance with the corporate laws of the Province of British Columbia, Canada and securities laws of
the provinces of Canada. As a &ldquo;foreign private issuer&rdquo; as defined under Rule 3b-4 under the <I>United States Securities
Exchange Act</I> of 1934, as amended (the &ldquo;<B>1934 Act</B>&rdquo;), the proxy solicitation rules under the 1934 Act, including
Regulation 14A thereunder, are not applicable to the Company or this solicitation, and this solicitation has been prepared in
accordance with the disclosure requirements of the securities laws of the provinces of Canada. Shareholders should be aware that
disclosure requirements under the securities laws of the provinces of Canada differ from the disclosure requirements under United
States securities laws.</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The enforcement
by Shareholders of civil liabilities under United States federal securities laws may be affected adversely by the fact that the
Company is incorporated under the <I>Business Corporations Act </I>(British Columbia), as amended, certain of its directors and
its executive officers are residents of Canada and a substantial portion of its assets and the assets of such persons are located
outside the United States. Shareholders may not be able to sue a foreign company or its executive officers or directors in a foreign
court for violations of United States federal securities laws. It may be difficult to compel a foreign company and its executive
officers and directors to subject themselves to a judgment by a United States court.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Revocation
of Proxies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In addition
to revocation in any other manner permitted by law, a registered shareholder who has given a proxy may revoke it by:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">executing
                                         a proxy bearing a later date or by executing a valid notice of revocation, either of
                                         the foregoing to be executed by the registered shareholder or the registered shareholder&rsquo;s
                                         authorized attorney in writing, or, if the registered shareholder is a corporation, under
                                         its corporate seal by an officer or attorney duly authorized, and by delivering the proxy
                                         bearing a later date or the valid notice of revocation, as applicable, to Computershare
                                         Investor Services Inc. or at the address of the registered office of the Company at 595
                                         Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, British
                                         Columbia V7X 1L3, at any time up to and including the last business day that precedes
                                         the day of the Meeting or, if the Meeting is adjourned, the last business day that precedes
                                         any reconvening thereof, or to the chairman of the Meeting on the day of the Meeting
                                         or any reconvening thereof, or in any other manner provided by law; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">personally
                                         attending the Meeting and voting the registered shareholder&rsquo;s Common Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">A revocation
of a proxy will not affect a matter on which a vote is taken before the revocation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Meeting
Webcast</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">If you
are unable to attend the meeting in person, you are encouraged to complete the enclosed form of proxy or, if applicable, voting
instruction form and return it within the time frames indicated so that your vote is counted at the meeting. If you are unable
to attend the meeting in person, you may also listen to a live webcast, which will be available on ESSA&rsquo;s website at www.essapharma.com
commencing at 2:00 p.m. (Vancouver time) on Wednesday, March 28, 2018; however you will not be able to vote or otherwise participate
in the meeting via the webcast.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">INTEREST
OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Except
as disclosed herein, no director or executive officer of the Company, nor any person who has held such a position since the beginning
of the last completed financial year end of the Company, nor any proposed nominee for election as a director of the Company, nor
any associate or affiliate of the foregoing persons, has any material interest, direct or indirect, by way of beneficial ownership
of securities or otherwise, in any matter to be acted on at the meeting other than (i) the election of directors, (ii) the appointment
of auditors, (iii) the ratification, confirmation and approval of the New Option Plan (as defined herein), as set forth under
the heading &ldquo;<I>Approval of Stock Option Plan</I>&rdquo;, (iv) the ratification, confirmation and approval of the re-grant
and repricing, and the extension of the expiry date of certain stock options, as set forth under the heading &ldquo;<I>Approval
of Stock Option Re-Grant and Repricing, and Extension of Expiry Dates</I>&rdquo;, (v) the ratification, confirmation and approval
of certain grants of certain stock options, as further set forth under the heading &ldquo;<I>Ratification of Stock Option Grants</I>&rdquo;,
and (vi) the ratification, confirmation and approval of the RSU Plan (as defined herein), as set forth under the heading &ldquo;<I>Approval
of RSU Plan</I>&rdquo;.</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">VOTING
SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The board
of directors (the &ldquo;<B>Board</B>&rdquo;) of the Company has fixed February 21, 2018 as the record date (the &ldquo;<B>Record
Date</B>&rdquo;) for determination of persons entitled to receive notice of and to vote at the Meeting. Only shareholders of record
at the close of business on the Record Date who either attend the Meeting personally or complete, sign and deliver a form of proxy
in the manner and subject to the provisions described above will be entitled to vote or to have their Common Shares voted at the
Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Common
Shares of the Company are listed for trading on the TSX Venture Exchange (the &ldquo;<B>TSXV</B>&rdquo;) and the Nasdaq Capital
Market (&ldquo;<B>Nasdaq</B>&rdquo;). As of the Record Date, there were 115,521,889 Common Shares issued and outstanding, each
carrying the right to one vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Other
than as disclosed herein, no group of shareholders has the right to elect a specified number of directors, nor are there cumulative
or similar voting rights attached to the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Clarus
Lifesciences III, L.P. (&ldquo;<B>Clarus</B>&rdquo;), which holds 33,371,212 Common Shares as at the date hereof (representing
approximately 28.9% of the issued and outstanding Common Shares, on a non-diluted basis), is entitled to nominate two directors
to the Board (the &ldquo;<B>Clarus Nominees</B>&rdquo;), one of which must be an independent director and pre-approved by the
Company. Clarus also holds 2,121,212 Common Share purchase warrants of the Company, with each such warrant being exercisable into
one Common Share at a price of $3.30 until January 16, 2023. Clarus&rsquo; nomination rights will continue for so long as Clarus
holds at least 1,060,606 Common Shares, subject to adjustment in certain circumstances. Effective January 14, 2016, Scott Requadt,
Managing Director of Clarus Ventures, LLC, an affiliate of Clarus, was appointed to the board of directors of the Company. The
nomination rights provided to Clarus were supported by a voting agreement (the &ldquo;<B>Voting Agreement</B>&rdquo;) dated January
14, 2016, among Clarus, Marianne Sadar, Raymond Andersen, Robert Rieder and Richard Glickman (collectively, the &ldquo;<B>Principal
Shareholders</B>&rdquo;). Pursuant to the Voting Agreement, the Principal Shareholders were required to vote their Common Shares
in favour of the election to the Board of the Clarus Nominees, for so long as Clarus holds at least 1,060,606 Common Shares. The
Voting Agreement has been terminated by the parties thereto on January 30, 2018. Mr. Requadt is the Clarus Nominee in connection
with the Meeting and Clarus has not nominated a second Clarus Nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Omega
Fund Management, LLC (&ldquo;<B>Omega</B>&rdquo;) which holds 10,996,969 Common Shares as at the date hereof (representing approximately
9.5% of the issued and outstanding Common Shares, on a non-diluted basis), is entitled to nominate one director to the Board (the
&ldquo;<B>Omega Nominee</B>&rdquo;), who must meet the Company&rsquo;s general criteria for directors.&nbsp;Omega also holds 10,700,000
pre-funded Common Share purchase warrants of the Company, with each such pre-funded warrant being exercisable into one Common
Share for a nominal price until January 16, 2023, and 606,060 Common Share purchase warrants of the Company, with each such warrant
being exercisable into one Common Share at a price of $3.30 until January 16, 2023. Omega&rsquo;s nomination right will continue
for so long as Omega holds at least 9.99% of the issued and outstanding Common Shares.&nbsp; Effective January 16, 2018, Hugo
Beekman, Principal at Omega, was appointed to the Board.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">To the
knowledge of the directors and executive officers of the Company, no persons or corporations beneficially owned (as determined
under applicable Canadian securities laws), directly or indirectly, or exercised control or direction over, Common Shares carrying
10% or more of the voting rights attached to all outstanding Common Shares of the Company as at the Record Date, except as follows:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Shareholder
    Name</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 11pt"><B>Number of Common</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 11pt"><B>Shares Held</B></FONT></P></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Percentage
    of Issued and Outstanding Common Shares</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-bottom: 3pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 11pt">Clarus
    Lifesciences III, L.P.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">33,371,212</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; font-size: 9pt"><FONT STYLE="font-size: 11pt">28.9%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0"><FONT STYLE="font-size: 11pt">FINANCIAL
STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The audited
financial statements of the Company for the year ended September 30, 2017, report of the auditor and related management discussion
and analysis, all of which may be obtained from SEDAR at www.sedar.com or from EDGAR at www.sec.gov, will be placed before the
Meeting and have been filed with the securities commissions or similar regulatory authority in British Columbia, Alberta and Ontario.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0"><FONT STYLE="font-size: 11pt">VOTES
NECESSARY TO PASS RESOLUTIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">A simple
majority of affirmative votes cast at the Meeting is required to pass the resolutions described herein, other than the Share Consolidation
Resolution (as defined herein), which must be passed by two-thirds of affirmative votes cast at the Meeting. In addition, the
Repricing Resolution, the Option Grant Resolution and the RSU Plan Resolution (each as defined herein) require that only disinterested
shareholders cast votes with respect to such resolutions, as further set out below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">If there
are more nominees for election as directors or appointment of the Company&rsquo;s auditor than there are vacancies to fill, those
nominees receiving the greatest number of votes will be elected or appointed, as the case may be, until all such vacancies have
been filled. If the number of nominees for election or appointment is equal to the number of vacancies to be filled all such nominees
will be declared elected or appointed by acclamation.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0"><FONT STYLE="font-size: 11pt">PARTICULARS
OF MATTERS TO BE ACTED UPON</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Setting
                                         the Number of Directors &ndash; See heading &ldquo;<I>Election of Directors</I>&rdquo;.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Election
                                         of Directors &ndash; See heading &ldquo;<I>Election of Directors</I>&rdquo;.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Appointment
                                         of Auditor &ndash; See heading &ldquo;<I>Appointment of Auditor</I>&rdquo;.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Approval
                                         of Stock Option Plan&ndash; See heading &ldquo;<I>Approval of Stock Option Plan&rdquo;.</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Approval
                                         of Stock Option Re-Grant and Repricing, and Extension of Expiry Dates &ndash; See heading
                                         &ldquo;<I>Approval of Stock Option Re-Grant and Repricing, and Extension of Expiry Dates&rdquo;</I>.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Ratification
                                         of Stock Option Grants &ndash; See heading &ldquo;<I>Ratification of Stock Option Grants</I>&rdquo;.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Approval
                                         of Common Share Consolidation &ndash; See heading <I>&ldquo;Approval of Common Share
                                         Consolidation&rdquo;.</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Approval
                                         of Restricted Share Unit Plan &ndash; See heading &ldquo;<I>Approval of RSU Plan</I>&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">ELECTION
OF DIRECTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Articles
of the Company set out that the number of directors of the Company will be a minimum of three and a maximum of the most recently
set of (i) the number of directors set by ordinary resolution and (ii) the number of directors set in the event that the places
of any retiring directors are not filled by an election at a meeting of shareholders. The term of office of each of the eight
current directors will end at the conclusion of the Meeting. Unless a director&rsquo;s office is vacated earlier in accordance
with provisions of the <I>Business Corporations Act </I>(British Columbia), each director elected will hold office until the conclusion
of the next annual meeting of the Company, or if no director is then elected, until a successor is elected.</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Company
has adopted a majority voting policy (the &ldquo;<B>Policy</B>&rdquo;). Pursuant to the Policy, shareholders vote for the election
of individual directors rather than for a fixed slate of directors. Further, in an uncontested election of directors, the votes
cast in favour of the election of a director nominee must represent a majority of the shares voted and withheld for the election
of the director. If that is not the case, that director must tender his or her resignation to the Chairman of the Board immediately.
The Board will promptly consider such tendered resignation and the action to be taken with respect to such tendered resignation.
Absent exceptional circumstances, the Board will be expected to accept the resignation tendered pursuant to the Policy, which
will be effective on such date. Following the Board&rsquo;s decision with respect to the tendered resignation, the Board must
promptly disclose such decision via press release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table sets out, among other things, the names of management&rsquo;s eight nominees for election as directors, all major offices
and positions with the Company each now holds, each nominee&rsquo;s principal occupation, business or employment, the period of
time during which each has been a director of the Company and the number of Common Shares of the Company beneficially owned by
each, directly or indirectly, or over which each exercised control or direction, as at February 23, 2018:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #BFBFBF">
    <TD STYLE="width: 21%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 11pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt"><B>Name,
    Country of Residence and Position</B></FONT></TD>
    <TD STYLE="width: 47%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 11pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt"><B>Principal
    Occupation or Business or Employment<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Period
    as a Director of the Company</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Common
    Shares Beneficially Owned, Controlled or Directed<SUP>(1)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt"><B>David
        R. Parkinson</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"><FONT STYLE="font-size: 11pt">California,
        United States of America</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>President,
        Chief Executive Officer and Director</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">President
        and Chief Executive Officer, ESSA Pharma Inc. (January 7, 2016 - Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        ESSA Pharma Inc. (June 24, 2015 -Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Venture
        Advisor, New Enterprise Associates (2012 &ndash; 2016)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Acting
        CEO, Zyngenia Inc. (2013 &ndash; 2014)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">President
        and Chief Executive Officer, Nodality Inc. (2007 &ndash; 2012)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 9pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    June 2015</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; font-size: 9pt"><FONT STYLE="font-size: 11pt">250,000<SUP>(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>Richard
        M. Glickman</B><SUP>(3)(4)</SUP><BR>
        British Columbia, Canada</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Chairman
        of the Board</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><FONT STYLE="font-size: 11pt">Chairman of the Board,
        ESSA Pharma Inc. (October 2010-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><FONT STYLE="font-size: 11pt">Co-founder and Executive
        Chairman (September 2013-February 2014) and Chairman of the Board (February 2014-Present) and Chief Executive Officer
        ( February 2017 &ndash; present) Aurinia Pharmaceuticals Inc.</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 9pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    October 2010</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; font-size: 9pt"><FONT STYLE="font-size: 11pt">775,000<SUP>(5)</SUP></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; border: Black 1pt solid; padding: 3pt 6pt; font-size: 11pt; text-align: left; background-color: Silver; vertical-align: bottom"><FONT STYLE="font-size: 11pt"><B>Name,
    Country of Residence and Position</B></FONT></TD>
    <TD STYLE="width: 47%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt; font-size: 11pt; text-align: left; background-color: Silver; vertical-align: bottom"><FONT STYLE="font-size: 11pt"><B>Principal
    Occupation or Business or Employment(1)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt; background-color: #BFBFBF; font-size: 9pt; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 11pt"><B>Period
    as a Director of the Company</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt; background-color: #BFBFBF; font-size: 9pt; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 11pt"><B>Common
    Shares Beneficially Owned, Controlled or Directed(1)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>Marianne
        Sadar</B><BR>
        British Columbia, Canada</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Chief
        Scientific Officer and Director</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director
        (January 6, 2009-Present), Chief Scientific Officer (October 11, 2010-Present) and President (January 6, 2009-October
        11, 2010), ESSA Pharma Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Distinguished
        Scientist (2012-Present) and Senior Scientist (1998-2012), British Columbia Cancer Agency</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Professor
        (2012-Present), Honorary Associate Professor (2009-2012), Pathology and Laboratory Medicine, University of British Columbia</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Provincial
        Program Leader for Prostate Cancer Research (2000-2012), British Columbia Cancer Agency</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Trustee,
        Ingenium, Crown Corporation, Government of Canada (November 1, 2017-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Officer
        (2007-2015), Past President (2014-Present), President (2013-2015), Vice President (2012-2013), and Treasurer (2007-2011),
        Society of Basic Urologic Research</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 9pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    January 2009</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; font-size: 9pt"><FONT STYLE="font-size: 11pt">2,889,296<SUP>(6)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>Raymond
        Andersen</B><BR>
        British Columbia, Canada</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Chief
        Technical Officer and Director</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Chief
        Technical Officer and Director (October 11, 2010-Present) and Secretary (January 6, 2009-Present), ESSA Pharma Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Professor
        of Chemistry and Earth, Ocean &amp; Atmospheric Sciences, University of British Columbia (1977-Present)</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 9pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    January 2009</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; font-size: 9pt"><FONT STYLE="font-size: 11pt">2,886,296<SUP>(7)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>Gary
        Sollis</B><SUP>(3)(4)(8)</SUP><BR>
        British Columbia, Canada</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Director</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        ESSA Pharma Inc. (April 26, 2012-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Partner,
        Dentons Canada LLP (May 1, 1995-Present)</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 9pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    April 2012</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; font-size: 9pt"><FONT STYLE="font-size: 11pt">0<SUP>(9)</SUP></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding: 3pt 6pt; font-size: 11pt; text-align: left; background-color: Silver; vertical-align: bottom; width: 21%"><FONT STYLE="font-size: 11pt"><B>Name,
    Country of Residence and Position</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt; font-size: 11pt; text-align: left; background-color: Silver; vertical-align: bottom; width: 47%"><FONT STYLE="font-size: 11pt"><B>Principal
    Occupation or Business or Employment(1)</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt; background-color: #BFBFBF; font-size: 9pt; text-align: center; vertical-align: bottom; width: 13%"><FONT STYLE="font-size: 11pt"><B>Period
    as a Director of the Company</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt; background-color: #BFBFBF; font-size: 9pt; text-align: center; vertical-align: bottom; width: 19%"><FONT STYLE="font-size: 11pt"><B>Common
    Shares Beneficially Owned, Controlled or Directed(1)</B></FONT></TD></TR>
</TABLE></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>Franklin
        M. Berger</B><SUP>(3)(4) (8)</SUP><BR>
        New York, United States of America</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Director</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; width: 47%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        ESSA Pharma Inc. (March 2015-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        Five Prime Therapeutics, Inc. (October 2010-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        Immune Design Corp. (March 2014-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        Tocagen Inc. (December 2, 2104-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        Bellus Health, Inc. (May 2010-Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        Seattle Genetics, Inc. (2003-May 2014)</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt; width: 13%; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    March 2015</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt; text-align: center; width: 19%"><FONT STYLE="font-size: 11pt">3,776,892<SUP>(10)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>Scott
        Requadt</B><SUP>(4)(8)</SUP><BR>
        Massachusetts, United States of America</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Director</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        ESSA Pharma Inc. (January 14, 2016 &ndash; Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Director,
        VBI Vaccines (formerly SciVac Therapeutics) (May 2016 &ndash; Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Managing
        Director, Clarus (September 2005 &ndash; Present)</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since
    January 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">0<SUP>(11)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt"><B>Hugo
        Beekman</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Massachusetts,
        United States of America</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>Director</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt"><I>&nbsp;</I></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"><FONT STYLE="font-size: 11pt">Director,
        ESSA Pharma Inc. (January 16, 2018 &ndash; Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"><FONT STYLE="font-size: 11pt">Principal,
        Omega Funds (May 2013 &ndash; Present)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: left"><FONT STYLE="font-size: 11pt">Associate,
        Wyvern Funds (November 2009 - March 2013)</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Since<BR>
    January 2018</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">0<SUP>(12)</SUP></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Notes:</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         information as to principal occupation, business or employment (for the preceding five
                                         years for any new director) and Common Shares beneficially owned, controlled or directed
                                         is not within the knowledge of the management of the Company and has been furnished by
                                         the respective nominees themselves. Beneficial ownership is determined in accordance
                                         with applicable Canadian securities laws.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">David
                                         R. Parkinson also holds stock options (&ldquo;<B>Options</B>&rdquo;) to purchase 5,350,000
                                         Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Member
                                         of the Audit Committee (as defined herein).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Member
                                         of the Compensation Committee (as defined herein).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Of
                                         the 775,000 Common Shares over which Richard M. Glickman exercises control, 100,000 are
                                         held in the name of his spouse. Richard M. Glickman also holds Options to purchase 240,000
                                         Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Marianne
                                         Sadar also holds Options to purchase 1,600,000 Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Raymond
                                         Andersen also holds Options to purchase 1,600,000 Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(8)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Member
                                         of the Corporate Governance and Nomination Committee (as defined herein).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(9)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Gary
                                         Sollis holds Options to purchase 240,000 Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(10)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Franklin
                                         Berger holds Options to purchase 240,000 Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(11)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Scott
                                         Requadt is an associate of Clarus. As at the date hereof, Clarus holds 33,371,212 Common
                                         Shares and 2,121,212 warrants to purchase Common Shares. Scott Requadt holds Options
                                         to purchase 240,000 Common Shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(12)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Hugo
                                         Beekman is an associate of Omega. As at the date hereof, Omega holds 10,996,969 Common
                                         Shares and 11,306,060 warrants to purchase Common Shares. Hugo Beekman holds Options
                                         to purchase 240,000 Common Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify"><FONT STYLE="font-size: 11pt">Other than
as disclosed herein, none of the proposed nominees for election as a director of the Company are proposed for election pursuant
to any arrangement or understanding between the nominee and any other person, except the directors and senior officers of the
Company acting solely in such capacity. See &ldquo;<I>Voting Securities And Principal Holders Of Voting Securities</I>&rdquo;
above.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Director
Biographies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>David
R. Parkinson President, Chief Executive Officer and Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Dr. David
R. Parkinson, 67, has served as a director of the Company since June 24, 2015 and has been employed full time as the President
and Chief Executive Officer of the Company since January 7, 2016. He is responsible for the management of the Company, developing
objectives, strategy and standards of performance, securing and leading a team of professionals and directing them to deliver
the required performance. Most recently Dr. Parkinson has served as a venture partner at New Enterprise Associates (NEA), Inc.,
and following his assumption of these new ESSA-related responsibilities he has moved to the role of venture advisor to NEA. From
2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a biotechnology company focused on the biological characterization
of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making.
Dr. Parkinson has previously led oncology clinical development activities at Novartis (1997-2003), Amgen (2003-2006) and Biogen
Idec (2006-2007). He worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch,
and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP). Dr. Parkinson is a past Chairman of the
Food &amp; Drug Administration (FDA) Biologics Advisory Committee, has also served on the FDA&rsquo;s Science Board, and is a
recipient of the FDA's Cody Medal. He has served on the National Cancer Policy Forum of the Institute of Medicine, as a board
director for the Ontario Institute for Cancer Research, and is a past co-chair of the Cancer Steering Committee of the NIH Foundation
Biomarkers Consortium. He currently serves as a Board Director for the Multiple Myeloma Research Foundation. He recently stepped
down as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for the last 15 years, and
is a former elected AACR Board Director. In addition, Dr. Parkinson was formerly a Director of Facet Biotech, Inc. and Ambit Biosciences,
both public biopharma companies which were acquired by large pharmaceutical companies. He currently serves as Director on the
Boards of 3SBio Inc., Tocagen Inc., and CTI Biopharma Corp. He has held academic positions both at Tufts and at the University
of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Richard
M. Glickman, Chairman of the Board</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Chairman
of the Board, Dr. Richard M. Glickman, 59, has served as the Chairman of the Board of the Company since October 2010. As the Chairman
of the Board, Dr. Glickman is responsible for the management of the Board to ensure the Company has appropriate objectives and
an effective strategy, and that it is operating in accordance with a high standard of corporate governance. Dr. Glickman was a
co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Inc. (&ldquo;<B>Aspreva</B>&rdquo;) which was acquired
by the Galenica Group for $915 million. Prior to establishing Aspreva, Dr. Glickman was the co-founder and Chief Executive Officer
of StressGen Biotechnologies Corporation. Dr. Glickman currently serves on Cardiome Pharma Corp.&rsquo;s Board of Directors as
a member of the Compensation and Audit Committees and as its lead independent director. In addition, Dr. Glickman serves as Chairman
of the Board and CEO of Aurinia Pharmaceuticals Inc., as Chairman of the Board of Engene Corporation and as a Director of Vida
Pharmaceuticals. In addition, he has served on numerous biotechnology boards including roles as Chairman of Life Sciences B.C.
(formerly the British Columbia Biotechnology Alliance), as a Director of the Canadian Genetic Diseases Network (a Canadian Centre
of Excellence), a member of the federal government&rsquo;s National Biotechnology Advisory Committee, a member of the British
Columbia Innovation Council and a director for the Vancouver Aquarium and Chair of its Research Committee. Dr. Glickman received
the Ernst &amp; Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group, both Canada&rsquo;s and
British Columbia&rsquo;s Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation
of America Leadership Award.</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Marianne
Sadar, Chief Scientific Officer and Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Dr. Marianne
Sadar, 56, is one of the co-founders of ESSA. Dr. Sadar has been a director of the Company since January 2009, and has acted as
the Chief Scientific Officer of the Company since October 2010. She is responsible for participating in the research and development
of ESSA&rsquo;s drug candidates, and with the assessment and review of business and scientific matters. As an independent consultant,
she devotes approximately 20% of her time to the affairs of the Company. She is a Distinguished Scientist at the BC Cancer Agency
and a Professor of Pathology and Laboratory Medicine at the University of British Columbia (&ldquo;<B>UBC</B>&rdquo;). Dr. Sadar
is internationally known for her research on identifying mechanisms of activating the androgen receptor (&ldquo;<B>AR</B>&rdquo;)
and developing therapeutics for advanced prostate cancer that target the N-terminal domain of the AR. Her research was the first
to show that the N-terminal domain of the AR could be activated by alternative pathways and she proposed this domain as a therapeutic
target in 1999. Later, Dr. Sadar provided the first proof-of-concept that targeting the N-terminus of the AR results in a therapeutic
response in an in vivo model of castration-resistant prostate cancer (&ldquo;<B>CRPC</B>&rdquo;). Dr. Sadar received her B.Sc.
from Simon Fraser University, and Ph.D. from the University of Bradford, U.K. She carried out post-doctoral training at AstraZeneca
(Astra H&auml;ssle), Department of Drug Metabolism and Pharmacokinetics in M&ouml;lndal, Sweden and at the BC Cancer Agency. Dr.
Sadar has served in numerous leadership roles internationally and is the 2017 Chair of the USA Army&rsquo;s Department of Defence&rsquo;s
Programmatic Panel for their Prostate Cancer Research Program. She was the President of the Society of Basic Urologic Research
(USA) and a member of the board of education, research, and scientific advisory committees and of boards for American and Canadian
non-profit societies. Dr. Sadar was appointed to the Board of Trustees for Canada&rsquo;s National Museum of Science and Technology
by the Minister of Heritage in Oct 2017. Dr. Sadar has served on over 50 grant panels including 5 years on the NIH study session
for Drug Discovery &amp; Molecular Pharmacology. Her research has also received awards such as the USA SWIU/SBUR Award for Excellence
in Urologic Research, Simon Fraser University&rsquo;s Outstanding Alumni Award for Academic Achievements, the Terry Fox Young
Investigator Award, and award for Excellence in Research and Discovery from UBC Department of Pathology and Laboratory Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Raymond
Andersen, Chief Technical Officer, Secretary and Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Dr. Raymond
Andersen, 71, is one of the co-founders of ESSA. He has served as the Secretary of the Company and a director since January 2009,
and as a Chief Technical Officer of the Company since October 2010. He is responsible for participating in the research and development
of ESSA&rsquo;s drug candidates, and with the assessment and review of business and scientific matters. As an independent consultant,
he devotes approximately 20% of his time to the affairs of the Company. He is also a Professor at UBC in the departments of Chemistry
and Earth &amp; Ocean Sciences. He is internationally known for his research into the identity and structure of novel chemical
compounds derived from marine organisms, the molecular routes to their biosynthesis, their role in ocean ecology, and their potential
as new drugs. Among them are compounds that have anti-inflammatory and anti-cancer properties and these compounds are being developed
as anti-asthma, and anti-tumour drugs. His discoveries represented core technologies of the UBC spinoff companies Aquinox Pharmaceuticals
Inc. and Inflazyme Pharmaceuticals. His industrial programs have led to deals with Aventis and Wyeth and the venture capital arms
of Johnson &amp; Johnson and Pfizer. Dr. Andersen received his B.Sc. degree from the University of Alberta, a M.Sc. from the University
of California, Berkeley, and Ph.D. from the University of California, San Diego. He carried out postdoctoral research at the Massachusetts
Institute of Technology. In recognition of his pioneering achievements, Dr. Andersen was inducted into the Royal Society of Canada
and recently received the R. U. Lemieux Award from the Canadian Society for Chemistry and the Jacob Biely Research Prize from
UBC. Dr. Andersen&rsquo;s consulting agreement contains non-competition and confidentiality clauses.</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Gary
Sollis, Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Mr. Gary
Sollis, 64, has served as a director of the Company since April 2012. Mr. Sollis is a partner at the law firm of Dentons Canada
LLP. He represents clients in the areas of corporate and securities law, with a focus on acquisitions, financings, reorganizations,
and corporate governance. Mr. Sollis is an adjunct professor of securities regulation at the Faculty of Law of University of British
Columbia, a frequent lecturer on corporate law for the British Columbia bar admission program and a regular contributor to the
American Bar Association&rsquo;s mergers and acquisitions deal point studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Franklin
M. Berger, Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Mr. Franklin
M. Berger, 68, has served as a director of the Company since March 2015. He started his consulting practice in 2003 after leaving
J.P. Morgan Securities, Inc. as their head of biotechnology equity research. His clients are exclusively biotechnology industry
participants including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and
venture capital companies. He currently serves on the board of directors of four public biotechnology companies: Tocagen Inc.,
Five Prime Therapeutics, Inc., Immune Design Corp. and Bellus Health, Inc. Previous public company board service included 11 years
with Seattle Genetics, Inc., seven years with VaxGen, Inc. (vaccines/biodefense) and Aurinia Pharmaceuticals Inc. (previously
Isotechnika), based in Canada. He also serves or has served on private biotechnology company board of directors, including iTherX
Pharma, Inc., Caprion Proteomics (sold in July 2012), Inc. and ViroChem Pharma, Inc. As a senior portfolio manager on the buy-side,
Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from 2007 through June 2008. Mr.
Berger spent 12 years in sell-side equity research, most recently as Managing Director, U.S. Equity Research, J. P. Morgan Securities,
Inc., from May 1998 to March 2003.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Institutional
Investor Magazine ranked Mr. Berger on J.P. Morgan&rsquo;s All-Star Research Team. The Wall Street Journal selected Mr. Berger
as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the Wall Street Journal&rsquo;s
2000 Survey. In 2000, he became a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine.
Mr. Berger received his MBA degree from Harvard Business School in 1975. Johns Hopkins University conferred both his MA and BA
degrees in 1971 and 1972, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Scott
Requadt, Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Mr. Requadt,
LL.B, MBA, 50, has served as a director of the Company since January 14, 2016. He is currently a Managing Director at Clarus,
a life sciences investment capital fund. Mr. Requadt has over 15 years of operating and investment experience in the pharmaceutical
industry. Prior to joining Clarus in 2005, Mr. Requadt was Director, Business Development of TransForm Pharmaceuticals, and previously
practiced for several years as a mergers and acquisitions attorney at the New York City-based law firm of Davis Polk &amp; Wardwell.
Before that, Mr. Requadt was a law clerk for a senior judge at the Supreme Court of Canada. Mr. Requadt holds a B.Com (Economics
&amp; Finance) from McGill University, an LL.B from University of Toronto and an MBA from Harvard Business School (Baker Scholar).
Mr. Requadt has been involved in multiple Clarus investments spanning both therapeutics and medtech, including Intercept Pharmaceuticals
as well as several research and development risk-sharing collaborations with large pharmaceutical partners. He has previously
been active on the board of directors of TyRx Inc., Catabasis Pharmaceuticals Inc., Oxford Immunotec Global PLC, Link Medicine
Corp., and Biolex Therapeutics Inc., and is currently a director of VBI Vaccines, Inc., AvroBio, Inc., and Edev S.a.r.l.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Hugo
Beekman</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">Hugo Beekman,
31, has served as a director of the Company since January 16, 2018. Mr. Beekman is currently a Principal at Omega, a life science
venture capital firm. Prior to joining Omega in 2013, Mr. Beekman began his career in 2009 at the Wyvern Funds, a hedge fund that
invests in publically listed shares of biotechnology and medical device companies, as an Associate. He holds his A.B. from Harvard
College, where he studied Environmental Science and Public Policy. Mr. Beekman has over eight years of investing experience in
the life sciences, having been involved with private and public investments across multiple therapeutics areas and modalities.
At Omega Mr. Beekman has focused his efforts on oncology &amp; immuno-oncology, immunology &amp; inflammation, technology platforms,
and rare diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Cease
Trade Orders and Bankruptcies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">No proposed
director of the Company is, as of the date of this Circular, or has been, within the ten years prior to the date hereof, a director
or chief executive officer or chief financial officer of any company (including the Company) that: (i) was subject to an order
that was issued while the proposed director was acting as a director, chief executive officer or chief financial officer; or (ii)
was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer or chief
financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief
executive officer or chief financial officer. For the purposes hereof, &ldquo;order&rdquo; means: (i) a cease trade order; (ii)
an order similar to a cease trade order; or (iii) an order that denied the relevant company access to any exemption under securities
legislation that was in effect for a period of more than 30 consecutive days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">No proposed
director of the Company is, at the date of this Circular, or has been within ten years before the date of this Circular, a director
or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year
of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy
or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver
manager or trustee appointed to hold its assets.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Penalties
and Sanctions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">No proposed
director of the Company has been subject to any penalties or sanctions imposed by a court relating to securities legislation or
by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority, or has
been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important
to a reasonable securityholder in deciding whether to vote for a proposed director.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Individual
Bankruptcies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">No proposed
director of the Company has, within the ten years before the date of this Circular, become bankrupt, made a proposal under any
legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise
with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">APPOINTMENT
OF AUDITOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Davidson
&amp; Company LLP, at its offices located at 1200 &ndash; 609 Granville Street, P.O. Box 10372, Pacific Centre, Vancouver, British
Columbia, Canada V7Y 1G6, will be nominated at the Meeting for reappointment as auditor of the Company at remuneration to be fixed
by the directors. Davidson &amp; Company LLP was first appointed as the Company&rsquo;s auditor on May 28, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">To be
approved, the resolution must be passed by a majority of the votes cast by the holders of Common Shares at the Meeting. <B>Management
recommends a vote &ldquo;for&rdquo; in respect of the resolution approving the appointment of the auditor and authorizing the
directors to fix the auditor&rsquo;s remuneration.</B></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">APPROVAL
OF STOCK OPTION PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">On November
27, 2017, the listing of ESSA&rsquo;s Common Shares was transferred from the Toronto Stock Exchange and such Common Shares were
conditionally listed on the TSXV. The policies of the TSXV require all companies listed on the TSXV to have a stock option plan
if the company intends to grant stock options. The Company has in place its existing amended and restated stock option plan (the
&ldquo;<B>Existing Option Plan</B>&rdquo;), which was approved by the Board on February 2, 2017, and by the Company&rsquo;s shareholders
on March 8, 2017. The Existing Option Plan is more fully described under the heading &ldquo;<I>Securities Authorized for Issuance
Under Equity Compensation Plans - Equity Compensation Plan Information</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">As a
condition to the transfer of the listing of the Common Shares from the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) to the
TSXV, the Company is required to adopt a stock option plan that complies with Policy 4.4 &ndash; <I>Incentive Stock Options</I>
of the TSXV Corporate Finance Manual. In order to comply with this condition, the Board approved a new stock option plan (the
&ldquo;<B>New Option Plan</B>&rdquo;) on February 21, 2018, which is a fixed number stock option plan that incorporates TSXV requirements
and will replace the Existing Option Plan. The Company will be asking its shareholders at the Meeting to consider, and if thought
fit, pass with or without amendment, an ordinary resolution set forth below (the &ldquo;<B>Option Plan Resolution</B>&rdquo;),
ratifying, confirming and approving the adoption of the New Option Plan, and reserving Common Shares from treasury for issuance
under the New Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The purpose
of the New Option Plan is to provide the Company with a share-related mechanism to attract, retain and motivate qualified directors,
officers, employees and consultants, and to reward such of those directors, officers, employees and consultants as may be awarded
Options under the New Option Plan by the Board from time to time for their contributions toward creating shareholder value through
achievement of the short and long term goals of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Particulars
of the New Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">A summary
of certain provisions of the New Option Plan is set out below. This summary is qualified in its entirety by the full text of the
New Option Plan which is attached as Schedule A to this Circular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Administration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The New
Option Plan is administered by the Board, subject to the Board&rsquo;s power to delegate such administrative duties and powers
as it may seem fit to a director or senior officer or employee of the Company, from time to time. In connection with its administrative
role, the Board may make, amend and repeal at any time and from time to time such policies not inconsistent with the New Option
Plan as it may deem necessary or advisable for the proper administration of the plan. ESSA&rsquo;s administration of the New Option
Plan will be consistent with the policies and rules of the TSXV and will comply with such other stock exchanges on which the Common
Shares may be listed from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Eligibility
Under the New Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the New Option Plan, Options may be granted to:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a director
                                         of the Company or any of its subsidiaries;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">an officer
                                         of the Company or any of its subsidiaries;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">an employee
                                         of the Company or any of its subsidiaries, which is (i) and individual that is considered
                                         an employee of the Company or any of its subsidiaries under the <I>Income Tax Act </I>(Canada);
                                         (ii) an individual who works full-time for the Company or any of its subsidiaries providing
                                         services normally provided by an employee and who is subject to the same control and
                                         direction by the Company over the details and methods of work as an employee of the Company,
                                         but for whom income tax deductions are not made at source; (iii) an individual who works
                                         for the Company or any of its subsidiaries on a continuing and regular basis for a minimum
                                         amount of time per week providing services normally provided by an employee and who is
                                         subject to the same control and direction by the Company over the details and methods
                                         of work as an employee of the Company, but for whom income tax deductions are not made
                                         at source;</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a management
                                         company employee, which is an individual employed by a person providing management services
                                         to the Company, which is required for the ongoing successful operation of the business
                                         enterprise of the Company, but excluding a person engaged in investor relations activities
                                         (as defined by the policies of the TSXV); and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a consultant
                                         to the Company or any of its subsidiaries, which is an individual (or a corporation or
                                         partnership of which the individual is an employee, shareholder or partner), other than
                                         an employee, officer, management company employee or a director of the Company, that
                                         (i) is engaged to provide on a bona fide basis, consulting, technical, management or
                                         other services to the Company or any of its subsidiaries, other than services provided
                                         in relation to a distribution; (ii) provides the services under a written contract between
                                         the Company or a subsidiary of the Company and the individual or the consultant company;
                                         (iii) in the reasonable opinion of the Company, spends or will spend a significant amount
                                         of time and attention on the affairs and business of the Company or its subsidiaries;
                                         and (iv) has a relationship with the Company or a subsidiary of the Company that enables
                                         the individual to be knowledgeable about the business and affairs of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Common
Shares Issuable Under the New Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Subject
to adjustments, the maximum number of Common Shares reserved for issuance pursuant to the exercise of Options granted under the
New Option Plan, together with the Existing Option Plan and the Company&rsquo;s other equity incentives plans in existence from
time to time, is 23,104,377. If any Option expires, is cancelled or otherwise terminated for any reason without having been exercised
in full, the number of Common Shares in respect of which such Option was not exercised will again be available for issuance under
the New Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Restrictions
on Option Grants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
has the power to determine, in its sole discretion, those directors, officers, employees, management company employees and consultant
to whom Options are to be awarded, subject to the following restrictions:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">no Option
                                         can be granted to any optionee unless the Board has determined that the grant of such
                                         Option and the exercise thereof by the Option will not violate the securities laws of
                                         the jurisdiction in which the optionee resides;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the number
                                         of Common Shares issuable pursuant to grants of Options under the New Option Plan, together
                                         with all of the Company&rsquo;s other security based compensation arrangements in existence
                                         from time to time, within a one-year period:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">subject
                                         to (ii) and (iii) immediately below, to any one person, shall not exceed 5% of the issued
                                         and outstanding Common Shares as at the time of the applicable grant;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to
                                         a consultant, shall not exceed 2% of the issued and outstanding Common Shares, as at
                                         the time of the applicable grant; and</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to
                                         persons employed to conduct investor relations activities (as defined by the policies
                                         of the TSXV), shall not exceed 2% of the issued and outstanding Common Shares, as at
                                         the time of the applicable grant;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">unless
                                         the Company obtains disinterested shareholder approval in accordance with the New Option
                                         Plan and the policies of the TSXV:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         maximum aggregate number of Common Shares that may be reserved for issuance to insiders
                                         of the Company under the New Option Plan; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         maximum aggregate number of Option granted to insiders of the Company under the New Option
                                         Plan within a one-year period,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-size: 11pt">may
not exceed 10% of the issued and outstanding Common Shares as the time of the applicable grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Exercise
Price of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The exercise
price of an Option will be determined by the Board when the Option is granted and shall not be less than the closing market price
of the Company&rsquo;s Common Shares on the Nasdaq or the TSXV, as the case may be, on the applicable date, if there is no closing
trading price at such time of grant of the Option, then on the trading day immediately prior to the date of the grant of the Option.
The exercise price per Common Share under an Option may be reduced at the discretion of the Board if (i) prior TSXV approval is
obtained and at least six months has elapsed since the later of the date such option was granted and the date the exercise price
for such option was last amended, and (ii) shareholder approval is obtained for any reduction in the exercise price of an Option
and, in the case of a reduction in the exercise price of an Option held by an insider of the Company, disinterested shareholder
approval is obtained for such reduction. The foregoing conditions to reduction of an exercise price shall not apply in the case
of certain adjustments, such as alterations to the capital structure of the Company, as set out in the New Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Vesting
of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Subject
to the policies of the TSXV, an Option granted under the New Option Plan shall vest and may be exercised during the term of the
Option in accordance with any vesting schedule as the Board may determine, in its sole discretion. However, Options issued to
persons retained to provide investor relations activities (as defined by the policies of the TSXV) will be subject to a vesting
schedule of at least 12 months whereby no more than 25% of the options granted may be vested in any three month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Term
of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The New
Option Plan provides that Options shall expire on the expiration date determined by the Board, provided that the term of an Option
shall not exceed ten years from its date of grant. Options must be exercised, if at all, on or before their respective expiration
date. In the event that the term of an Option expires during a blackout period (as defined by the policies of the TSXV) such term
will automatically be extended to the date that is ten business days following the end of such blackout period and, in the event
that a blackout period is imposed during such extension period, the extension period will be deemed to commence following the
end of the additional blackout period to enable the exercise of the applicable Option within ten business days following the end
of the last imposed blackout period. The maximum term an Option may be extended by the Board, provided that the Board obtains
shareholder approval for such extension.</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Termination
of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">To the
extent not earlier exercised or terminated in accordance with the New Option Plan, an Option will terminate at the earliest of:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the termination
                                         date set by the Board upon the grant of the Option, subject to extension in case of a
                                         blackout period, as further set out above under the subheading &ldquo;- <I>Term of Options</I>&rdquo;;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">where
                                         the optionee&rsquo;s position as an employee, consultant, director or officer is terminated
                                         for just cause, the date of such termination for just cause;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">unless
                                         determined otherwise by the Board, where the optionee&rsquo;s position as an employee,
                                         consultant, director or officer terminates for a reason other than the optionee&rsquo;s
                                         disability, death, or termination for just cause, on the termination date with respect
                                         to the Options that have not vested at such termination date, and 90 days after such
                                         date of termination with respect to the Options that have vested as at such termination
                                         date, provided that if an optionee&rsquo;s position with the Company changes from one
                                         of the said categories to another category, such change shall not constitute termination;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the date
                                         of any sale, transfer, assignment or hypothecation, or any attempted sale, transfer,
                                         assignment or hypothecation, of such Option in violation of the New Option Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Transferability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Options
granted under the New Option Plan are non-transferable and non-assignable, except as specifically provided under the New Option
Plan in the event of the death or disability of an optionee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Effect
of Death, Disability or Retirement of Optionee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">If the
position of an optionee as a director, officer, employee or consultant of the Company or any of its subsidiaries, is terminated
as a result of his or her death, any Options held by such optionee shall pass to the person who is entitled to ownership of such
Options pursuant to a will or the applicable laws of descent and distribution upon death (a &ldquo;<B>Qualified Successor</B>&rdquo;),
and shall be exercisable by the Qualified Successor for a period of one year following such death, provided that in no case shall
the term of the Option extend beyond ten years from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">If the
position of an optionee as a director, officer, employee or consultant of the Company or any of its subsidiaries, is terminated
by reason of such optionee's disability, any Option held by such optionee that could have been exercised immediately prior to
such termination shall be exercisable by such optionee, or by his or her guardian, for a period of one year following the termination
of such optionee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">If an
optionee who has ceased to be employed by the Company or any of its subsidiaries by reason of such optionee's disability dies
within 30 days after the termination of such employment, any Option held by such optionee that could have been exercised immediately
prior to his or her death shall pass to the Qualified Successor of such optionee, and shall be exercisable by the Qualified Successor
for a period of one year following the death of such optionee, provided that in no case shall the term of the Option extend beyond
five years from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Options
held by a Qualified Successor or exercisable by a guardian shall, during the period prior to their termination, continue to vest
in accordance with any vesting schedule to which such Options are subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In the
event of the termination of employment of an optionee who is an employee at any time during the term of an Option by reason of
the deemed retirement of such employee, as may be determined by the Board, in its sole discretion, then the rights to purchase
Common Shares under the Option which have accrued to the optionee and remain unexercised at, or which accrue subsequent to, the
date of his or her retirement shall remain exercisable by the optionee (or by the optionee's legal personal representative or
representatives if the optionee dies before the last date of exercise of the Option) for a period of one year following the retirement
of such optionee in accordance with the terms of the Option.</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Tax
Withholding</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the New Option Plan, the Company may implement such procedures and conditions as it determines appropriate with respect to
the withholding and remittance of taxes imposed under applicable law, or the funding of related amounts for which liability may
arise under such applicable law. Without limiting the generality of the foregoing, an optionee who wishes to exercise an Option
must, as a condition of exercise, comply with the various procedures set out in the New Option Plan, including but not limited
to delivering to the Company an amount determined by the Company to be appropriate to account for such taxes or related amounts,
and must in all other respects follow any related procedures and conditions imposed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Adjustment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The New
Option Plan contains provisions for the adjustment in the number of Common Shares subject to the New Option Plan and issuable
upon the exercise of Options, and the exercise price thereof in the event of any stock dividend, stock consolidations, subdivisions
or reclassifications of shares, amalgamations, mergers, plans of arrangement, change of control (as defined in the New Option
Plan) transactions, take-over bid transactions or events which the Board determines affects the Common Shares such that an adjustment
is appropriate to prevent dilution or enlargement of the rights of persons eligible to receive Options under the New Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Termination
of, and Amendments to, the New Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Subject
to acceptance of the TSXV and other applicable regulatory authorities, and the policies and requirements thereof, the Board may
terminate, suspend or amend the terms of the New Option Plan; provided, however that the Board must obtain shareholder approval
(and where required, disinterested shareholder approval) for the following actions:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">increasing
                                         the maximum number of Common Shares that may be reserved for issuance upon the exercise
                                         of Options under the New Option Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">placing
                                         limitations on the number of Options that may be granted to any one person or category
                                         of persons;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">reducing
                                         the exercise price of Options;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">granting
                                         to insiders, within a 12-month period, an aggregate number of Options exceeding 10% of
                                         the Company&rsquo;s issued Common Shares, calculated at the date that the applicable
                                         Option is granted;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">granting
                                         to any one optionee, within a 12-month period, an aggregate number of Options exceeding
                                         5% of the Company&rsquo;s issued Common Shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">reserving
                                         for issuance such number of Common Shares under the New Option Plan and all of the Company&rsquo;s
                                         other security based compensation arrangements in existence from time to time, where
                                         such reservation could result in the aggregate number of Common Shares granted to insiders
                                         exceeding 10% of the Company&rsquo;s issued Common Shares;</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">materially
                                         modifying the requirements as to eligibility for participation in the New Option Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">materially
                                         increasing the benefits accruing to participants under the New Option Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">modifying
                                         the method for determining the exercise price of the Options;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">modifying
                                         the maximum term of the Options;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">modifying
                                         the expiry and termination provisions applicable to Options;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">expanding
                                         the types of awards which may be granted under the New Option Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">extending
                                         the duration of the New Option Plan; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">modifying
                                         the termination and amendment provision of the New Option Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 11pt">Notwithstanding
the above, the Board may, without shareholder approval:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">make
                                         any amendment of a typographical, grammatical, clerical or administrative nature or clarification
                                         correcting or rectifying any ambiguity, immaterial inconsistency, defective provision,
                                         mistake, or error or omission in the New Option Plan or any Option;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">make
                                         any addition to, deletion from or alteration of the provisions of the New Option Plan
                                         or any Option that are necessary to comply with applicable law or the requirements of
                                         any regulatory or governmental agency or applicable stock exchange and to avoid unanticipated
                                         consequences deemed by the Board to be inconsistent with the purpose of the New Option
                                         Plan; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">make
                                         any amendments to clarify existing provisions of the new Option Plan or any Option provided
                                         that such changes do not have the effect of altering the scope, nature and intent of
                                         the New Option Plan or any Option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 11pt"><B>Option
Plan Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Under
the requirements of the TSXV and the Nasdaq, the New Option Plan must be approved by a simple majority of the votes cast by the
Company&rsquo;s shareholders at the Meeting. The New Option Plan is intended to serve as the successor to the Existing Option
Plan. If approved, the New Option Plan will become effective and replace the Existing Option Plan in its entirety. All outstanding
Options granted under the Existing Option Plan prior to February 28, 2017 shall be governed solely by the terms and conditions
of the instrument evidencing such Options and the Existing Option Plan; whereas each Option granted on or after February 28, 2017
will be governed solely by the terms and conditions of the instrument evidencing such Option and the New Option Plan. Pursuant
to the New Option Plan, the Company will continue to grant Options to purchase Common Shares to selected directors, officers,
employees and consultants of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>The
Board continues to believe that Options are an important element of the Company&rsquo;s compensation structure and unanimously
recommends that you vote &ldquo;for&rdquo; in respect of the Option Plan Resolutions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&ldquo;BE IT RESOLVED AS AN
ORDINARY RESOLUTION THAT:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The stock
                                         option plan (the &ldquo;New Option Plan&rdquo;) of ESSA Pharma Inc. (the &ldquo;Company&rdquo;)
                                         in substantially the form described in, and appended to, the management information circular
                                         of the Company dated February 23, 2018, be and the same is hereby ratified, confirmed
                                         and approved, subject to acceptance by the TSX Venture Exchange, and shall thereafter
                                         continue and remain in effect until ratification is required pursuant to the rules of
                                         the TSX Venture Exchange or other applicable regulatory requirements.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The number
                                         of common shares of the Company reserved for issuance under the New Option Plan, together
                                         with the Company&rsquo;s amended and restated stock option plan dated March 8, 2017 and
                                         the Company&rsquo;s other equity incentives plans in existence from time to time, is
                                         23,104,377.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">All unallocated
                                         options to acquire common shares of the Company, rights or other entitlements available
                                         under the New Option Plan are hereby approved and authorized.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The board
                                         of directors of the Company is authorized and directed to make any changes to the New
                                         Option Plan, if required by the TSX Venture Exchange.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Any one
                                         director or officer of the Company is authorized and directed on behalf of the Company,
                                         to take all necessary steps and proceedings and to execute, deliver and file any and
                                         all declarations, agreements, documents and other instruments, and do all such other
                                         acts and things that may be necessary or desirable to give effect to the foregoing resolutions.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">APPROVAL
OF STOCK OPTION RE-GRANT AND REPRICING, AND EXTENSION OF EXPIRY DATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The significant
drop in the trading price of the Company&rsquo;s Common Shares on the TSXV has meant that the outstanding incentive stock options
as currently priced no longer offer an adequate incentive to directors, officers, employees and consultants of the Company. Recognizing
that the stock option grants are a critical element of the Company&rsquo;s compensation policy, the Board is of the view that
it is in the best interests of the Company to re-grant and reprice, and to extend the expiry date of certain of the outstanding
stock options granted to certain directors, officers, employees and consultants of the Company, to be more in line with the market
price of the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">By directors&rsquo;
resolution effective February 21, 2018, the Board resolved that, subject to approval of the TSXV and the Company&rsquo;s shareholders
by way of disinterested shareholder approval at the Meeting, that the existing outstanding Options held by certain directors,
officers, employees and consultants of the Company be cancelled and replaced by an aggregate of up to 1,667,000 Options under
the New Option Plan, and that the expiry date thereof be extended as further set out in the table below. The Company received
confirmation from the TSXV of its acceptance of the cancellation of the Company&rsquo;s outstanding Options and replacement thereof
by an aggregate of up to 1,667,000 Options, as further set out in the table below; however, such replacement Options are not exercisable
until such time as the Company has obtained disinterested shareholder approval. For a description of the Company&rsquo;s New Option
Plan, see &ldquo;<I>Approval of Stock Option Plan</I>&rdquo; above.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #BFBFBF">
    <TD STYLE="border: Black 1pt solid; padding-top: 6pt; text-align: center; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 10pt"><B>Existing
    Outstanding Options Cancelled</B></FONT></TD>
    <TD COLSPAN="5" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 10pt"><B>Options
    Granted</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #F2F2F2">
    <TD STYLE="width: 10%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 3pt"><FONT STYLE="font-size: 10pt"><B>Name
    of Optionee</B></FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date
    of Grant</B></FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry
    Date</B></FONT></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Current
    Exercise Price</B></FONT></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No.
    of Optioned Common Shares</B></FONT></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No.
    Of Optioned Common Shares</B></FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise
    Price</B></FONT></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry
    Date</B></FONT></TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Vesting
    Schedule</B></FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Conditions
    to Exercise</B></FONT></TD></TR>
<TR>
    <TD NOWRAP ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Wood</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Oct-13</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Oct-18</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Oct-23</FONT></TD>
    <TD ROWSPAN="12" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Vesting
    in 48 equal instalments, with the first instalment vesting on March 21, 2018, and subsequent instalments vesting every one
    month anniversary thereafter</FONT></TD>
    <TD ROWSPAN="12" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
    Shareholder Approval for the respective grant is obtained at the Meeting</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30-Jul-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30-Jul-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$2.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30-Jul-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Kally
    Singh</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Gary
    Sollis</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Richard
    Glickman</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Daisy
    Wong</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Frank
    Perabo</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">8-Sep-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">8-Sep-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$2.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">450,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">160,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">8-Sep-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Leah
    DiMascio</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">19-Dec-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">2-Dec-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$2.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">19-Dec-24</FONT></TD></TR>
<TR>
    <TD NOWRAP ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Parkinson</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12-Jan-16</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12-Jan-21</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$6.25</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12-Jan-26</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">23-Jun-15</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">23-Jun-25</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$14.90</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">23-Jun-25</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Peter
    Virsik</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">9-Aug-16</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">9-Aug-21</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$3.49</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">290,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">290,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">9-Aug-26</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Franklin
    Berger</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">5-Mar-15</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">3-Mar-25</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$5.35</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">5-Mar-25</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">No financial
assistance will be provided to the option holders listed above by the Company to facilitate the exercise of the Options described
above.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Repricing
Resolution</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the policies of the TSXV and the New Option Plan, the re-grant and repricing of the Options, and the extension of the expiry
dates thereof, as further described above, requires disinterested shareholder approval. Disinterested shareholder approval is
the approval by a majority of the votes cast on the ordinary resolution by all shareholders at the Meeting, excluding the votes
attached to Common Shares beneficially owned by insiders (as defined under the policies of the TSXV) of the Company to whom options
may be granted under the New Option Plan and their associates (as defined under the policies of the TSXV). Based on the present
shareholdings of the insiders to whom Options may be granted under the New Option Plan and their associates, a total of up to
<B>[43,948,796]</B> Common Shares will be excluded from voting on the Repricing Resolution (as defined below), representing <B>[38.04]%
</B>of the issued and outstanding Common Shares as of the Record Date. The replacement Options cannot be exercised by their respective
holders unless and until the grants thereof are ratified, confirmed and approved by the Company&rsquo;s disinterested shareholders
at the Meeting. Accordingly, at the Meeting, the Company&rsquo;s disinterested shareholders will be asked to consider, and if
thought fit, to pass with or without amendment, an ordinary resolution as follows (the &ldquo;<B>Repricing Resolution</B>&rdquo;).</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Management
unanimously recommends that you vote &ldquo;for&rdquo; in respect of the Repricing Resolution. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;BE
IT RESOLVED AS AN ORDINARY RESOLUTION, with votes of certain insiders and their associates excluded therefrom, THAT:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The re-grant
                                         and re-pricing, and the extension of the expiry dates of stock options exercisable for
                                         an aggregate of up to 1,667,000 common shares of ESSA Pharma Inc. (the &ldquo;Company&rdquo;),
                                         previously granted to such persons, all as set out below, be and is hereby ratified,
                                         confirmed and approved:</FONT></TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #BFBFBF">
    <TD STYLE="border: Black 1pt solid; padding-top: 6pt; text-align: center; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 10pt"><B>Existing
    Outstanding Options Cancelled</B></FONT></TD>
    <TD COLSPAN="5" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 10pt"><B>Options
    Granted</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #F2F2F2">
    <TD STYLE="width: 10%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 3pt"><FONT STYLE="font-size: 10pt"><B>Name
    of Optionee</B></FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date
    of Grant</B></FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry
    Date</B></FONT></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Current
    Exercise Price</B></FONT></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No.
    of Optioned Common Shares</B></FONT></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No.
    Of Optioned Common Shares</B></FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise
    Price</B></FONT></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry
    Date</B></FONT></TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Vesting
    Schedule</B></FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; padding: 6pt 3pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Conditions
    to Exercise</B></FONT></TD></TR>
<TR>
    <TD NOWRAP ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Wood</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Oct-13</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Oct-18</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Oct-23</FONT></TD>
    <TD ROWSPAN="12" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Vesting
    in 48 equal instalments, with the first instalment vesting on March 21, 2018, and subsequent instalments vesting every one
    month anniversary thereafter</FONT></TD>
    <TD ROWSPAN="12" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
    Shareholder Approval for the respective grant is obtained at the Meeting</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30-Jul-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30-Jul-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$2.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30-Jul-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Kally
    Singh</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Gary
    Sollis</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Richard
    Glickman</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Daisy
    Wong</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">20-May-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-May-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Frank
    Perabo</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">8-Sep-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">8-Sep-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$2.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">450,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">160,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">8-Sep-24</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Leah
    DiMascio</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">19-Dec-14</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">2-Dec-19</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$2.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">19-Dec-24</FONT></TD></TR>
<TR>
    <TD NOWRAP ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Parkinson</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12-Jan-16</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12-Jan-21</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$6.25</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">12-Jan-26</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">23-Jun-15</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">23-Jun-25</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$14.90</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">23-Jun-25</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Peter
    Virsik</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">9-Aug-16</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">9-Aug-21</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$3.49</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">290,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">290,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">9-Aug-26</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Franklin
    Berger</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">5-Mar-15</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">3-Mar-25</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$5.35</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">5-Mar-25</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The board
                                         of directors of the Company be and is hereby authorized in its absolute discretion to
                                         determine whether or not to proceed with the above resolution without further ratification
                                         or approval by the shareholders.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Any one
                                         director or officer of the Company is authorized and directed on behalf of the Company,
                                         to take all necessary steps and proceedings and to execute, deliver and file any and
                                         all declarations, agreements, documents and other instruments, and do all such other
                                         acts and things that may be necessary or desirable to give effect to the foregoing resolutions.&rdquo;</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">RATIFICATION
OF STOCK OPTION GRANTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">At the
Meeting, shareholders will be asked to consider, and if thought fit, to pass with or without amendment, an ordinary resolution
(the &ldquo;<B>Option Grant Resolution</B>&rdquo;) as set forth below to ratify, confirm and approve previous grants of Options
under the New Option Plan, exercisable for an aggregate of up to 14,523,000 common shares of the Company, to certain directors,
officers, employees and consultants of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In September
of 2017, ESSA announced that it will alter its strategic plans by discontinuing further clinical development of its EPI-506 N-terminal
domain (&ldquo;<B>NTD</B>&rdquo;) inhibitor of the androgen receptor (&ldquo;<B>AR</B>&rdquo;), and by focusing its research and
development resources on its next-generation NTD-inhibitor compounds. In order to properly incentivize and compensate certain
existing and new directors, officers, employees and consultants, and align such persons&rsquo; interests with those of the Company
and its shareholders, the Board granted an aggregate of 14,523,000 Options (collectively, the &ldquo;<B>New Options</B>&rdquo;)
under the New Option Plan to such individuals and on such terms as set out in the table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #F2F2F2">
    <TD STYLE="width: 16%; border: Black 1pt solid; padding: 6pt 3pt"><FONT STYLE="font-size: 10pt"><B>Name
    of Optionee</B></FONT></TD>
    <TD STYLE="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date
    of Grant</B></FONT></TD>
    <TD STYLE="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry
    Date</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise
    Price </B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No.
    of Optioned Common Shares</B></FONT></TD>
    <TD STYLE="width: 29%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Conditions
    to Exercise</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Vesting
    Schedule</B></FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Marianne
    Sadar</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1,600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
                                         Shareholder Approval for the respective grant is obtained at the Meeting</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">And</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Optionee
        and the Company enter into a consulting agreement or similar agreement, on mutually acceptable terms (with both parties
        acting reasonably)</FONT></P></TD>
    <TD ROWSPAN="20" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Vesting
    in 48 equal instalments, with the first instalment vesting on March 21, 2018, and subsequent instalments vesting every one
    month anniversary thereafter</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Raymond
    Andersen</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1,600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
                                         Shareholder Approval for the respective grant is obtained at the Meeting</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">And</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Optionee
        and the Company enter into a consulting agreement or similar agreement, on mutually acceptable terms (with both parties
        acting reasonably)</FONT></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Wood</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1,325,000</FONT></TD>
    <TD ROWSPAN="18" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
    Shareholder Approval for the respective grant is obtained at the Meeting</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Kally
    Singh</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">55,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Gary
    Sollis</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Richard
    Glickman</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">165,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Daisy
    Wong</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">113,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Leah
    DiMascio</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">225,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Parkinson</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">4,700,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Peter
    Virsik</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">3,460,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Franklin
    Berger</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">190,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Esther
    Valadez</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Gowri
    Sukumar</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Samantha
    Shorter</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">95,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Jasmine
    Lau</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Annie
    Zou</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Michele
    Benjamin</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">95,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Robyn
    Freels</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Scott
    Requadt</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">240,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Hugo
    Beekman</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">240,000</FONT></TD></TR>
<TR STYLE="background-color: #D9D9D9">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 3pt"><FONT STYLE="font-size: 11pt"><B>TOTAL
    Optioned Common Shares</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>14,523,000</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The New
Options cannot be exercised by their respective holders unless and until the grants thereof are ratified, confirmed and approved
by the Company&rsquo;s disinterested shareholders at the Meeting.</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Option
Grant Resolution</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the policies of the TSXV and the New Option Plan, the grants of New Options, as further described above, require disinterested
shareholder approval. Disinterested shareholder approval is the approval by a majority of the votes cast on the ordinary resolution
by all shareholders at the Meeting, excluding the votes attached to Common Shares beneficially owned by insiders (as defined under
the policies of the TSXV) of the Company to whom options may be granted under the New Option Plan and their associates (as defined
under the policies of the TSXV). Based on the present shareholdings of the insiders to whom Options may be granted under the New
Option Plan and their associates, a total of up to <B>[43,948,796]</B> Common Shares will be excluded from voting on the Option
Grant Resolution, representing <B>[38.04]</B>% of the issued and outstanding Common Shares as of the Record Date. If the Option
Grant Resolution is not approved by disinterested shareholders at the Meeting, the New Options cannot be exercised by their respective
holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Management
unanimously recommends that you vote &ldquo;for&rdquo; in respect of the Option Grant Resolution. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;BE
IT RESOLVED AS AN ORDINARY RESOLUTION, with votes of certain insiders and their associates excluded therefrom, THAT:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The grant
                                         of stock options under the stock option plan of ESSA Pharma Inc. (the &ldquo;Company&rdquo;),
                                         dated February 21, 2018, exercisable for an aggregate of up to 14,523,000 common shares
                                         of the Company, to such individuals and on such terms as set out in the table below,
                                         be and is hereby ratified, confirmed and approved:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #F2F2F2">
    <TD STYLE="width: 16%; border: Black 1pt solid; padding: 6pt 3pt"><FONT STYLE="font-size: 10pt"><B>Name
    of Optionee</B></FONT></TD>
    <TD STYLE="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date
    of Grant</B></FONT></TD>
    <TD STYLE="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry
    Date</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise
    Price </B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No.
    of Optioned Common Shares</B></FONT></TD>
    <TD STYLE="width: 29%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Conditions
    to Exercise</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Vesting
    Schedule</B></FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Marianne
    Sadar</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1,600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
                                         Shareholder Approval for the respective grant is obtained at the Meeting</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">And</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Optionee
        and the Company enter into a consulting agreement or similar agreement, on mutually acceptable terms (with both parties
        acting reasonably)</FONT></P></TD>
    <TD ROWSPAN="20" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Vesting
    in 48 equal instalments, with the first instalment vesting on March 21, 2018, and subsequent instalments vesting every one
    month anniversary thereafter</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Raymond
    Andersen</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1,600,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
                                         Shareholder Approval for the respective grant is obtained at the Meeting</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">And</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Optionee
        and the Company enter into a consulting agreement or similar agreement, on mutually acceptable terms (with both parties
        acting reasonably)</FONT></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Wood</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1,325,000</FONT></TD>
    <TD ROWSPAN="18" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">Disinterested
    Shareholder Approval for the respective grant is obtained at the Meeting</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Kally
    Singh</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">55,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Gary
    Sollis</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Richard
    Glickman</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">165,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Daisy
    Wong</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">113,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Leah
    DiMascio</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">225,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Parkinson</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">4,700,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Peter
    Virsik</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">3,460,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Franklin
    Berger</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">190,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Esther
    Valadez</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Gowri
    Sukumar</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Samantha
    Shorter</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">95,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Jasmine
    Lau</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Annie
    Zou</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Michele
    Benjamin</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">95,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Robyn
    Freels</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">C$0.245</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">30,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Scott
    Requadt</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">240,000</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-size: 10pt">Hugo
    Beekman</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2018</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">21-Feb-2028</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">US$0.20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">240,000</FONT></TD></TR>
<TR STYLE="background-color: #D9D9D9">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 3pt"><FONT STYLE="font-size: 11pt"><B>TOTAL
    Optioned Common Shares</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>14,523,000</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Any one
                                         director or officer of the Company is authorized and directed on behalf of the Company,
                                         to take all necessary steps and proceedings and to execute, deliver and file any and
                                         all declarations, agreements, documents and other instruments, and do all such other
                                         acts and things that may be necessary or desirable to give effect to the foregoing resolutions.&rdquo;</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">APPROVAL
OF COMMON SHARE CONSOLIDATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">At the
Meeting, shareholders will be asked to consider, and if thought fit, to pass with or without amendment, a special resolution set
forth below (the &ldquo;<B>Share Consolidation Resolution</B>&rdquo;) to approve a consolidation (the &ldquo;<B>Consolidation</B>&rdquo;)
of the issued and outstanding Common Shares on a basis of up to 20 pre-Consolidation Common Shares being consolidated into one
post-Consolidation Common Share, or such lesser number of pre-Consolidation Common Shares as may be accepted by the TSXV and approved
by the Board, in its sole discretion. Approval of the Share Consolidation Resolution does not necessarily mean that the Board
will implement the Consolidation. Even if the Share Consolidation Resolution is approved by shareholders at the Meeting, and accepted
by the TSXV, the Board will have the discretion not to proceed with the Consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In connection
with the Consolidation, each stock option, warrant or other security of the Company convertible into pre-Consolidation Common
Shares (the &ldquo;<B>Convertible Securities</B>&rdquo;) that has not been exercised or cancelled prior to the effective date
of the implementation of the Consolidation will be adjusted pursuant to the terms thereof at the same Consolidation ratio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">As at
the date hereof, a total of 115,521,889 Common Shares in the capital of the Company were issued and outstanding. Accordingly,
if the Consolidation is put into effect on the basis of the maximum authorized ratio of 20 pre-Consolidation Common Shares for
every one post-Consolidation Common Share, a total of approximately 5,776,094 Common Shares in the capital of the Company would
be issued and outstanding following the Consolidation, assuming no other changes to the issued capital.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Purpose
of the Consolidation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
believes the Consolidation to be in the best interest of the Company because it believes that the Consolidation is the only opportunity
to avoid a delisting of the Common Shares from the Nasdaq, on which the Common Shares are currently listed and posted for trading
in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The continued
listing requirements of the Nasdaq include that a security must maintain a bid price of at least $1.00 per Common Share. On July
20, 2017, the Company announced that it had received a letter from the Nasdaq indicating, among other things, that the minimum
closing bid price of the Common Shares had fallen below $1.00 per Common Share for 30 consecutive trading days, and therefore,
the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the &ldquo;<B>Rule</B>&rdquo;). The letter required the
Company to regain compliance with the Rule by January 15, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">On January
16, 2018, the Company was granted an additional 180 calendar days, or until July 16, 2018, to regain compliance with the Rule.
To regain compliance, the closing bid price of the Common Shares must be above $1.00 per Common Share for a minimum of ten consecutive
business days. A decrease in the number of issued and outstanding Common Shares resulting from the Consolidation should, absent
other factors, help to ensure that the Company&rsquo;s closing bid price per Common Share remains above $1.00 per Common Share.
However, no assurance can be given that the Company will regain compliance during that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Procedure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In the
event the Consolidation is approved by the shareholders, accepted by the TSXV, and implemented by the Board, the registered holders
of Common Shares will be required to exchange the certificates representing their pre-Consolidation Common Shares for new certificates
representing post-Consolidation Common Shares. Following the determination of the Consolidation ratio by the Board, and as soon
as possible following the effective date of the Consolidation, the registered holders of Common Shares of the Company will be
sent a transmittal letter by the Company&rsquo;s transfer agent, Computershare. The letter of transmittal will contain instructions
on how to surrender Common Share certificate(s) representing pre-Consolidation Common Shares to the transfer agent. The transfer
agent will forward to each registered shareholder who has sent the required documents a new Common Share certificate representing
the number of post-Consolidation Common Shares to which the shareholder is entitled.</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Shareholders
will not have to pay a transfer or other fee in connection with the exchange of certificates. Shareholders should not submit certificates
for exchange until required to do so. Until surrendered, each certificate formerly representing the Common Shares will be deemed
for all purposes to represent the number of Common Shares to which the holder thereof is entitled as a result of the Consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Other
Considerations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Consolidation
will not materially affect the percentage ownership in the Company by shareholders even though such ownership will be represented
by a lesser number of Common Shares. The Consolidation will proportionately reduce the number of Common Shares held by all the
shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">There
can be no assurance that the market price of the post-Consolidation Common Shares will increase as a result of the Consolidation.
There are numerous factors and contingencies that could affect the price of the Common Shares, including the status of the market
for the Common Shares at the time, the Company&rsquo;s operations and general economic, stock market and industry conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Accordingly,
the total market capitalization of the Common Shares after the Consolidation may be lower than the total market capitalization
before the Consolidation, and, in the future, the market price of the post-Consolidation Common Shares may not exceed or remain
higher than the market price prior to the Consolidation. As a result, the marketability and trading liquidity of the post-Consolidation
Common Shares of the Company may not improve. The Consolidation may result in some shareholders owning &ldquo;odd lots&rdquo;
of Common Shares which may be more difficult for such shareholders to sell or which may require greater transaction costs per
share to sell. If the Consolidation is implemented and the market price of the Common Shares declines, the percentage decline
may be greater than would occur in the absence of the Consolidation. The market price of the Common Shares will, however, also
be based on the Company&rsquo;s performance and other factors, which are unrelated to the number of Common Shares outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">No fractional
Common Shares will be issued pursuant to the Consolidation. Pursuant to Section 83 of the <I>Business Corporations Act </I>(British
Columbia), in the event that a shareholder would otherwise be entitled to a fractional Common Share hereunder, the number of Common
Shares issued to such shareholder shall be rounded up to the next greater whole number of Common Shares, if the fractional entitlement
is equal to or greater than 0.5 and shall, without any additional compensation, be rounded down to the next lesser whole number
of Common Shares if the fractional entitlement is less than 0.5.</FONT></P>

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Share
Consolidation Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the <I>Business Corporations Act </I>(British Columbia), the Company&rsquo;s constating documents, and the requirements of
the TSXV, the Share Consolidation Resolution must be passed by two-thirds of the votes cast by shareholders present in person
and represented by proxy at the Meeting. In the event that the Share Consolidation Resolution is not passed by a special resolution,
the Company will not proceed with the Consolidation. The Consolidation is also subject to the approval of the TSXV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Management
unanimously recommends that you vote &ldquo;for&rdquo; in respect of the Share Consolidation Resolution.</B></FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;BE
IT RESOLVED AS A SPECIAL RESOLUTION THAT:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The authorized
                                         share structure of ESSA Pharma Inc. (the &ldquo;Company&rdquo;) may be altered by consolidating
                                         all of the issued and outstanding common shares of the Company on the basis to be selected
                                         by the Company&rsquo;s board of directors, in its absolute discretion, provided that
                                         the consolidation shall be no greater than 20 pre-consolidation common shares for every
                                         one post-consolidation common share.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Any fractional
                                         common shares resulting from the consolidation of the common shares be converted to whole
                                         common shares pursuant to the provisions of Section 83 of the <I>Business Corporations
                                         Act</I> (British Columbia).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The board
                                         of directors of the Company is hereby authorized, at any time in its absolute discretion,
                                         to determine whether or not to proceed with the above resolution without further approval,
                                         ratification or confirmation by the shareholders.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Any one
                                         director or officer of the Company is authorized and directed on behalf of the Company,
                                         to take all necessary steps and proceedings and to execute, deliver and file any and
                                         all declarations, agreements, documents and other instruments, and do all such other
                                         acts and things that may be necessary or desirable to give effect to the foregoing resolutions.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">APPROVAL
OF RSU PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">At the
Meeting, shareholders will be asked to consider, and if thought fit, pass with or without amendment, an ordinary resolution set
forth below (the &ldquo;<B>RSU Plan Resolution</B>&rdquo;) to ratify, confirm and approve the Company&rsquo;s restricted share
unit plan (the &ldquo;<B>RSU Plan</B>&rdquo;) and to reserve Common Shares from treasury for issuance under the RSU Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
has adopted the RSU Plan for the benefit of the Company&rsquo;s directors, officers, employees and consultants, on February 21,
2018. The RSU Plan has been established as a vehicle by which equity-based incentives may be awarded to the employees, consultants,
directors and officers of the Company, to recognize and reward their significant contributions to the long-term success of the
Company including to align the employees&rsquo;, consultants&rsquo; directors&rsquo; and officers&rsquo; interests more closely
with the shareholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
intends to use Restricted Share Units (&ldquo;<B>RSUs</B>&rdquo;) issued under the RSU Plan, as well as the Options issued under
the New Option Plan as part of the Company&rsquo;s overall executive compensation plan. Since the value of RSUs increase or decrease
with the price of the Common Shares, RSUs reflect a philosophy of aligning the interests of holders there with those of the shareholders
by tying compensation to share price performance. In addition, RSUs assist in the retention of qualified and experienced persons
by rewarding those individuals who make a long term commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Particulars
of the RSU Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">A summary
of certain provisions of the RSU Plan is set out below. This summary is qualified in its entirety by the full text of the RSU
Plan which is attached as Schedule B to this Circular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Administration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The RSU
Plan is administered by the Compensation Committee of the Board (in this section, the &ldquo;Committee&rdquo;) or such other committee
as the Board determines. Subject to the limitations of the RSU Plan, without limiting the generality of the foregoing, the Committee
has the power to: (i) interpret and administer the Plan; (ii) establish, amend and rescind any rules and regulations relating
to the Plan; (iii) make any other determinations that the Committee deems necessary or desirable for the administration and operation
of the RSU Plan; and (iv) prescribe, amend and rescind rules and procedures relating to the RSU Plan. The Board has the authority
to designate Eligible Persons and determine the grant of RSUs to them.</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Eligibility
Under the RSU Plans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the RSU Plan, RSUs may be granted to the following persons (collectively, the &ldquo;<B>Eligible Persons</B>&rdquo;), from
time to time by the Board, subject to the limitations set forth in the RSU Plan, but may not be granted when that grant would
be prohibited by or in breach of applicable laws or any black out period then in effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
director of the Company or any of its subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
officer of the Company or any of its subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
employee of the Company or any of its subsidiaries; and</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a consultant
                                         to the Company or any of its subsidiaries, which is an individual (or a corporation or
                                         partnership of which the individual is an employee, shareholder or partner), other than
                                         an employee, officer, management company employee or a director of the Company, that
                                         (i) is engaged to provide on a bona fide basis, consulting, technical, management or
                                         other services to the Company or any of its subsidiaries, other than services provided
                                         in relation to a distribution; (ii) provides the services under a written contract between
                                         the Company or a subsidiary of the Company and the individual or the consultant company;
                                         (iii) in the reasonable opinion of the Company, spends or will spend a significant amount
                                         of time and attention on the affairs and business of the Company or its subsidiaries;
                                         and (iv) has a relationship with the Company or a subsidiary of the Company that enables
                                         the individual to be knowledgeable about the business and affairs of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Common
Shares Reserved for Issuance Under the RSU Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The number
of Common Shares which may be reserved for issuance under the Plan, shall not exceed 23,104,377 Common Shares, provided that at
no time may the number of Common Shares issuable under any and all of the Company&rsquo;s equity incentive plans in existence
from time to time on and after the effective date of the Plan, including the New Option Plan, exceed 23,104,377 Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Limits
on RSU Grants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The RSU
Plan provides for the following limits on grants, unless approval by disinterested shareholders in accordance with the rules of
the TSXV is obtained:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the maximum
                                         number of Common Shares which may be issuable to insiders of the Company under the RSU
                                         Plan and all of the Company&rsquo;s other share compensation arrangement in existence
                                         from time to time may not exceed 10% of the issued and outstanding Common Shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the maximum
                                         number of Common Shares which may be issuable to any one Eligible Person under the RSU
                                         Plan and all of the Company&rsquo;s other share compensation arrangement in existence
                                         from time to time may not exceed 5% of the issued and outstanding Common Shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the maximum
                                         number of Common Shares which may be issuable to any one consultant under the RSU Plan
                                         and all of the Company&rsquo;s other share compensation arrangement in existence from
                                         time to time may not exceed 2% of the issued and outstanding Common Shares; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the maximum
                                         number of Common Shares which may be issuable to all Eligible Persons retained by the
                                         Company to provide investor relations activities (as defined by the policies of the TSXV)
                                         as a group, under the RSU Plan and all of the Company&rsquo;s other share compensation
                                         arrangement in existence from time to time may not exceed 2% of the issued and outstanding
                                         Common Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Grants
and Vesting of RSUs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Committee
may in its own discretion, at any time, and from time to time, grant RSUs to Eligible Persons as it determines appropriate, subject
to the limitations set out in the RSU Plan. Subject to the terms of the RSU Plan, the Committee may from time to time establish
the grant date and grant to any Eligible Person one or more RSUs as the Committee deems appropriate. RSUs shall vest pursuant
to the vesting schedule set out in an Eligible Person&rsquo;s grant agreement evidencing the grant of the particular RSUs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Notwithstanding
any other provision of the RSU Plan, the Committee may in its sole and absolute discretion accelerate and/or waive any vesting
or other conditions, for all or any RSUs for any Eligible Person at any time and from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Redemption
of RSUs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Unless
redeemed earlier in accordance with the RSU Plan and subject to any black-out periods then in effect, each one RSU will be redeemed
by the Company on or about its applicable vesting date and, at such time, the holder thereof will be entitled to receive (i) one
Common Share, (ii) cash representing the fair market value of such Common Share on the vesting date or (iii) a combination of
(i) and (ii) above, as determined by the Committee in its sole discretion. Certain holders of RSUs may defer the receipt of all
or any part of their entitlement to Common Shares and/or cash consideration in lieu of such Common Shares until a later date,
in accordance with, and subject to restrictions as further set out in the RSU Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Transferability
of RSUs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">RSUs
are non-assignable and non-transferable except by will or by the laws of descent and distribution. All benefits and rights granted
under the RSU Plan may only be exercised by the Eligible Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Cessation
of Employment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Unless
otherwise determined by the Committee in its sole discretion, or as specified in the applicable RSU agreement:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">subject
                                         to certain restrictions, if a holder of RSUs is terminated by the Company for cause or
                                         if a holder of RSUs voluntarily terminates his or her employment for any reasons or resigns
                                         as a director, as applicable, all of his or her RSUs that have not reached their respective
                                         redemption dates as at the date of termination will be cancelled, and all of his or her
                                         RSUs that have reached their respective redemption dates as at the date of termination
                                         but redemption thereof has been deferred by such holder will be redeemed as soon as possible
                                         for Common Shares, cash consideration in lieu thereof or a combination of both, as determined
                                         by the Committee in its sole discretion;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">subject
                                         to certain restrictions, in the event that the employment of a holder of RSUs is involuntarily
                                         terminated for reasons other than cause, his or her RSUs will be redeemed on the date
                                         of termination for Common Shares, cash consideration in lieu thereof or a combination
                                         of both, as determined by the Committee in its sole discretion, provided such RSUs have
                                         vested at such time;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">subject
                                         to certain restrictions, in the event that a director is not re-elected at an annual
                                         or special meeting of shareholders of the Company, his or her RSUs will be redeemed on
                                         the date of the annual or special meeting of shareholders for Common Shares, cash consideration
                                         in lieu thereof or a combination of both, as determined by the Committee in its sole
                                         discretion, provided such RSUs have vested at such time;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">subject
                                         to certain restrictions, in the event that an Eligible Person dies, his or her RSUs will
                                         be redeemed upon the date of death for Common Shares, Cash Consideration in lieu thereof
                                         or a combination of both, as determined by the Committee in its sole discretion; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">if an
                                         RSU holder&rsquo;s employment is terminated, for reasons other than cause, at any time
                                         within 12 months following a change of control (as defined in the RSU Plan), subject
                                         to the prior approval of the TSXV if required, the Company will redeem all outstanding
                                         RSUs granted to such holder, within 30 days following the date such holder provides actual
                                         service to the Company pursuant to a written notice of termination, for an equal number
                                         of Common Shares, cash consideration in lieu thereof or a combination of both, as determined
                                         by the Committee in its sole discretion. No fractional RSUs may be issued.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>No
Compensation for Cancelled RSUs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">An Eligible
Person ceases to be an eligible to receive RSUs under the RSU Plan on his or her last day of actual and active employment with
the Company or one of its subsidiaries. For the purposes of the RSU Plan, no period of notice of termination of employment that
is or ought to have been given to an Eligible Person, after the date on which the he or she ceases to be an Eligible Person shall
be included in determining such person&rsquo;s entitlement under the RSU Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Tax
Withholding</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Company
may take such steps as are considered necessary or appropriate for the withholding of any taxes which the Company is required
by any law or regulation of any governmental authority whatsoever to withhold in connection with any Common Share and/or cash
consideration including, without limiting the generality of the foregoing, the withholding of the issue of Common Shares and/or
the withholding of all or any portion of any payment of the cash consideration, as applicable, to be issued and/or paid under
the RSU Plan, until such time as the Eligible Person has paid the Company for any amount which the Company is required to withhold
with respect to such taxes or other amounts. Without limitation to the foregoing, the Committee may, if applicable, adopt administrative
rules under the RSU Plan which provide for the sale of Common Shares (or a portion thereof) in the market upon the issuance of
such Common Shares under the provisions of the RSU Plan to satisfy withholding obligations under the RSU Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Termination
of RSU Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
may terminate the RSU Plan at any time in its absolute discretion. If the RSU Plan is so terminated, no further RSUs will be granted,
but the RSUs then outstanding will continue in full force and effect in accordance with the provisions of the RSU Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Adjustments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The RSU
Plan contains provisions for the adjustment in the number of Common Shares subject to the RSU Plan and issuable on redemption
of RSUs in the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation, recapitalization,
amalgamation, plan of arrangement, reorganization, spin-off or other distribution (other than ordinary dividends) of the Company
assets to shareholders or any other similar corporate transaction or event which the Board determines affects the Common Shares
such that an adjustment is appropriate to prevent dilution or enlargement of the rights of Eligible Persons under the RSU Plan.</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Amendments
to the RSU Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Subject
to applicable laws and regulatory approvals, the RSU Plan may be amended without shareholder approval for the following:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments
                                         to the terms and conditions of the RSU Plan necessary to ensure that the RSU Plan complies
                                         with the applicable regulatory requirements, including the rules of the TSXV, in place
                                         from time to time;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments
                                         to the provisions of the RSU Plan respecting administration of the RSU Plan and eligibility
                                         for participation under the RSU Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments
                                         to the provisions of the RSU Plan respecting the terms and conditions on which RSUs may
                                         be granted pursuant to the plan, including the provisions relating to the payment of
                                         the RSUs; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">minor
                                         changes of a &ldquo;house-keeping nature&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Disinterested
shareholder approval is required for any amendments related to:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the number
                                         or percentage of issued and outstanding Common Shares available for grant under the RSU
                                         Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a change
                                         in the method of calculation of redemption of RSUs held by Eligible Persons; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">an extension
                                         to the term for redemption of RSUs held by Eligible Persons.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>RSU
Plan Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Pursuant
to the rules of the TSXV, the RSU Plan Resolution must be passed by a majority of the votes cast on the ordinary resolution by
all shareholders at the Meeting, excluding the votes attached to Common Shares beneficially owned by insiders (as defined under
the policies of the TSXV) of the Company to whom RSUs may be granted under the RSU Plan and their associates (as defined under
the policies of the TSXV). Based on the present shareholdings of the insiders to whom RSUs may be granted under the RSU Plan and
their associates, a total of up to <B>[43,948,796] </B>Common Shares will be excluded from voting on the RSU Plan Resolution,
representing <B>[38.04]</B>% of the issued and outstanding Common Shares as of the Record Date. If the RSU Plan Resolution is
not approved by disinterested shareholders at the Meeting, the RSU Plan will be terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Management
unanimously recommends that you vote &ldquo;for&rdquo; in respect of the RSU Plan Resolution.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;BE
IT RESOLVED AS AN ORDINARY RESOLUTION THAT:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The restricted
                                         share unit plan (the &ldquo;RSU Plan&rdquo;) of ESSA Pharma Inc. (the &ldquo;Company&rdquo;)
                                         in substantially the form described in, and appended to, the management information circular
                                         of the Company dated February 23, 2018, be and the same is hereby ratified, confirmed
                                         and approved, subject to acceptance by the TSX Venture Exchange, and shall thereafter
                                         continue and remain in effect until ratification is required pursuant to the rules of
                                         the TSX Venture Exchange or other applicable regulatory requirements.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The number
                                         of common shares of the Company reserved for issuance under the RSU Plan, together with
                                         the Company&rsquo;s other equity incentive plans in existence from time to time is 23,104,377.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">All unallocated
                                         restricted share units of the Company, rights or other entitlements available under the
                                         RSU Plan are hereby approved and authorized, and the Company will have the ability to
                                         issue restricted share units which may be settled in common shares of the Company.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The directors
                                         of the Company or any committee of the board of directors of the Company are hereby authorized
                                         to grant restricted share units pursuant to the RSU Plan to those eligible to receive
                                         restricted share units thereunder.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Notwithstanding
                                         that these resolutions be passed by the shareholders of the Company, the adoption of
                                         the RSU Plan is conditional upon receipt of final approval of the TSXV, and the board
                                         of directors of the Company is hereby authorized and empowered to make any changes to
                                         the RSU Plan, if required by the TSX Venture Exchange, or to revoke these resolutions,
                                         without any further approval of the shareholders of the Company, at any time if such
                                         revocation is considered is considered necessary or desirable to the board of directors.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Any one
                                         director or officer of the Company is authorized and directed on behalf of the Company,
                                         to take all necessary steps and proceedings and to execute, deliver and file any and
                                         all declarations, agreements, documents and other instruments, and do all such other
                                         acts and things that may be necessary or desirable to give effect to the foregoing resolutions.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">CORPORATE
GOVERNANCE</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">General</FONT></TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Corporate
governance refers to the policies and structure of the board of directors of a corporation, whose members are elected by and are
accountable to the shareholders of the corporation. Corporate governance encourages establishing a reasonable degree of independence
of the board of directors from executive management and adoption of policies to ensure the board of directors recognizes the principles
of good management. The Board is committed to sound corporate governance practices, as such practices are both in the interests
of shareholders and help to contribute to effective and efficient decision-making.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
believes that good corporate governance improves corporate performance and benefits all shareholders. The Canadian Securities
Administrators (the &ldquo;<B>CSA</B>&rdquo;) have adopted National Policy 58-201 <I>Corporate Governance Guidelines</I>, which
provides non-prescriptive guidelines on corporate governance practices for reporting issuers such as the Company. In addition,
the CSA have implemented National Instrument 58-101 <I>Disclosure of Corporate Governance Practices</I> (&ldquo;<B>NI 58-101</B>&rdquo;),
which prescribes certain disclosure by the Company of its corporate governance practices. This section sets out the Company&rsquo;s
approach to corporate governance and addresses the Company&rsquo;s compliance with NI 58-101.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Board
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
currently consists of eight directors: David R. Parkinson (President and Chief Executive Officer), Richard M. Glickman (Chairman
of the Board), Marianne Sadar (Chief Scientific Officer), Raymond Andersen (Chief Technical Officer), Gary Sollis, Franklin M.
Berger, Scott Requadt and Hugo Beekman.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
has adopted the Board Mandate, a copy of which is attached hereto as Schedule C. Pursuant to the Board Mandate, the Board is responsible
for the proper stewardship of the Company, and is mandated to represent the shareholders to select the appropriate Chief Executive
Officer (&ldquo;<B>CEO</B>&rdquo;), assess and approve the strategic direction of the Company, ensure that appropriate processes
for risk assessment, management and internal control are in place, monitor management performance against agreed bench marks,
develop the Company&rsquo;s approach to corporate governance, and assure the integrity of financial reports.</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Company&rsquo;s
approach to corporate governance is set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
assumes responsibility for the stewardship of the Company and the creation of shareholder value. The Board is responsible for,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-size: 11pt">(a)
adopting a strategic planning process and approving a strategic plan each year which takes into account, among other things, the
opportunities and risks of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-size: 11pt">(b)
reporting to the shareholders of the Company and developing a formal or informal communication policy that includes measures for
receiving feedback from the Company&rsquo;s shareholders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-size: 11pt">(c)
developing and formalizing the responsibilities for each member of the Board, including the responsibilities of the CEO vis-&agrave;-vis
corporate objectives;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 11pt">(d)
ensuring that the risk management of ESSA is prudently addressed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 11pt">(e)
overseeing succession planning for management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The frequency
of meetings of the Board and the nature of agenda items may change from year to year depending upon the activities of ESSA. However,
the Board meets at least quarterly and at each meeting there is a review of the business of ESSA. The Board facilitates its exercise
of independent supervision over the Company&rsquo;s management through regular meetings of the Board being held to obtain an update
on significant corporate activities and plans, both with and without members of the Company&rsquo;s management being in attendance.
Since the beginning of ESSA&rsquo;s most recently completed financial year, the independent directors of the Board held seven
meetings with additional in camera sessions following Audit Committee meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
is composed of eight directors, three of whom qualify as independent directors under applicable Canadian securities laws. For
this purpose, a director is independent if he or she has no direct or indirect &ldquo;material relationship&rdquo; with ESSA.
A &ldquo;material relationship&rdquo; is a relationship which could, in the view of the Board, be reasonably expected to interfere
with the exercise of the director&rsquo;s independent judgment. An individual who has been an employee or executive officer of
the Company within the last three years is considered to have a material relationship with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Of the
directors, Richard Glickman (Chair of the Board), Gary Sollis and Franklin M. Berger are considered independent. The following
five directors are not considered independent: (i) David R. Parkinson, President and Chief Executive Officer of the Company; (ii)
Marianne Sadar, Chief Scientific Officer of the Company; (iii) Raymond Andersen, Secretary and Chief Technical Officer of the
Company; (iv) Scott Requadt; and (v) Hugo Beekman. The Board has determined that Scott Requadt is not considered independent due
to his relationship with Clarus and the nomination rights granted to Clarus in relation to certain transactions involving the
Company. The Board has determined that Hugo Beekman is not considered independent due to his relationship with Omega and the nomination
right granted to Omega in relation to certain transactions involving the Company. For further information see heading &ldquo;<I>Voting
Securities and Principal Holders of Voting Securities</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The size
of the Company is such that all the Company&rsquo;s operations are conducted by a small management team which is also represented
on the Board. The Board believes that management is effectively supervised by the three independent directors, as the independent
directors are actively and regularly involved in reviewing the operations of the Company and have regular and full access to management
not represented on the Board. The Company encourages the independent judgment of the independent directors by providing direct
access to the Company&rsquo;s auditor and external consultants. The Chairman facilitates in camera sessions at Board and Audit
Committee meetings.</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Composition
of the Board is such that the independent directors have significant experience in corporate affairs. As a result, these Board
members are able to provide significant and valuable independent supervision over management.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 11pt">Directorships</FONT></TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
directors of the Company are also directors of other reporting issuers as set out below:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Name
    of Director</B></FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt"><B>Name
    of Reporting Issuer</B></FONT></TD>
    <TD NOWRAP STYLE="width: 31%; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt"><B>Name
    of Exchange Listed On</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left"><FONT STYLE="font-size: 11pt">Richard Glickman </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Cardiome
        Pharma Corp.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Aurinia
        Pharmaceuticals Corp.</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">TSX,
        Nasdaq</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">TSX</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left"><FONT STYLE="font-size: 11pt">Franklin M. Berger</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Five
        Prime Therapeutics, Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Immune
        Design Corp.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Proteostasis
        Therapeutics, Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Bellus
        Health, Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Tocagen
        Inc.</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">TSX</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left"><FONT STYLE="font-size: 11pt">David R. Parkinson</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">CTI Biopharma Corporation</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">3SBio
        Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Tocagen
        Inc.</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">HKG
        / SEHK</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: left"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left"><FONT STYLE="font-size: 11pt">Scott Requadt</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">VBI Vaccines, Inc.</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Nasdaq</FONT></TD></TR>
</TABLE>
<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-indent: 0in"><FONT STYLE="font-size: 11pt">Director
Attendance at Board Meetings</FONT></P>

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">The
directors&rsquo; attendance at Board, Audit Committee and Compensation Committee meetings since the beginning of ESSA&rsquo;s
most recently completed financial year is set forth in the table below. </FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 24%; border: Black 1pt solid; padding-top: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt"><B>Director</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Attendance
    at Board Meetings</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Attendance
    at Audit Committee Meetings</B></FONT></TD>
    <TD STYLE="width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Attendance
    at Compensation Committee Meetings</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr.
    David R. Parkinson</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">7/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Richard
    M. Glickman</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">6/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">5/6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">3/3</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr.
    Marianne Sadar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">7/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr.
    Raymond Andersen</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">7/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Gary
    Sollis</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">7/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">6/6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">3/3</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Franklin
    M. Berger</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">7/7
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">6/6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Scott
    Requadt</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">7/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">3/3
    </FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Hugo
    Beekman<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">1/7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Note:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.
Beekman was appointed to the Board on January 16, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">No Corporate Governance and
Nomination Committee meetings have been held since the beginning of the ESSA&rsquo;s most recently completed financial year.</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Position
Descriptions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
has not developed a written position description for the CEO, the Chairman of the Board and the chairs of each of the committees
of the Board. Given the size of the Company, the Board does not feel that it is necessary at this time to formalize such position
descriptions. Guidance is generally provided through reference to industry norms, past practice and relying upon the provisions
of the constating documents of the Company and the statutory and common law. The CEO is principally responsible for overseeing
the operations and affairs of the Company, including strategic organizational and financial management, business development,
regulatory compliance, and clinical development. The Chairman of the Board is principally responsible for overseeing the operations
and affairs of the Board. With respect to the chairs of each of the committees of the Board, it is currently the Board&rsquo;s
view that the general mandates of committees on which such directors may sit are sufficient to delineate the role and responsibilities
of the chair of each committee. The chair of each Board committee is required to ensure the committee meets regularly and performs
the duties as set forth in the committee mandate, and reports to the Board on the activities of the committee.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Orientation
and Continuing Education</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">ESSA
will provide new directors with copies of relevant financial, technical and other information regarding its research and development
programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Board
members are also encouraged to communicate with management and the Company&rsquo;s auditor, and to keep themselves current with
industry trends and developments. Board members have full access to the Company&rsquo;s records. The Company will support Board
members who wish to engage in ongoing director&rsquo;s education in particular areas to maintain the skill and knowledge necessary
to effectively perform their duties.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Ethical
Business Conduct</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
will from time to time discuss and emphasize the importance of matters relating to conflicts of interest, protection and proper
use of corporate assets and opportunities, confidentiality of corporate information, compliance with laws and the reporting of
any illegal or unethical behavior. ESSA has adopted a written code of business conduct and ethics (the &ldquo;<B>Code</B>&rdquo;)
which may be obtained from the Company&rsquo;s website at www.essapharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">It is
recognized within the Code that in certain situations, compliance may be difficult to monitor. The Code sets out a framework for
compliance. A compliance officer is appointed by the Board to deal with questions or concerns relating to compliance that cannot
be dealt with by management. The Board has also adopted a Whistle Blower Policy which sets forth the procedures for (i) the receipt,
retention and treatment of complaints and concerns regarding accounting, internal accounting controls and auditing matters; and
(ii) the confidential and anonymous submission of complaints or concerns regarding questionable accounting or auditing matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">In considering
transactions and agreements in respect of which a director or executive officer has a material interest, the Board ensures that
the individual director or executive officer abstains from the discussion and conclusion with respect to the transaction or agreement,
as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Corporation
is committed to maintaining the highest standards of corporate governance and this philosophy is continually communicated by the
Board to management which in turn is emphasized to the employees of the Corporation on a continuous basis.</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Nomination
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">It is
the view of the Board that all directors, individually and collectively, should assume responsibility for nominating directors.
The Board is responsible for identifying and recommending potential nominees for directorship and senior management. Additionally,
the Corporate Governance and Nomination Committee will, in consultation with the CEO, identify and recommend new directors with
appropriate skills for the Board. In making its recommendations, the Corporate Governance and Nomination Committee will consider
the competencies and skills of the existing directors, the competencies and skills of each new nominee, and the competencies and
skills considered necessary for the Board as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Assessments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
and each individual director are regularly assessed on effectiveness and contribution. The assessment considers and takes into
account:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">in
                                         the case of the Board, its mandate; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">in
                                         the case of an individual director, attendance at Board and committee meetings, the competencies
                                         and skills each individual director is expected to possess, and experience relevant to
                                         the Company at its current stage of development.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">For
further information, see director nominee considerations under heading &ldquo;<I>Board Committees&rdquo;</I>.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><FONT STYLE="font-size: 11pt">Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The CEO&rsquo;s
compensation is determined by the Board (excluding the CEO), based on the recommendation of the Board&rsquo;s Compensation Committee
(the &ldquo;<B>Compensation Committee</B>&rdquo;). The Compensation Committee, in making its recommendations regarding the CEO&rsquo;s
compensation, reviews and considers the Company&rsquo;s corporate goals and objectives as well as performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">For further
information, see heading &ldquo;<I>Statement of Executive Compensation &ndash; Compensation Discussion and Analysis &ndash; Compensation
Committee</I>&rdquo;.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Board
Committees</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
believes that its proper governance and effectiveness in carrying out its duties is greatly enhanced by the use of committees.
To assist in the discharge of its responsibilities, the Board has designated three standing committees: the Audit Committee (the
&ldquo;<B>Audit Committee</B>&rdquo;), the Compensation Committee and the Corporate Governance and Nomination Committee (the &ldquo;<B>Corporate
Governance and Nomination Committee</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Audit
Committee is comprised of Franklin Berger (Chair), Richard Glickman, and Gary Sollis all of whom are &ldquo;financially literate&rdquo;
as defined in National Instrument 52-110 <I>Audit Committees</I> (&ldquo;<B>NI 52-110</B>&rdquo;). Each member of the Audit Committee
is considered independent pursuant to NI 52-110, the rules of the Nasdaq and Rule 10A-3 under the 1934 Act. A description of the
education and experience of each Audit Committee member that is relevant to the performance of his responsibilities as an Audit
Committee member may be found above under the heading &ldquo;<I>Election of Directors &ndash; Director Biographies</I>&rdquo;.
The Audit Committee is responsible for reviewing the Company&rsquo;s financial reporting procedures, internal controls and the
performance of the financial management and the Company&rsquo;s auditor. The Audit Committee also reviews the annual audited financial
statements and makes recommendations to the Board. Details regarding the Audit Committee and its mandate are disclosed in the
Company&rsquo;s Annual Report on Form 20-F dated December 11, 2017, a copy of which is available on SEDAR at www.sedar.com and
on EDGAR at www.sec.gov, and in the Company&rsquo;s Audit Committee Charter set out therein, under the heading &ldquo;<I>Directors,
Senior Management and Employees &ndash; C. Board Practices &ndash; Audit Committee &ndash; Audit Committee Charter</I>&rdquo;.</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Compensation
Committee is composed of Scott Requadt (Chair), Richard Glickman, and Gary Sollis. Other than Scott Requadt, each member of the
Compensation Committee is considered independent pursuant to NI 52-110 and the rules of the Nasdaq. See heading &ldquo;<I>Election
of Directors - Director Biographies</I>&rdquo; above for a description of the education and experience of each of the members
of the Compensation Committee that is relevant to their performance as a Compensation Committee member. Each of the members of
the Compensation Committee is familiar with designing and reviewing executive compensation packages through his roles within those
companies described under the heading &ldquo;<I>Election of Directors &ndash; Director Biographies</I>&rdquo;. The Compensation
Committee determines compensation levels with reference to third party compensation surveys and other comparable information,
to ensure an objective process is taken in determining such compensation levels. For further information on the Compensation Committee,
see the heading &ldquo;<I>Statement of Executive Compensation &ndash; Compensation Discussion and Analysis &ndash; Compensation
Committee</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Corporate
Governance and Nomination Committee is composed of Gary Sollis (Chair), Scott Requadt, and Franklin Berger. Other than Scott Requadt,
each member of the Corporate Governance and Nomination Committee is considered independent pursuant to NI 52-110 and the rules
of the Nasdaq. See heading &ldquo;<I>Election of Directors - Director Biographies</I>&rdquo; above for a description and experience
of each of the members of the Corporate Governance and Nomination Committee that is relevant to their performance as a Corporate
Governance and Nomination Committee member. The Corporate Governance and Nomination Committee assists the Board in fulfilling
its responsibilities in relation to the monitoring and oversight of the quality and effectiveness of the Company&rsquo;s governance
practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Corporate
Governance and Nomination Committee will, in consultation with the CEO, identify and recommend new directors with appropriate
skills for the Board. In making its recommendations, the Corporate Governance and Nomination Committee will consider the competencies
and skills of the existing directors, the competencies and skills of each new nominee, and the competencies and skills considered
necessary for the Board as a whole. The Nomination Policy ensures that ESSA identifies nominees for the Board in compliance with
applicable securities laws and regulations and exchange requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Director
nominees will be recommended for the Board&rsquo;s selection by a minimum of two independent directors constituting a majority
of the Board&rsquo;s independent directors in a vote in which only independent directors participate. The term &ldquo;independent
director&rdquo; has the meaning given to such term in the listing standards of the Nasdaq. In making nominee recommendations,
such independent directors will consider:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD><FONT STYLE="font-size: 11pt">the
                                         competencies and skills considered necessary for the Board as a whole to possess;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD><FONT STYLE="font-size: 11pt">the
                                         competencies and skills that each existing director possesses;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD><FONT STYLE="font-size: 11pt">the
                                         competencies and skills each new nominee will bring to the Board; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD><FONT STYLE="font-size: 11pt">whether
                                         the nominee will be an independent director.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">In addition,
such independent directors will consider whether each new nominee can devote sufficient time and resources to his or her duties
as a member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Other
Board Committees</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
has from time to time designated, and may in the future designate, ad-hoc committees to assist in the discharge of its responsibilities.
During the financial year ended September 30, 2017, the Company designated an ad-hoc finance committee, composed of Richard Glickman,
Scott Requadt, Franklin M. Berger, Gary Sollis, and David R. Parkinson, to provide direction to the Company on financing options.</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Director
Term Limits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Company
has not adopted term limits for directors on the Board. It is the Company&rsquo;s view that the membership of its Board, including
the retirement of directors, is best assessed by the Board in consideration of a variety of factors, including individual director
performance, the existing mix of skills and experience of the members of the Board. The Company believes that the implementation
of term limits could require directors to retire, even when doing so would not be in the best interests of the Company, taking
into account the overall composition of the Board and a particular director&rsquo;s skills and experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Gender
Diversity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
of directors has adopted a written policy relating to the gender diversity of its directors and executive officers. The Company
values diversity of view, experience, skillset, gender and ethnicity as it believes this results in better leadership and decision
making for its business. Pursuant to such policy, gender diversity is one factor that is taken into account in identifying and
selecting Board members and in considering the hiring, promotion and appointment of executive officers. The Company does not have
specific targets respecting representation on its Board or in executive officer positions based on any particular personal experience
or characteristic, including gender. Instead, the Company focuses on choosing the most appropriate candidate for the position,
having regard to the experience, skillset, gender, ethnicity and other personal characteristics of both the candidate and, as
applicable, the Board and executive team as a whole. In conducting its search processes for Board and executive officer appointments,
the Company will review the extent to which its current appointees reflect gender diversity, and in assessing the appropriateness
of candidates for those appointments, will consider the desirability of an increased level of representation of females relative
to the level attained as at the date of the gender diversity policy. The Board will consider the Company&rsquo;s progress towards
achieving the objectives of the gender diversity policy, as well as the effectiveness of the policy, in connection with its continuing
mandate to consider the composition of the Board. Marianne Sadar is currently the only female on the Board and the only female
executive officer, representing 12.5% of the Company&rsquo;s directors and 20% of the executive officers.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">STATEMENT
OF EXECUTIVE COMPENSATION</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Named
Executive Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
individuals are defined as &ldquo;<B>named executive officers</B>&rdquo; or &ldquo;<B>NEOs</B>&rdquo; pursuant to Form 51-102F6
&ndash; <I>Statement of Executive Compensation</I>:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         CEO of ESSA or any person that acted in a similar capacity during the most recently completed
                                         fiscal year;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         Chief Financial Officer (the &ldquo;<B>CFO</B>&rdquo;) of ESSA or any person that acted
                                         in a similar capacity during the most recently completed fiscal year;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">each
                                         of the three most highly compensated executive officers of ESSA, including its subsidiary,
                                         ESSA Pharmaceuticals Corp., other than the CEO and the CFO, who were serving as executive
                                         officers at the end of the most recently completed fiscal year and whose total compensation
                                         was individually more than C$150,000 per year; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">any
                                         additional individuals for whom disclosure would have been provided under paragraph (c)
                                         except that the individual was not serving as an executive officer of ESSA at the end
                                         of the most recently completed financial year.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Each of
Dr. David R. Parkinson, the President and CEO of the Company, David Wood, CFO, Dr. Frank Perabo, former Executive Vice President
of Clinical Development and Chief Medical Officer (&ldquo;<B>EVP &amp; CMO</B>&rdquo;), Peter Virsik, Executive Vice President
and Chief Operating Officer (&ldquo;<B>EVP &amp; COO</B>&rdquo;), Dr. Paul Cossum, former Executive Vice President of Research
and Development (&ldquo;<B>EVP of R&amp;D</B>&rdquo;), and Dr. Marianne Sadar, Chief Scientific Officer (&ldquo;<B>CSO</B>&rdquo;),
is or was an NEO of the Company during the fiscal year ended September 30, 2017 for purposes of this disclosure.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Summary
of Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table sets forth all annual and long-term compensation for services paid to or earned by the named executive officers for the
three most recently completed financial years.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; border-left: Black 1pt solid; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and Principal Position</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Salary
    ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share-based
    awards ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option-based
    awards ($)<SUP>(1)</SUP></B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-bottom: 10pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Non-equity
    incentive Plan compensation&nbsp;($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pension
    Value ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>All
    Other Compensation </B><BR>
    <B>($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total
    Compensation </B><BR>
    <B>($)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Annual
    Incentive Plans </B><BR>
    <B>($)<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Long-term
    incentive plans </B><BR>
    <B>($)</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 19%; border-left: Black 1pt solid; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Dr.
                                         David R. Parkinson<SUP>(3)</SUP></B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>CEO, President</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Appointed January 7, 2016</I></FONT></P></TD>
    <TD STYLE="width: 6%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">436,450</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">329,532</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">3,000</FONT></P></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">527,526</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">707,120</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">204,483</FONT></P></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">963,976</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">1,036,652</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">207,483</FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>David
                                         Wood</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>CFO</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">227,761<SUP>(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">198,477<SUP>(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">197,668<SUP>(4)</SUP></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">9,953</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">70,218</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">90,960</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">25,539<SUP>(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">30,769<SUP>(4)</SUP></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">237,714</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">294,234</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">319,397</FONT></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Dr.
                                         Frank Perabo</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Former EVP &amp; CMO</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Resigned January 31, 2018</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">445,179</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">434,300</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">215,000</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">39,981</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">112,791</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">338,210</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">25,000</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">485,160</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">572,091</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">553,210</FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Peter
                                         Virsik</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>EVP &amp; COO</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Appointed August 1, 2016</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">365,000</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">60,833</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">210,714</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">32,991</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">575,714</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">93,824</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Dr.
                                         Paul Cossum</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Former EVP of R&amp;D</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Deceased July 2017</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">229,194</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">282,800</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">140,000</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">26,435</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">216,748</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">229,194</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">309,235</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">356,748</FONT></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Dr.
                                         Marianne Sadar</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>CSO and Director</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2,325</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">51,855<SUP>(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">141,749<SUP>(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">16,366<SUP>(4)</SUP></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">135,594<SUP>(4)(5)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">136,072<SUP>(4)(5)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">122,742<SUP>(4)(5)</SUP></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">187,449</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">277,821</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">141,433</FONT></P></TD></TR>
</TABLE>
<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">Notes:</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Option-based
                                         awards represent the vesting of stock options granted in the current and previous years
                                         under the Existing Option Plan. The Company&rsquo;s stock options are denominated in
                                         Canadian dollars and are converted at fair value to US dollars at the respective historical
                                         rates on grant date. The fair value of the stock options granted is calculated as of
                                         the grant date using the Black-Scholes option pricing model. This approach is consistent
                                         with the majority of companies in our industries and is sensitive to the assumptions
                                         used. Under this method, the weighted average fair value of stock options granted to
                                         the NEOs in 2017 was $nil (2016 &ndash; C$2.71, 2015 &ndash; C$3.36) using the following
                                         assumptions:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Annual
    dividends per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Expected
    stock price volatility</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">72.93%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">79.26%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Risk-free
    interest rate</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.63%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.52%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Expected
    life of options (in years)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">3.58</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">3.36</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Non-equity
                                         annual incentive plan compensation relates to discretionary cash bonuses that were granted
                                         to NEOs for the respective fiscal years. These bonuses were payable by their terms at
                                         the discretion of the Board.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Dr.
                                         David R. Parkinson was appointed to the Board of Directors on June 24, 2015, and as CEO
                                         and President on January 7, 2016. He earned $3,000, $14,750 and $nil in directors&rsquo;
                                         fees and $204,483, $707,120 and $527,526 in option-based awards in 2015, 2016 and 2017,
                                         respectively.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">These
                                         amounts were incurred in Canadian dollars and converted at the average rates of exchange
                                         for the respective fiscal years: 2017 &ndash; 0.7627; 2016 &ndash; 0.7546; 2015 &ndash;
                                         0.8205;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Dr.
                                         Marianne Sadar has a consulting agreement with the Company, pursuant to which she was
                                         paid a monthly fee of C$15,000.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">Compensation
Discussion and Analysis</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><FONT STYLE="font-size: 11pt">Performance
Graph</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table and graph compare the cumulative total shareholder return on C$100 invested in Common Shares of the Company with C$100 invested
in the S&amp;P/TSX Composite Index from January 27, 2015 (the day the Common Shares were listed on the TSXV) to September 30,
2017 (the Company&rsquo;s most recent financial year end). All dollar amounts are reflected in Canadian dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="vertical-align: bottom; width: 20%; border: Black 1pt solid; padding-top: 6pt; text-align: justify; padding-left: 3pt"><FONT STYLE="font-size: 11pt"><B>Date</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>January
    27, 2015</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>September
    30, 2015</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>September
    30, 2016</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>September
    30, 2017</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 3pt"><FONT STYLE="font-size: 11pt">ESSA&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$100</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$194.12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$84.71</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$8.47</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 3pt"><FONT STYLE="font-size: 11pt">S&amp;P/TSX
    Composite Index</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$100</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$87.41</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$98.48</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$104.13</FONT></TD></TR>
</TABLE>
<BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;&nbsp;</B></FONT><IMG SRC="image_002.jpg" ALT="" STYLE="height: 225; width: 670"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">The trend
in overall compensation paid to the NEOs over the past three years has generally not tracked the performance of the market price
of the Common Shares, nor has it tracked the S&amp;P/TSX Composite Index during the period. The Company has not included market
price targets of the Common Shares as a component of the Company&rsquo;s Executive Compensation Program (as defined below) and
strategy.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><FONT STYLE="font-size: 11pt">Compensation
Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Compensation
Committee is comprised of Scott Requadt (Chair), Richard Glickman and Gary Sollis. The Compensation Committee is responsible for
reviewing the compensation plans and severance arrangements for management, to ensure they are commensurate with comparable companies.
For a detailed description of the relevant experience of each member of the Compensation Committee, please see the section &ldquo;<I>Election
of Directors &ndash; Director Biographies</I>&rdquo; above. The Compensation Committee:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">reviews
                                         and makes recommendations to the Board about the objectives, performance and compensation
                                         of the CEO;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">reviews
                                         the recommendations of the CEO regarding: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">compensation
                                         of the senior executive officers of the Company that report to the CEO;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         compensation policy of the Company (the &ldquo;<B>Executive Compensation Program</B>&rdquo;),
                                         including internal structure, annual review and relationship to market levels and changes
                                         to ensure the relationship between senior management performance and compensation is
                                         appropriate; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">significant
                                         changes in Company&rsquo;s benefit plan and human resources policies with emphasis on
                                         overall strategy and programs relating to the recruitment, development and retention
                                         of personnel; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">recommends
                                         the issuance of stock options to employees, consultants, and directors which the Board
                                         then decides whether to approve; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">reviews
                                         overall compensation programs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Factors
that are taken into consideration when making compensation decisions include:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         financial resources available or expected to be available to the Company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">comparative
                                         compensations levels for companies of ESSA&rsquo;s size in the biopharmaceutical industry;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         capabilities of individual contributors to the Company&rsquo;s success;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the
                                         reasonable compensation expectations of the individual contributor; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">relative
                                         equity with other ESSA contributors.</FONT></TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><FONT STYLE="font-size: 11pt">Compensation
Discussion and Analysis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">ESSA&rsquo;s
compensation philosophy for NEOs is focused on its belief that capable and qualified employees are critical to the Company&rsquo;s
success. Therefore, its compensation plan is designed to attract the very best individuals in each expertise arena and to use
salaries and long term incentive compensation in the form of stock options or other suitable long-term incentives to attract and
retain such employees. In making its determinations regarding the various elements of executive stock option grants, ESSA will
seek to meet the following objectives:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">(a)
to attract, retain and motivate talented executives who create and sustain ESSA&rsquo;s continued success within the context of
compensation paid by other companies of comparable size engaged in similar business in appropriate regions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 11pt">(b)
to align the interests of the ESSA&rsquo;s NEOs with the interests of shareholders of ESSA; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 11pt">(c)
to incent extraordinary performance from the Company&rsquo;s key employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Elements
of Compensation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><U>Base
Salary</U> &ndash; The base salary review of any NEO takes into consideration the current competitive market conditions, experience,
proven or expected performance, and the particular skills of the NEO. Base salary is not evaluated against a formal &ldquo;peer
group&rdquo;. The base salaries for NEOs of ESSA as of the Company&rsquo;s most recently completed financial year were:</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 76%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>NEO</B></FONT></P></TD>
    <TD STYLE="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>BASE
        SALARY</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. David R. Parkinson (CEO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">$438,600/year</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">David Wood (CFO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">$230,000/year</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Peter Virsik (EVP &amp; COO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">$365,000/year</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. Frank Perabo (EVP &amp; CMO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">$447,372/year</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. Paul Cossum (EVP of R&amp;D)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">$291,312/year</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. Marianne Sadar (CSO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">C$180,000/year</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><U>Performance-Based
Cash Bonuses</U> &ndash; Cash bonuses are not a normal part of ESSA&rsquo;s executive compensation. However, the Company may elect
to utilize such incentives where the role-related context and competitive environment suggest that such a compensation modality
is appropriate. When and if utilized, the amount of cash bonus compensation will normally be paid on the basis of timely achievement
of specific pre-agreed milestones. Each milestone will be selected based upon consideration of its impact on shareholder value
creation and the ability of the Company to achieve the milestone during a specific interval. The amount of bonus compensation
will be determined based upon achievement of the milestone, its importance to the Company&rsquo;s near and long term goals at
the time such bonus is being considered, the bonus compensation awarded to similarly situated executives in similarly situated
development stage life-sciences companies or any other factors the Company may consider appropriate at the time such performance-based
bonuses are decided upon. The quantity of bonus will normally be a percentage of base salary not to exceed 100%. However, in exceptional
circumstances, the quantity of bonus paid may be connected to the shareholder value creation embodied in the pre-agreed milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">The
bonuses available to the NEOs as of September 30, 2017 were:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B>NEO</B></FONT></P></TD>
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>BONUS
        PAYABLE</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. David R. Parkinson (CEO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">Up to 50% of
    Base Salary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">David Wood (CFO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">Up to 30% of
    Base Salary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Peter Virsik (EVP &amp; COO) &#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">Up to 40% of
    Base Salary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. Frank Perabo (EVP &amp; CMO) &#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 11pt">Nil</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Dr. Marianne Sadar (CSO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">C$10,000
        per provisional patent application filed,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 11pt">C$10,000
        per publication completed</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">Up
to the date of this Circular, the Company has generally relied on a flexible and informal approach to executive compensation.</FONT></P>

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Stock
Options</U> &ndash; Options are a key compensation element for companies such as ESSA. Given that many of the most capable employees
in ESSA&rsquo;s industry work for pharmaceutical companies who can offer attractive cash and bonus compensation and a high level
of employment security, Options to purchase Common Shares of ESSA, governed by the Company&rsquo;s stock option plan represent
a compensation element that balances the loss of employment security that such employees must accept when moving to a small development-stage
company like ESSA. Options are also an important component of aligning the objectives of ESSA employees with those of shareholders.
ESSA has issued significant Options positions to senior employees and lesser amounts to lower-level employees. The precise amount
of Options offered was and continues to be governed by the importance of the role within ESSA, by the competitive environment
within which ESSA operates, by the regulatory limits on stock option grants that cover organizations such as ESSA, and by previous
Options granted, if applicable. This reflects ESSA&rsquo;s commitment to attracting and retaining world-level expertise to the
Company. The Options granted to the Company&rsquo;s NEOs as of the Company&rsquo;s most recently completed financial year are
as follows: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NEO</B></P></TD>
    <TD STYLE="width: 62%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OPTIONS</B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(223,222,222)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. David R. Parkinson (CEO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">50,000 Options (C$14.90 exercise price per Common Share, expiring June 23, 2025) and</FONT></P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">600,000 Options (C$6.25 exercise price per Common Share, expiring January 12, 2021)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">David Wood (CFO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">75,000 Options (C$0.80 exercise price per Common Share, expiring October 1, 2018) and</FONT></P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">200,000 Options (C$2.00 exercise price per Common Share, expiring July&nbsp;30, 2019)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(223,222,222)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Peter Virsik (EVP &amp; COO) &#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">290,000 Options (C$3.49 exercise price per Common Share, expiring August 9, 2021)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. Frank Perabo (EVP &amp; CMO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">450,000 Options (C$2.00 exercise price per Common Share, expiring September&nbsp;8, 2019)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(223,222,222)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. Paul Cossum (EVP of R&amp;D)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">400,000 Options (C$2.00 exercise price per Common Share, expiring April&nbsp;14, 2019)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. Marianne Sadar (CSO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">300,000 Options (C$0.80 exercise price per Common Share, expiring January 31, 2018)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Compensation-Related
Actions Subsequent to Most Recently Completed Financial Year</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">Following
the Company&rsquo;s most recently completed financial year, the Company adopted the New Option Plan, which is subject to shareholder
approval at the Meeting, and which is described in further detail under the heading &ldquo;<I>Approval of Stock Option Plan</I>&rdquo;
above. In addition, the Company re-granted and repriced, and extended the expiry dates of the Options held by certain Option holders,
including NEOs Dr. Parkinson, Mr. Wood, Mr. Virsik, Dr. Perabo, and Dr. Sadar, as further set out under the heading &ldquo;<I>Approval
of Stock Option Re-Grant and Repricing, and Extension of Expiry Dates</I>&rdquo; above. In addition, the Company granted additional
Options to certain persons, including Dr. Parkinson, Mr. Wood, Mr. Virsik, Dr. Perabo, and Dr. Sadar, as further set out under
the heading &ldquo;<I>Ratification of Stock Option Grants</I>&rdquo; above. The re-granted Options and the newly-granted Options
cannot be exercised by their respective holders until, among other things, the Company obtains disinterested shareholder approval
of the Repricing Resolution and the Option Grant Resolution, respectively, at the Meeting. Provided that the Repricing Resolution
and the Option Grant Resolution are passed by way of disinterested shareholder approval at the Meeting, and the Company obtains
all the necessary exchange and regulatory consents (including consent of the TSXV) and satisfies all other applicable regulatory
and exchange requirements, Options granted to the Company&rsquo;s NEOs will be as follows (on a pre-Consolidation basis):&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NEO</B></P></TD>
    <TD STYLE="width: 62%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OPTIONS</B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(223,222,222)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. David R. Parkinson (CEO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0; text-align: justify; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">600,000 Options (US$0.20 exercise price per Common Share, expiring January 12, 2026), 50,000</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Options (US$0.20 exercise price per Common Share, expiring June 23, 2025) and 4,700,000</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Options (US$0.20&nbsp;&nbsp;exercise price per Common Share, expiring February 21, 2028)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">David Wood (CFO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0; text-align: justify; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">75,000 Options (C$0.245 &nbsp;exercise price per Common Share, expiring October 1, 2023), 200,000</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Options (C$0.245 &nbsp;exercise price per Common Share, expiring July 30, 2024) and 1,325,000</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Options (C$0.245 &nbsp;exercise price per Common Share, expiring February 21, 2028)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(223,222,222)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Peter Virsik (EVP &amp; COO) &#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0; text-align: justify; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">290,000 Options (US$0.20 exercise price per Common Share, expiring August 9, 2026) and 3,460,000</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Options (US$0.20 &nbsp;exercise price per Common Share, expiring February 21, 2028)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. Frank Perabo (EVP &amp; CMO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">160,000 Options (US$0.20 exercise price per Common Share, expiring September 8, 2024)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(223,222,222)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. Paul Cossum (EVP of R&amp;D)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">400,000 Options (C$2.00 exercise price per Common Share, expiring April&nbsp;14, 2019)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dr. Marianne Sadar (CSO)&#9;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-size: 10pt">1,600,000 Options (C$0.245 exercise price per Common Share, expiring February 21, 2028)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">In
addition, subsequent to the Company&rsquo;s most recently completed financial year, the Board adopted the RSU Plan for the benefit
of the Company&rsquo;s directors, officers, employees and consultants, on February 21, 2018. The RSU Plan has been established
as a vehicle by which equity-based incentives may be awarded to the employees, consultants, directors and officers of the Company,
to recognize and reward their significant contributions to the long-term success of the Company including to align the employees&rsquo;,
consultants&rsquo; directors&rsquo; and officers&rsquo; interests more closely with the shareholders of the Company. The Board
intends to use RSUs issued under the RSU Plan, as well as the Options issued under the New Option Plan as part of the Company&rsquo;s
overall executive compensation plan. Since the value of RSUs increase or decrease with the price of the Common Shares, RSUs reflect
a philosophy of aligning the interests of holders there with those of the shareholders by tying compensation to share price performance.
In addition, RSUs assist in the retention of qualified and experienced persons by rewarding those individuals who make a long
term commitment. The RSU Plan is subject to the approval by a majority of the Company&rsquo;s disinterested shareholders at the
Meeting. For additional information regarding the RSU Plan and the RSU Plan Resolution, please see &ldquo;<I>Approval of RSU Plan</I>&rdquo;
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Compensation
Risks</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">The
Board has an active role in risk oversight regarding the Company&rsquo;s compensation policies and practices. In making its compensation-related
decisions, the Board considers all factors related to an executive&rsquo;s performance and carefully reviews and considers the
Company&rsquo;s compensation policy and the risks implicitly or explicitly connected to such compensation-related decisions. These
risks include the risks associated with employing executives who are not world-class in their capabilities and experience, the
risk of losing capable but under-compensated executives, and the financial risks connected to the Company&rsquo;s operations,
of which executive compensation is an important part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">In
adopting the compensation philosophy described above, the principal risks identified by ESSA are:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">that
                                         the Company will be forced to raise additional funding (causing dilution to shareholders)
                                         in order to attract and retain the calibre of executive employees that it seeks; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">that
                                         the Company will have insufficient funding to achieve its objectives.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">After
careful consideration of these risks, the Board has adopted the compensation policy described above.</FONT></P>

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">Directors
and NEOs are prohibited from directly or indirectly entering into short sales or buying or selling a call or put in respect of
the Company&rsquo;s securities. In addition, directors are not permitted to purchase financial instruments (including prepaid
variable forward contracts, equity swaps, collars or units of exchange funds) designed to hedge or offset a decrease in the market
value of ESSA&rsquo;s equity securities granted as compensation or held, directly or indirectly, by the director or NEO.</FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">NEO
Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">As
of September 30, 2017, ESSA had five NEOs: Dr. David R. Parkinson, President and CEO of the Company, David Wood, CFO, Peter Virsik,
EVP &amp; COO, Dr. Frank Perabo, EVP &amp; CMO, and Dr.&nbsp;Marianne Sadar, CSO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Defined
Benefits Plans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">ESSA
currently does not have a defined benefits pension plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Defined
Contribution Plans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">ESSA
currently does not have a defined contribution plan.</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Deferred
Compensation Plans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">ESSA
currently does not have a deferred compensation plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Termination
and Change of Control Benefits</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">Except
as described below, there are no contracts, agreements, plans or arrangements that provide for payments to a NEO at, following,
or in connection with any termination (whether voluntary, involuntary or constructive), resignation, retirement, a change in control
of the Company or its subsidiary or a change in a NEO&rsquo;s responsibilities (excluding perquisites and other personal benefits
if the aggregate of this compensation is less than C$50,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">The
Company has entered into employment agreements with certain NEOs, which provide for certain rights upon termination of employment
or a change of control of ESSA. ESSA believes that these provisions of the NEO employment agreements are reasonable in the context
of similar-sized biopharmaceutical companies. The Company expects to offer similar provisions to executive-level employees in
the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">Specific
termination and change-of-control provisions of each NEO include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">For
Dr. David R. Parkinson:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">A
                                         payment of six months of base salary upon termination without cause and a payment of
                                         one year of base salary upon termination without cause after 12 months of employment.
                                         This amount increases to 18 months if the termination without cause occurs after a change
                                         of control event or within 60 days prior to a change of control event where such event
                                         was under consideration at the time of termination. Had Dr.&nbsp;Parkinson&rsquo;s employment
                                         been terminated without cause on September&nbsp;30, 2017, he would have received $219,300.
                                         Had Dr.&nbsp;Parkinson&rsquo;s employment been terminated without cause after a change
                                         of control event or within 60 days prior to a change of control event where such event
                                         was under consideration at the time of termination, he would have received $657,900.
                                         </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Immediate
                                         vesting of all stock options upon occurrence of a change of control event. As of the
                                         date of this Circular, Dr.&nbsp;Parkinson held 650,000 Options, which had a value of
                                         <B>C$</B>nil based on the TSX closing price of C$0.37 per Common Share as at September
                                         29, 2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">For
David Wood:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">A
                                         payment to the employee of up to one year of base salary for termination without cause,
                                         whether or not the termination was caused by a change of control event. Had Mr.&nbsp;Wood
                                         been terminated without cause on September 30, 2017, whether or not the termination was
                                         caused by a change of control event, he would have received up to $230,000. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Immediate
                                         vesting of all stock options upon occurrence of a change of control event. As of the
                                         date of this Circular, Mr.&nbsp;Wood held 275,000 Options, which had a value of C$nil
                                         based on the TSX closing price of C$0.37 per Common Share as at September 29, 2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">For
Dr. Frank Perabo:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">A
                                         payment to the employee of up to one year of base salary for termination without cause,
                                         whether or not the termination was caused by a change of control event. Had Dr. Perabo
                                         been terminated without cause on September 30, 2017, he would have received $447,372.
                                         If there is a change of control, and continuing employment is not offered, Dr. Perabo
                                         will receive one year of base salary.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Immediate
                                         vesting of all stock options upon occurrence of a change of control event. As of the
                                         date of this Circular, Dr. Perabo held 450,000 Options, which had a value of C$nil based
                                         on the TSX closing price of C$0.37 per Common Share as at September 29, 2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">For
Mr. Peter Virsik:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">A
                                         payment of six months of base salary upon termination without cause and a payment of
                                         one year of base salary upon termination without cause after 12 months of employment.
                                         This amount increases to 18 months if the termination without cause occurs within 18
                                         months after a change of control event. Had Mr. Virsik&rsquo;s employment been terminated
                                         without cause on September&nbsp;30, 2017, he would have received $182,500. Had Mr. Virsik&rsquo;s
                                         employment been terminated without cause within 18 months after a change of control event,
                                         he would have received $547,500. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Immediate
                                         vesting of all stock options upon occurrence of a change of control event. As of the
                                         date of this Circular, Mr. Virsik held 290,000 Options, which had a value of C$nil based
                                         on the TSX closing price of C$0.37 per Common Share as at September 29, 2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt">For
Dr. Marianne Sadar:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 11pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">None</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><FONT STYLE="font-size: 11pt">Outstanding
Option-Based and Share-Based Awards</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table discloses the particulars of each NEO for awards outstanding at the end of the financial period ended on September 30, 2017.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD ROWSPAN="2" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and principal position</B></FONT></TD>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option-based
    Awards</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share-based
    Awards</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of securities underlying unexercised options</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option
    exercise price ($)<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option
    expiration date</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Value
    of unexercised in-the-money options ($)<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of shares or units of shares that have not vested</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Market
    or payout value of share- based awards that have not vested ($)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Market
    or payout value of vested share-based awards not paid out or distributed ($)</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr.
    David R. Parkinson (CEO)</FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">600,000</FONT></P></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">11.94</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">5.01</FONT></P></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">June
                                         23, 2025</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">January
        12, 2021</FONT></P></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">David
    Wood (CFO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">200,000</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">0.64</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">1.60</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">October
                                         1, 2018</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">July
        30, 2019</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Peter
    Virsik (EVP &amp; CMO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">290,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">2.80</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">August
    9, 2021</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr.
    Frank Perabo (EVP &amp; CMO)<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>4</B>50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1.60</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">September
    8, 2019</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr.
    Paul Cossum (EVP of R&amp;D)<SUP>(4)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">400,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">1.60</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">April
    14, 2019</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr.
    Marianne Sadar (CSO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">300,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">0.64</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">January
    31, 2018</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-style: normal">Notes:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">The
                                         Company&rsquo;s Options are granted based on exercise price in Canadian dollars; such
                                         amount has been converted to US dollars using the closing exchange rate of 0.8013 as
                                         of September 29, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based
                                         on a closing share price of $0.29 on the Nasdaq as of September 29, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Dr.
                                         Perabo resigned from his role as Chief Medical Officer of the Company effective January
                                         31, 2018.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Deceased
                                         July 2017.</FONT> </TD></TR></TABLE>

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">The
Company did not reprice downward any options during its financial year ended September 30, 2017. However, subsequent to the most
recently completed financial year, by directors&rsquo; resolution effective February 21, 2018, the Board resolved that, subject
to approval of the TSXV and the Company&rsquo;s shareholders by way of disinterested shareholder approval at the Meeting, that
the existing outstanding Options held by certain persons (including Dr. Parkinson, Mr. Wood, Mr. Virsik, Dr. Perabo, and Dr. Sadar)
be cancelled and replaced by an aggregate of up to 1,667,000 Options, and that the expiry date thereof be extended as further
set out under the heading &ldquo;<I>Approval of Stock Option Re-Grant and Repricing, and Extension of Expiry Dates</I>&rdquo;.
The Company also granted additional Options to certain directors, officers, employees and consultants of the Company (including
Dr. Parkinson, Mr. Wood, Mr. Virsik, Dr. Perabo, and Dr. Sadar), as further set out under the heading &ldquo;<I>Ratification of
Stock Option Grants</I>&rdquo; above; however, such Options cannot be exercised by their respective holders until, among other
things, the Company obtains disinterested shareholder approval of the Option Grant Resolution at the Meeting.</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-style: normal">Incentive
Plan Awards - Value Vested or Earned During the Year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table sets forth, for each of the NEOs, the value of option-based awards and share-based awards which vested or were earned during
the financial period ended September 30, 2017.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 25%; border: Black 1pt solid; padding-top: 6pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt"><B>Name
    and principal position</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Option-based
    awards &ndash; value vested during the year ($)</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Share-based
    awards &ndash; value vested during the year ($)</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Non-equity
    incentive plan compensation &ndash; value earned during the year ($)</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Dr.
    David R. Parkinson (CEO)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">527,526</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">David
    Wood (CFO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">9,953</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Peter
    Virsik (EVP &amp; COO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">210,714</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Dr.
    Frank Perabo (EVP &amp; CMO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">39,981</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Dr.
    Paul Cossum (EVP of R&amp;D)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Dr.
    Marianne Sadar (CSO)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-indent: 0in"><FONT STYLE="font-size: 11pt">Director
Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">On January
1, 2015, ESSA adopted a compensation plan for independent members of the Board. Pursuant to this compensation plan, both cash
payments and Options are offered to independent directors. Each independent director will receive a retainer of $25,000 per annum.
In addition, the Chairman of the Board will receive a premium of $25,000 per annum and the Chair of each sub-committee will receive
a premium of $10,000 per annum. Independent directors will also be paid a cash fee of $1,500 per in-person meeting, and $1,000
per teleconference meeting, $1,000 per sub-committee meeting, and receive an Option grant of 50,000 Options, with 20,000 Options
vesting upon appointment to the Board, 15,000 vesting on the first anniversary of the grant and the remainder vesting on the second
anniversary of the grant. Directors who are ESSA&rsquo;s officers, employees or consultants will receive no compensation under
the terms of this compensation plan. Compensation of non-independent directors is determined by the Board, which may receive input
from the Compensation Committee with respect to such compensation. Scott Requadt is not considered to be independent due to his
affiliations with Clarus, a significant shareholder of the Company with certain Board nomination rights. Hugo Beekman, who was
appointed to the Board on January 16, 2018, is not an independent director due to his affiliations with Omega, a significant shareholder
of the Company with certain Board nomination rights.</FONT></P>

<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 11pt; font-weight: normal"><I>Summary
of Compensation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">As at
September 30, 2017, the end of the Company&rsquo;s last fiscal year, non-NEO directors held 545,000 Options in the Company, granted
in prior years, resulting in $14,068 vested or earned in the year ended September 30, 2017. The following table sets forth all
annual and long-term compensation for services paid to or earned by the non-NEO directors for the three most recently completed
financial years.</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; border-left: Black 1pt solid; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and Principal Position<SUP>(1)</SUP></B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Fees
    earned ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share-based
    awards ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option-based
    awards ($)<SUP>(2)</SUP></B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Non-equity
    incentive Plan compensation ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pension
    Value ($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>All
    Other Compensation </B><BR>
    <B>($)</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total
    Compensation </B><BR>
    <B>($)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Annual
    Incentive Plans </B><BR>
    <B>($)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6.7pt; padding-bottom: 6pt; padding-left: 6.7pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Long-term
    incentive plans </B><BR>
    <B>($)</B></FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="width: 19%; border-left: Black 1pt solid; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Richard
                                         Glickman</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Chairman</I></FONT></P></TD>
    <TD STYLE="width: 6%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="width: 7%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">58,000</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">71,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">55,248</FONT></P></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">1,914</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">5,669</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">11,648</FONT></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">59,914</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">77,169</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">66,896</FONT></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Gary
                                         Sollis</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Corporate</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Governance and</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Nomination Committee Chair</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">45,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">56,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">41,725</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">3,146</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">9,178</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">18,492</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">48,646</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">65,678</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">60,217</FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Franklin
                                         Berger</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Audit Committee Chair</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">45,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">54,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">32,082</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">9,008</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">39,104</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">94,460</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">54,508</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">93,604</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">126,542</FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Scott
                                         Requadt</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Compensation</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Committee
        Chair</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">42,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">42,500</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Raymond
                                         Andersen</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Director</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2,331</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">11,966<SUP>(3)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">44,935<SUP>(3)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">8,205<SUP>(3)</SUP></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">85,327<SUP>(3)(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">83,005<SUP>(3)(4)</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">98,460<SUP>(3)(4)</SUP></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">97,293</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">127,940</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">108,996</FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Hugo
                                         Beekman<SUP>(5)</SUP></B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Director</I></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.7pt; padding-left: 6.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></P></TD></TR>
</TABLE>
<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">Notes:</FONT></TD><TD></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">The
                                         relevant disclosure regarding Dr. David R. Parkinson&rsquo;s compensation received as
                                         a director of the Company is set out in the table under the heading &ldquo;<I>Statement
                                         of Executive Compensation &ndash; Summary of Compensation&rdquo;</I>.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Option-based
                                         awards represent the vesting of stock options granted in the current and previous years
                                         under the Existing Option Plan. The Company&rsquo;s stock options are denominated in
                                         Canadian dollars and are converted at fair value to US dollars at the respective historical
                                         rates on grant date. The fair value of the stock options granted is calculated as of
                                         the grant date using the Black-Scholes option pricing model. This approach is consistent
                                         with the majority of companies in our industries and is sensitive to the assumptions
                                         used. Under this method, the weighted average fair value of stock options granted to
                                         the non-management directors in 2017 was nil (2016 &ndash; nil, 2015 &ndash; C$3.51)
                                         using the following assumptions:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Annual
    dividends per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Expected
    stock price volatility</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">78.28%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Risk-free
    interest rate</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.95%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Expected
    life of options (in years)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">5.45</FONT></TD></TR>
</TABLE>
<P STYLE="color: #0F0F0F; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">These
                                         amounts were incurred in Canadian dollars and converted at the average rates of exchange
                                         for the respective fiscal years: 2017 &ndash; 0.7627; 2016 &ndash; 0.7546; 2015 &ndash;
                                         0.8205;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: #0F0F0F; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-weight: normal">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Dr.
                                         Raymond Andersen has a consulting agreement with the Company, pursuant to which he was
                                         paid a monthly fee of C$10,000.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Mr.
                                         Beekman was appointed as a director of the Company on January 16, 2018. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #0F0F0F; font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 11pt"><I>Incentive
Plan Awards Outstanding</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table discloses the particulars of each non-NEO director for awards outstanding at the end of the financial period ended on September
30, 2017.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD ROWSPAN="2" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and principal position</B></FONT></TD>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option-based
    Awards</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share-based
    Awards</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of securities underlying unexercised options</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option
    exercise price ($)<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option
    expiration date</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Value
    of unexercised in-the-money options ($)<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of shares or units of shares that have not vested</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Market
    or payout value of share- based awards that have not vested ($)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Market
    or payout value of vested share-based awards not paid out or distributed ($)</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Richard
    Glickman</FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">0.64</FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">May
    20, 2019</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Gary
    Sollis</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">0.64</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">May
    20, 2019</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Franklin
    Berger</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">4.29</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">March
    3, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Scott
    Requadt</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Raymond
    Andersen</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">300,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">0.64</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">January
    31, 2018</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Hugo
    Beekman<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-style: normal">Notes:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">The
                                         Company&rsquo;s Options are granted based on exercise price in Canadian dollars; such
                                         amount has been converted to US dollars using the closing exchange rate of 0.8013 as
                                         of September 29, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based
                                         on a closing share price of $0.29 on the Nasdaq as of September 29, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Mr.
                                         Beekman was appointed as a director of the Company on January 16, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal; font-style: normal">The
Company did not reprice downward any options during its financial year ended September 30, 2017. However, subsequent to the most
recently completed financial year, by directors&rsquo; resolution effective February 21, 2018, the Board resolved that, subject
to approval of the TSXV and the Company&rsquo;s shareholders by way of disinterested shareholder approval at the Meeting, that
the existing outstanding Options held by certain persons (including Dr. Glickman, Mr. Sollis, Mr. Berger, and Dr. Andersen) be
cancelled and replaced by an aggregate of up to 1,667,000 Options, and that the expiry date thereof be extended as further set
out under the heading &ldquo;</FONT><FONT STYLE="font-size: 11pt">Approval of Stock Option Re-Grant and Repricing, and Extension
of Expiry Dates</FONT><FONT STYLE="font-style: normal">&rdquo;. The Company also granted additional Options to certain directors, officers,
employees and consultants of the Company (including Dr. Glickman, Mr. Sollis, Mr. Berger, Mr. Requadt, Mr. Beekman, and Dr. Andersen),
as further set out under the heading &ldquo;</FONT><FONT STYLE="font-size: 11pt">Ratification of Stock Option Grants</FONT><FONT STYLE="font-style: normal">&rdquo;
above; however, such Options cannot be exercised by their respective holders until, among other things, the Company obtains disinterested
shareholder approval of the Option Grant Resolution at the Meeting.</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">Incentive
Plan Awards - Value Vested or Earned During the Year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The following
table sets forth, for each of the non-NEO directors, the value of option-based awards and share-based awards which vested or were
earned during the financial period ended September 30, 2017.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 25%; border: Black 1pt solid; padding-top: 6pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt"><B>Name
    and principal position</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Option-based
    awards &ndash; Value vested during the year ($)</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Share-based
    awards &ndash; Value vested during the year ($)</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Non-equity
    incentive plan compensation &ndash; Value earned during the year ($)</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Richard
    Glickman</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">1,914</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Gary
    Sollis</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">3,146</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Franklin
    Berger</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">9,008</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Scott
    Requadt</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">Nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Raymond
    Andersen</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">Nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Hugo
    Beekman<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">Nil</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-style: normal">Notes:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Mr.
                                         Beekman was appointed as a director of the Company on January 16, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">SECURITIES
AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The shareholders
of the Company approved the Company&rsquo;s stock option plan at the annual and special general meeting of shareholders held on
May 21, 2015. On January 12, 2016, the Board approved an amendment to the Company&rsquo;s stock option plan to increase the maximum
number of Common Shares that may be reserved and available for issuance upon exercise of Options issuable by 500,000 Common Shares,
in order to provide for a grant of Options to Dr. David R. Parkinson in connection with the appointment of Dr. Parkinson as the
President and Chief Executive Officer of the Company. On March 10, 2016, the shareholders of the Company ratified the stock option
grant to Dr. David R. Parkinson and approved an amendment and restatement of the Company&rsquo;s stock option plan. Such amendments:
(i) increased the maximum number of Common Shares reserved and available for issuance upon exercise of Options under the stock
option plan to 5,000,000 Common Shares and removed the rolling number (equal to 15% of the issued and outstanding Common Shares)
in respect of the maximum number of Common Shares that may be reserved and available for issuance under the prior stock option
plan; (ii) replaced all provisions in the prior stock option plan that provided for the grant of Options in respect of an issuer
whose Common Shares were listed on the TSXV (which were superseded by provisions designed to comply with the requirements of the
TSX (the &ldquo;<B>TSX Provisions</B>&rdquo;) at the time of listing of the Common Shares on the TSX) with the TSX Provisions;
(iii) provide that where an optionee&rsquo;s position as an employee, consultant, officer or director of the Company terminates
other than for just cause, disability or death, then any options held by such optionee that have not vested on the termination
date will terminate on such date, and any options that have vested on the termination will terminate 90 days after such date;
and (iv) made minor changes of a &ldquo;housekeeping&rdquo; nature. On February 2, 2017, the Board approved an amendment to the
Company&rsquo;s stock option plan to: (i) amend the maximum number of Common Shares that may be reserved and available for issuance
upon exercise of Options, from 5,000,000 Common Shares to a greater of (a) 5,000,000 Common Shares and (b) a rolling number equal
to 15% of the total number of issued and outstanding Common Shares (on a non-diluted basis) at the relevant time; (ii) provide
a replenishment feature such that, following the exercise of any Options under the stock option plan (as well as expiration, cancellation
or other termination thereof), the number of Common Shares equal to the number of Options or rights so exercised (as well as expired,
cancelled or terminated, as applicable) shall immediately and automatically become available for issuance in respect of the Options
that may be subsequently granted under the stock option plan; (iii) amend the various provisions pertaining to the exercise period,
terms and termination of Options, such that in the event that an exercise period of an Option is terminated (or, in other words,
the expiry date of an Option occurs) during a Blackout Period, such exercise period (or expiry date) will be extended to the date
that is ten business days following the end of such Blackout Period, and to address the scenario where an additional Blackout
Period is imposed during an Extension Period, in which case the Extension Period will be deemed to commence following the end
of such additional Blackout Period to enable the exercise of the applicable Option within ten business days following the end
of the last imposed Blackout Period; (iv) provide a prohibition on the granting of Options following March 8, 2027 unless the
shareholders of the Company shall have approved the extension of such date (provided that, in the event that the shareholders
of the Company do not approve the extension of such date by March 8, 2027, the terms and conditions of any Option awarded prior
to March 8, 2027 shall not be altered, and any right of any optionee pursuant to any Option awarded prior to March 8, 2027 shall
not be impaired and shall continue to be governed by the provisions of the stock option plan); and (v) make minor changes of a
&ldquo;housekeeping&rdquo; nature. On March 8, 2017, the shareholders ratified and approved these amendments to the stock option
plan. On February 21, 2018, the Board approved the New Option Plan, in connection with the transfer of ESSA&rsquo;s Common Shares
from the TSX to the TSXV. The New Option Plan is intended to serve as the successor to the Existing Option Plan, and to replace
the Existing Option Plan in its entirety (other than with respect to Options granted prior to February 28, 2017). The New Option
Plan is subject to approval from the Company&rsquo;s shareholders by way of an ordinary resolution to be passed at the Meeting,
and acceptance by the TSXV. For a detailed description of the provisions of the New Option Plan, please see &ldquo;<I>Approval
of Stock Option Plan</I>&rdquo; above.</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>Equity
Compensation Plan Information </B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 28%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; text-align: center; padding-left: 6pt"><FONT STYLE="font-size: 11pt"><B>Plan
    Category</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Number
        of securities to be issued upon exercise of outstanding options</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>(as
        at September 30, 2017)</B></FONT></P></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Weighted-average
        exercise price of outstanding options</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>(as
        at September 30, 2017)</B></FONT></P></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Number
        of securities remaining available for future issuance under equity compensation plans (excluding securities reflected
        in column (a))</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>(as
        at September 30, 2017)</B></FONT></P></TD></TR>
<TR>
    <TD STYLE="border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Equity
    compensation plans approved by securityholders<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">3,717,519<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">C$2.78</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">1,282,481<SUP>(3)</SUP></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt">Equity
    compensation plans not approved by securityholders</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 11pt"><B>Total</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>3,717,519<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>C$2.78</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>1,282,481<SUP>(3)</SUP></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Notes:
</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Existing Option Plan, after giving effect to the amendments approved by shareholders
                                         on March 8, 2017, provides that the maximum number of Common Shares to be acquired pursuant
                                         to Options granted under the Existing Option Plan is a greater of (i) 5,000,000 Common
                                         Shares and (ii) a rolling number equal to 15% of the total number of issued and outstanding
                                         Common Shares (on a non-diluted basis) at the relevant time. The Existing Option Plan
                                         enables the directors, executive officers, employees and consultants of the Company and
                                         its affiliates to participate in the growth and development of the Company by providing
                                         such persons with the opportunity, through options to purchase Common Shares, to acquire
                                         an increased proprietary interest in the Company that is aligned with the interests of
                                         the shareholders.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This
                                         number represents 3.2% of the 115,521,889 issued and outstanding Common Shares as of
                                         the Record Date.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This
                                         number is derived from subtracting the total number of Options issued and total number
                                         of Options exercised pursuant to the Existing Option Plan as at September 30, 2017 from
                                         the maximum number of Common Shares to be acquired pursuant to Options granted under
                                         the Existing Option Plan.</FONT> </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt"><B>Particulars
of the Existing Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt"><I>Administration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">The
Existing Option Plan is administered by the Board, or by the Compensation Committee, in accordance with such terms and conditions
as the Board may prescribe. ESSA&rsquo;s administration of the Existing Option Plan is consistent, and will comply, with the policies
and rules of the stock exchanges on which the Common Shares are listed, and the stock exchanges on which the Common Shares may
be listed in the future. The following is a brief description of the material provisions of the Existing Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Eligibility
Under the Existing Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Persons
eligible to participate under the Existing Option Plan include any person who is a <I>bona fide</I> director, officer, employee
or consultant (each an &ldquo;<B>Eligible Participant</B>&rdquo;) and also includes a company, 100% of the share capital of which
is beneficially owned by one or more Eligible Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Common
Shares Issuable Under the Existing Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Existing
Option Plan provides that the maximum number of Common Shares that may be reserved and available for issuance upon exercise of
Options, is a greater of (i) 5,000,000 Common Shares and (ii) a rolling number equal to 15% of the total number of issued and
outstanding Common Shares (on a non-diluted basis) at the relevant time. In addition, the Existing Option Plan provides a replenishment
feature such that, following the exercise of any Options under the Existing Option Plan (as well as expiration, cancellation or
other termination thereof), the number of Common Shares equal to the number of Options or rights so exercised (as well as expired,
cancelled or terminated, as applicable) shall immediately and automatically become available for issuance in respect of the Options
that may be subsequently granted under the Existing Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Restrictions
on Option Grants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The number
of Common Shares reserved for issuance to any one person pursuant to Options granted under the Existing Option Plan within any
12 month period shall not exceed 5% of the issued and outstanding Common Shares, being 5,776,094 Common Shares as at the date
hereof, with the exception of a consultant, who may not receive grants of more than 2% of the issued and outstanding Common Shares,
being 2,310,437 Common Shares as at the date hereof, in any 12 month period. In addition, no more than an aggregate of 2% of the
issued and outstanding Common Shares may be reserved for issue upon exercise of Options granted to persons employed to conduct
investor relations activities at any one time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The number
of Common Shares which may be issuable pursuant to Options granted under the Existing Option Plan (i) to insiders of the Company
within any one-year period, and (ii) to insiders of the Company, at any time, under the Existing Option Plan, or when combined
with all of the Company&rsquo;s other security based compensation arrangements, cannot exceed 10% of the Company&rsquo;s total
issued and outstanding securities, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Exercise
Price of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">The exercise
price of an Option will be determined by the Board of directors when the Option is granted and shall not be less than the volume
weighted average trading price of the securities (calculated by dividing the total value by the total volume of securities traded
for the relevant period) on the TSX, or another stock exchange where the majority of the trading volume and value of the listed
securities occurs for the five trading days immediately preceding the relevant date.</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Vesting
of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Options
shall vest as the Board determines, in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Term
of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Existing
Option Plan provides that Options shall expire on the expiration date determined by the Board, and must be exercised, if at all,
on or before the expiration date. In no event shall the expiration date be more than ten years after the date of grant provided
that, in the event that an exercise period of an Option is terminated (or, in other words, the expiry date of an Option occurs)
during a blackout period, such exercise period (or expiry date) will be automatically extended to the date that is ten business
days following the end of such blackout period. In addition, the Existing Option Plan contains language to address the scenario
where an additional blackout period is imposed during an extension period, in which case the extension period will be deemed to
commence following the end of such additional blackout period to enable the exercise of the applicable Option within ten business
days following the end of the last imposed blackout period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Transferability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">Options
granted under the Existing Option Plan are non-transferable and non-assignable other than by will or the laws of descent and distribution,
in limited circumstances, upon the termination of the optionee due to the optionee&rsquo;s disability, or upon settlement of the
Options pursuant to the net settlement provisions of the Existing Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Termination
of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">To the
extent not earlier exercised or terminated, an Option shall terminate at the earliest of the following dates: (a) the termination
date specified for such Option in the Option certificate; (b) where the optionee&rsquo;s position as an employee, consultant,
director or officer is terminated for just cause, the date of such termination for just cause; (c) where the optionee&rsquo;s
position as an employee, consultant, director or officer terminates for a reason other than the optionee&rsquo;s disability, death,
or termination for just cause, on the termination date with respect to the Options that have not vested at such termination date,
and 90 days after such date of termination with respect to the Options that have vested as at such termination date, provided
that if an optionee&rsquo;s position with the Company changes from one of the said categories to another category, such change
shall not constitute termination; and (d) the date of any sale, transfer, assignment or hypothecation, or any attempted sale,
transfer, assignment or hypothecation, of such Option in violation of the assignment provisions of the Existing Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Term
of the Existing Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Existing
Option Plan prohibits the granting of Options under such plan following March 8, 2027 unless the shareholders of the Company shall
have approved the extension of such date; provided that, in the event that the shareholders of the Company do not approve the
extension of such date by March 8, 2027, the terms and conditions of any Option awarded prior to March 8, 2027 shall not be altered,
and any right of any optionee pursuant to any Option awarded prior to March 8, 2027 shall not be impaired and shall continue to
be governed by the provisions of the Existing Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Effect
of Death, Disability or Retirement of Optionee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">If an
optionee dies while acting as an employee, consultant, director or officer of the Company or any affiliate of the Company, any
Option held by him or her at the date of death will become exercisable by a Qualified Successor. All such Options are exercisable
for the period of time expiring on the earlier of: (i) the regular expiration of the Option period in respect thereof, and (ii)
one year, provided that in no case shall the exercise period of the Option extend beyond ten years from the award date. Options
held by a Qualified Successor will, during the period prior to their termination, continue to vest in accordance with any vesting
schedule to which such Options are subject.</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">If an
optionee is terminated while acting as an employee, consultant, director or officer of the Company or any affiliate of the Company,
by reason of such optionee&rsquo;s disability, any Option held by such optionee that could have been exercised immediately prior
to such termination of service will be exercisable by such optionee or by his or her appointed guardian for a period of one year
following the termination of service of such optionee. Options exercisable by the optionee&rsquo;s appointed guardian will, during
the period prior to their termination, continue to vest in accordance with the vesting schedule to which such Options are subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">If an
optionee who has ceased to be employed by the Company or any affiliate of the Company by reason of such optionee&rsquo;s disability
dies within 30 days after the termination of such employment, any Option held by such optionee that could have been exercised
immediately prior to his or her death will be exercisable by the Qualified Successor. All such Options are exercisable for a period
of one year following the death of such Optionee, provided that in no case shall the exercise period of the Option extend beyond
five years from the award date. Options held by a Qualified Successor or exercisable by an appointed guardian will, during the
period prior to their termination, continue to vest in accordance with any vesting schedule to which such Options are subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">If an
optionee&rsquo;s employment with the Company is terminated by reason of deemed retirement, the rights to purchase Common Shares
under the Options which have accrued to the optionee and remain unexercised at, or which accrue subsequent to, the date of his
or her retirement will remain exercisable by the optionee, (or by the optionee&rsquo;s legal personal representative(s) if the
Optionee dies before the last date of exercise of the applicable Option) for a period of one year following retirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Net
Settlement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">In lieu
of exercising an Option by delivery of an exercise notice and payment of the exercise price, any optionee or his or her personal
representative may, with the prior written approval of the Board, elect to transfer and dispose of such Option to the Company
in exchange for a number of Common Shares having a fair market value equal to the intrinsic value of such Option. Upon the net
settlement of Options, the Company will deliver to the optionee, such number of Common Shares equal to the number of disposed
Options multiplied by the quotient obtained by dividing the difference of the market price of one Common Share on the exercise
date and the exercise price of the Option, by the market price of one Common Share on the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt"><I>Amendment
of the Existing Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Amendments
to the terms of previously granted Options are subject to regulatory approval, if required. If required by an exchange on which
the Company&rsquo;s securities are listed, disinterested shareholder approval shall be obtained for any reduction in the Option
price of a previously granted Option if the optionee is an insider of ESSA at the time of the proposed reduction in the Option
price. Subject to the requirements of an exchange on which the Company&rsquo;s securities are listed and matters for which disinterested
shareholder approval is required, as described below, the Board may amend any of the provisions of the Existing Option Plan or
any Option in any manner without consent or approval from any participant or shareholder of the Company (provided that no such
amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the
participant without consent by such participant), including without limitation:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to amend,
                                         modify or terminate the Existing Option Plan with respect to all Common Shares in respect
                                         of Options which have not yet been granted thereunder;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to make
                                         any amendment of a typographical, grammatical, clerical or administrative nature or clarification
                                         correcting or rectifying any ambiguity, immaterial inconsistency, defective provision,
                                         mistake, or error or omission in the Existing Option Plan or any Option;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to change
                                         the provisions relating to the manner of exercise of Options, including changing or adding
                                         any form of financial assistance provided by the Company, or if the Existing Option Plan
                                         has a fixed number of securities issuable, adding or amending provisions relating to
                                         a cashless exercise of Options which provisions so added or amended provide for a full
                                         deduction of the underlying Common Shares from the maximum number reserved for issuance
                                         under the Existing Option Plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to change
                                         the terms, conditions and mechanics of grant, vesting, exercise and early expiry of Options,
                                         provided that no such change may extend an outstanding Option certificate&rsquo;s expiry
                                         date;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to change
                                         the provisions for termination or cancellation of Options, or to extend an outstanding
                                         Option certificate&rsquo;s expiry date; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to make
                                         any addition to, deletion from or alteration of the provisions of the Existing Option
                                         Plan or any Option that are necessary to comply with applicable law or the requirements
                                         of any regulatory or governmental agency or applicable stock exchange and to avoid unanticipated
                                         consequences deemed by the Board to be inconsistent with the purpose of the Existing
                                         Option Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Matters
under the Existing Option Plan which require disinterested shareholder approval prior to becoming effective include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
reduction in the exercise price of an Option previously granted to an insider;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
extension of the expiry date of an Option previously granted to an insider; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
amendment to remove or to exceed the insider participation limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">At the
Meeting, shareholders of the Company will be asked to pass an ordinary resolution to, among other things, approve the New Option
Plan, as described above, and under the heading, &ldquo;<I>Approval of Stock Option Plan</I>&rdquo;.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">INDEBTEDNESS
OF DIRECTORS AND EXECUTIVE OFFICERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 11pt; font-weight: normal"><I>Aggregate
Indebtedness</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">As
of this date of this Circular, there is no indebtedness owing to the Company or the Company&rsquo;s subsidiary from any of our
current, or former, officers, directors, or employees, including in respect of indebtedness to others where the indebtedness is
the subject of a guarantee, support agreement, letter of credit or other similar arrangement provided by the Company or the Company&rsquo;s
subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 11pt; font-weight: normal"><I>Indebtedness
of Directors and Executive Officers under Securities Purchase and Other Programs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 11pt">No person
who is, or at any time during the most recently completed financial year was, a director or executive officer of the Company,
and no associate of any such director or officer is, or at any time since the beginning of the most recently completed financial
year of the Company has been, indebted to the Company or the Company&rsquo;s subsidiary, and no such persons owe a debt to another
entity, which is the subject of a guarantee, support agreement, letter of credit or other similar arrangement provided by the
Company or the Company&rsquo;s subsidiary.</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">INTEREST
OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">This
Circular briefly describes (and, where practicable, states the approximate amount of) any material interest, direct or indirect,
of any informed person of the Company, any proposed director of the Company, or any associate or affiliate of any informed person
or proposed director, in any transaction since the commencement of the Company&rsquo;s most recently completed financial year
or in any proposed transaction which has materially affected or would materially affect the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">MANAGEMENT
CONTRACTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Except
as set out herein, there are no management functions of the Company which are to any substantial degree performed by a person
or company other than the directors or executive officers of the Company.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">DIRECTORS&rsquo;
AND OFFICERS&rsquo; LIABILITY INSURANCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt; font-weight: normal">We
carry directors&rsquo; and officers&rsquo; liability insurance for our directors and officers. Currently, primary insurance covers
the liabilities of our directors and officers up to a maximum claim of $10,000,000 for each loss at an annual premium of $326,250
with an excess coverage package for an additional $10,000,000 at an annual premium of $106,300. We believe this level of coverage
is appropriate for a biopharmaceutical company at our stage of development. In addition, the Company has entered into indemnification
agreements with each of its directors and officers. The indemnification agreements generally require that the Company indemnify
and hold the indemnitees harmless to the greatest extent permitted by law for liabilities arising out of the indemnitees&rsquo;
service to the Company as directors and officers, if the indemnitees acted honestly and in good faith with a view to the best
interests of the Company and, with respect to criminal and administrative actions or other non-civil proceedings that are enforced
by monetary penalty, if the indemnitee had reasonable grounds to believe that his or her conduct was lawful. The indemnification
agreements also provide for the advancing of defence expenses to the indemnitees by the Company. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">ADDITIONAL
INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Additional
information relating to the Company is available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Financial information
is provided in the Company&rsquo;s audited consolidated financial statements and management&rsquo;s discussion and analysis for
the years ended September 30, 2017, 2016 and 2015. The Company will provide to any person or company, upon request, one copy of
the comparative financial statements of the Company filed with the applicable securities regulatory authorities for the Company&rsquo;s
two most recently completed financial years in respect to which such financial statements have been issued, together with the
report of the auditor, related management&rsquo;s discussion and analysis and any interim financial statements of the Company
filed with the applicable securities regulatory authorities subsequent to the filing of the annual financial statements. The Company
may be contacted by telephone (778) 331-0962, by mail: Suite 720, 999 West Broadway, Vancouver, BC, V5Z 1K5, or via their website
http://www.essapharma.com/contact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Copies
of the above documents will be provided free of charge to security holders of the Company. The Company may require payment of
a reasonable charge from any person or company who is not a security holder of the Company, who requests a copy of any such document.
The foregoing documents are also available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">OTHER
MATTERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The Board
is not aware of any other matters which it anticipates will come before the Meeting as of the date of mailing of this Circular.</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">FORWARD
LOOKING INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">This
Circular contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of applicable Canadian securities legislation and U.S. securities legislation. Forward-looking information involves statements
that relate to future events and often addresses expected future business and financial performance, containing words such as
&quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, the matters to be brought before the meeting,
the expected actions by the Board upon receipt of any resignations pursuant to the Company&rsquo;s majority voting policy, the
administration of the New Option Plan and RSU Plan, the Company&rsquo;s alteration of its strategic plans and focus on its next-generation
N-terminal domain inhibitor compounds, the Company&rsquo;s expected compliance with Nasdaq policies and the potential delisting
of the Company&rsquo;s Common Shares from the Nasdaq, the procedures related to the Consolidation and the potential effect of
the Consolidation on the market price of the Common Shares, the Board&rsquo;s use of Options and RSUs as part of the Company&rsquo;s
overall executive compensation plan, the establishment of an ad-hoc nomination committee from time to time, the Company&rsquo;s
discussion of diversity targets and the general process of nominating new Board members, and the Company&rsquo;s compensation
philosophies and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Forward-looking
statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability
of ESSA to control or predict, and which may cause ESSA&rsquo;s actual results, performance or achievements to be materially different
from those expressed or implied thereby. Such statements reflect ESSA&rsquo;s current views with respect to future events, are
subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered
reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic,
competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various
material assumptions, including but not limited to (i) the accuracy of ESSA&rsquo;s financial projections; (ii) the Company&rsquo;s
ability to identify a product candidate; (iii) the Company&rsquo;s ability to obtain approval to commence a clinical trial; (iv)
the Company&rsquo;s ability to obtain positive results of its research and development activities, including clinical trials;
(v) obtaining necessary regulatory approvals; (vi) the Company&rsquo;s ability to successfully out-license or sell its future
products, if any, and in-license and develop new products; (vii) favorable general business, market and economic conditions (viii)
the availability of financing on reasonable terms;(ix) the Company&rsquo;s ability to attract and retain skilled staff; (x) market
competition; (xi) the products and technology offered by the Company&rsquo;s competitors; and (xii) the Company&rsquo;s ability
to protect patents and proprietary rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">Forward-looking
information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA&rsquo;s
Annual Report on Form 20-F dated December 11, 2017 under the heading &ldquo;<I>Risk Factors</I>&rdquo;, a copy of which is available
on ESSA&rsquo;s profile on the SEDAR website at www.sedar.com, ESSA&rsquo;s profile on EDGAR at www.sec.gov, and as otherwise
disclosed from time to time on ESSA&rsquo;s SEDAR profile. Forward-looking statements are made based on management's beliefs,
estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements
if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian
and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.</FONT></P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">DIRECTORS&rsquo;
APPROVAL</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt">The contents
of this Circular and its distribution to shareholders have been approved by the Board of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>DATED
</B>at Vancouver, British Columbia, February 23, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><B>BY
ORDER OF THE BOARD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-size: 11pt"><U>(signed)
<I>David R. Parkinson</I></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt">David R.
Parkinson<BR>
President, Chief Executive Officer and Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">SCHEDULE
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Stock
Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">(See attached)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>February 21, 2018</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>STOCK OPTION PLAN</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Approved by the Board on February 21, 2018</P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;TABLE OF CONTENTS</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="width: 90%; text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Article&nbsp;1 DEFINITIONS AND INTERPRETATION</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 12pt; padding-bottom: 12pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">1.1&nbsp;&nbsp;&nbsp;Definitions</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">1.2&nbsp;&nbsp;&nbsp;Choice of Law</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">1.3&nbsp;&nbsp;&nbsp;Headings</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Article&nbsp;2 PURPOSE AND PARTICIPATION</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">2.1&nbsp;&nbsp;&nbsp;Purpose</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">2.2&nbsp;&nbsp;&nbsp;Eligibility</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">2.3&nbsp;&nbsp;&nbsp;Notification of Award</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">2.4&nbsp;&nbsp;&nbsp;Copy of Plan</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">2.5&nbsp;&nbsp;&nbsp;Limitation</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Article&nbsp;3 TERMS AND CONDITIONS OF OPTIONS</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.1&nbsp;&nbsp;&nbsp;Board to Issue Common Shares</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.2&nbsp;&nbsp;&nbsp;Number of Common Shares</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.3&nbsp;&nbsp;&nbsp;Option Details</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.4&nbsp;&nbsp;&nbsp;Term of Option</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.5&nbsp;&nbsp;&nbsp;Termination of Options</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.6&nbsp;&nbsp;&nbsp;Exercise Price</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.7&nbsp;&nbsp;&nbsp;Reduction in Exercise Price</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.8&nbsp;&nbsp;&nbsp;Additional Terms</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.9&nbsp;&nbsp;&nbsp;Assignment of Options</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.10&nbsp;&nbsp;&nbsp;Adjustment of Options</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">11</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.11&nbsp;&nbsp;&nbsp;Option Grant and Vesting Terms</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">3.12&nbsp;&nbsp;&nbsp;U.S. Participants</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Article&nbsp;4 EXERCISE OF OPTION</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">4.1&nbsp;&nbsp;&nbsp;Exercise of Option</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">4.2&nbsp;&nbsp;&nbsp;Issue of Share Certificates</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">4.3&nbsp;&nbsp;&nbsp;Condition of Issue</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">4.4&nbsp;&nbsp;&nbsp;Exchange Hold Period&rsquo;s and Resale Restrictions</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">4.5&nbsp;&nbsp;&nbsp;Tax Withholding and Procedures</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Article&nbsp;5 ADMINISTRATION</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">5.1&nbsp;&nbsp;&nbsp;Administration</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">5.2&nbsp;&nbsp;&nbsp;Interpretation</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; text-align: center">i</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in; width: 90%">Article&nbsp;6 AMENDMENT, TERMINATION AND NOTICE</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt; width: 10%">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">6.1&nbsp;&nbsp;&nbsp;Termination and Amendment of Plan</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">6.2&nbsp;&nbsp;&nbsp;Approvals</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">6.3&nbsp;&nbsp;&nbsp;Term of Plan</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">6.4&nbsp;&nbsp;&nbsp;Termination</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">6.5&nbsp;&nbsp;&nbsp;Agreement</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt">6.6&nbsp;&nbsp;&nbsp;Notice</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Schedule&nbsp;A</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">A-1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0in">Schedule&nbsp;B</TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">B-1</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">ii</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">STOCK OPTION PLAN</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;1<BR>
DEFINITIONS AND INTERPRETATION</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">1.1</FONT></TD><TD STYLE="text-align: justify">Definitions</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As used herein, unless there is something
in the subject matter or context inconsistent therewith, the following terms will have the meanings set forth below:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Administrator</B>&rdquo; means, initially, the Chief Financial Officer of the Company
and thereafter will mean such director or other senior officer or employee of the Company as may be designated as Administrator
by the Board from time to time.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; has the meaning given to such term in Policy 1.1 of the policy manual
of the TSXV.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Award Date</B>&rdquo; means the date on which the Board awards a particular Option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Blackout Period</B>&rdquo; has the meaning given to that term in Policy 4.4 of the policy
manual of the TSXV.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Board</B>&rdquo; means the board of directors of the Company, or any committee thereof
to which the board of directors of the Company has delegated the power to administer and grant Options under the Plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Cause</B>&rdquo; means:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Cause as such term is defined in the written employment agreement between the Company and the Optionee;
or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in the event there is no written employment agreement between the Company and the Optionee or Cause
is not defined therein, the usual meaning of just cause under the common law or the laws of the jurisdiction in which the Optionee
is employed.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Change of Control</B>&rdquo; means the occurrence of any of the following events:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the direct or indirect acquisition or conversion of more than 50% of the issued and outstanding
shares of the Company by a Person or group of Persons acting in concert, other than through an employee share purchase plan or
employee share ownership plan and other than by Persons who are or who are controlled by, the existing shareholders of the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a merger, amalgamation or arrangement of the Company or of the voting shares of the Company where
the voting shares of the resulting merged, amalgamated or arranged company, as applicable, are owned or controlled by shareholders
of whom more than 50% are not the same as the shareholders of the Company immediately prior to the merger, amalgamation or arrangement;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">a sale by the Company of greater than 50% of the fair market value of the assets of the Company,
through one or a series of transactions, to an entity that is not controlled by either the shareholders of the Company or by the
Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B>Code</B>&rdquo; has the meaning given to that term under Section 3.12.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Common Share</B>&rdquo; or &ldquo;<B>Common Shares</B>&rdquo; means, as the case may
be, one or more common shares in the capital of the Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B>Company</B>&rdquo; means ESSA Pharma Inc., a company incorporated under the laws of the
Province of British Columbia.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="letter-spacing: -0.15pt">(k)</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Consultant</B>&rdquo; means an individual or Consultant Company, other than an Employee,
a Director or an Officer of the Company, that:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">is engaged to provide on a <I>bona fide</I> basis, consulting, technical, management or other services
to the Company or an Affiliate, other than services provided in relation to a distribution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">provides the services under a written contract between the Company or an Affiliate of the Company
and the individual or the Consultant Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">in the reasonable opinion of the Company, spends or will spend a significant amount of time and
attention to the affairs and business of the Company or an Affiliate; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">has a relationship with the Company or an Affiliate that enables the individual to be knowledgeable
about the business and affairs of the Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B>Consultant Company</B>&rdquo; means for an individual Consultant, a company or partnership
of which the individual is an employee, shareholder or partner.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&ldquo;<B>Director</B>&rdquo; means any individual holding the office of director of the Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">&ldquo;<B>Disability</B>&rdquo; means a medically determinable physical or mental impairment expected
to result in death or to last for a continuous period of not less than 12 months which causes an individual to be unable to engage
in any substantial gainful activity.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">&ldquo;<B>Disinterested Shareholder Approval</B>&rdquo; means approval by a majority of the votes
cast by the Company&rsquo;s shareholders at a duly constituted shareholders meeting, excluding votes attached to the Common Shares
beneficially owned by Insiders to whom Options may be granted under the Plan and their associates and affiliates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">&ldquo;<B>Employee</B>&rdquo; means</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an individual who is considered an employee of the Company or its subsidiary under the <I>Income
Tax Act</I> (Canada);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">an individual who works full-time for the Company or its subsidiary providing services normally
provided by an employee and who is subject to the same control and direction by the Company over the details and methods of work
as an employee of the Company, but for whom income tax deductions are not made at source;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">an individual who works for the Company or its subsidiary on a continuing and regular basis for
a minimum amount of time per week providing services normally provided by an employee and who is subject to the same control and
direction by the Company over the details and methods of work as an employee of the Company, but for whom income tax deductions
are not made at source; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">a Management Company Employee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">&ldquo;<B>Equity Securities</B>&rdquo; means:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">shares or any other security of the Company that carries the residual right to participate in the
earnings of the Company and, on liquidation, dissolution or winding-up, in the assets of the Company, whether or not the security
carries voting rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any warrants, options or rights entitling the holders thereof to purchase or acquire any such securities;
or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any securities issued by the Company which are convertible or exchangeable into such securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exchange</B>&rdquo; means a stock exchange, inter-dealer quotation network or other organized
trading facilities on which the Common Shares are listed.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exchange Hold Period</B>&rdquo; has the meaning ascribed thereto in Policy 1.1 of the
policy manual of the TSXV.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exercise Notice</B>&rdquo; means the notice respecting the exercise of an Option, in
the form set out as Schedule&nbsp;B hereto, duly executed by the Optionee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exercise Period</B>&rdquo; means the period during which a particular Option may be exercised
and is the period from and including the Award Date through to and including the Expiry Date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exercise Price</B>&rdquo; means the price at which an Option may be exercised as determined
in accordance with Section 3.6.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">&ldquo;<B>Expiry Date</B>&rdquo; means the expiry date of an Option as specified in the Option
Certificate.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&ldquo;<B>Guardian</B>&rdquo; means the guardian, if any, appointed for an Optionee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">&ldquo;<B>Insider</B>&rdquo; has the meaning given to such term in Policy 1.1 of the policy manual
of the TSXV.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="letter-spacing: -0.15pt">(z)</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Investor Relations Activities</B>&rdquo; means any activities or oral or written communications,
by or on behalf of the Company or shareholder of the Company, that promote or reasonably could be expected to promote the purchase
or sale of securities of the Company, but does not include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the dissemination of information provided, or records prepared, in the ordinary course of business
of the Company:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to promote the sale of products or services of the Company; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to raise public awareness of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify">that cannot reasonably be considered
to promote the purchase or sale of securities of the Company;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">activities or communications necessary to comply with the requirements of:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">applicable securities laws; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Exchange requirements or the by-laws, rules or other regulatory instruments
of any other self-regulatory body or Exchange having jurisdiction over the Company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">communications by a publisher of, or writer for, a newspaper, magazine or business or financial
publication, that is of general and regular paid circulation, distributed only to subscribers to it for value or to purchasers
of it, if:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the communication is only through the newspaper, magazine or publication;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the publisher or writer receives no commission or other consideration
other than for acting in the capacity of publisher or writer; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">activities or communications that may be otherwise specified by an Exchange.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD STYLE="text-align: justify">&ldquo;<B>ISO</B>&rdquo; has the meaning given to that term under Section 3.12.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Management Company Employee</B>&rdquo; means an individual employed by a Person providing
management services to the Company, which are required for the ongoing successful operation of the business enterprise of the Company,
but excluding a Person engaged in Investor Relations Activities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(cc)</TD><TD STYLE="text-align: justify">&ldquo;<B>Market Price</B>&rdquo; means an amount which is not less than the closing market price
for the Company&rsquo;s Common Shares on the Nasdaq Stock Market or the TSXV, as the case may be, on the applicable date, or if
there is no closing trading price at such time of grant of the Options, then on the trading day prior to the date of grant of the
Options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(dd)</TD><TD STYLE="text-align: justify">&ldquo;<B>Offer</B>&rdquo; has the meaning given to such term in Section 3.10(f).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ee)</TD><TD STYLE="text-align: justify">&ldquo;<B>Officer</B>&rdquo; means any individual who is serving as a duly appointed officer of
the Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ff)</TD><TD STYLE="text-align: justify">&ldquo;<B>Option</B>&rdquo; means an option to acquire Common Shares, awarded to a Director, Officer,
Employee or Consultant, including all options granted under the Plan or any prior version of the Plan or pursuant to individual
option agreements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(gg)</TD><TD STYLE="text-align: justify">&ldquo;<B>Option Certificate</B>&rdquo; means the certificate, in the form set out as Schedule&nbsp;A
hereto, evidencing an Option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(hh)</TD><TD STYLE="text-align: justify">&ldquo;<B>Optionee</B>&rdquo; means a Person to whom an Option has been granted hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Person</B>&rdquo; means any individual, partnership, joint venture, syndicate, sole proprietorship,
company or corporation with or without share capital, trust, trustee, executor, administrator, or other legal personal representatives,
regulatory body or agency, government or governmental agency, authority or entity howsoever designated or constituted.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(jj)</TD><TD STYLE="text-align: justify">&ldquo;<B>Personal Representative</B>&rdquo; means:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the case of a deceased Optionee, the executor or administrator of the deceased duly appointed
by law or by a court or public authority having jurisdiction to do so; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in the case of an Optionee who for any reason is unable to manage his or her affairs, the person
entitled by law to act on behalf of such Optionee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(kk)</TD><TD STYLE="text-align: justify">&ldquo;<B>Plan</B>&rdquo; means this stock option plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ll)</TD><TD STYLE="text-align: justify">&ldquo;<B>Qualified Successor</B>&rdquo; means a Person who is entitled to ownership of an Option
upon the death of an Optionee, pursuant to a will or the applicable laws of descent and distribution upon death.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(mm)</TD><TD STYLE="text-align: justify">&ldquo;<B>Regulatory Authorities</B>&rdquo; means all stock exchanges, inter-dealer quotation networks
and other organized trading facilities on which the Common Shares are listed and all securities commissions or similar securities
regulatory bodies having jurisdiction over the Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(nn)</TD><TD STYLE="text-align: justify">&ldquo;<B>Termination Date</B>&rdquo; means:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the case of the resignation of the Optionee&rsquo;s employment or the termination of the Optionee&rsquo;s
consulting or service contract by the Optionee, the date that the Optionee provides notice of such resignation or termination to
the Company; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in the case of the termination of the Optionee&rsquo;s employment or consulting or service contract
by the Company for any reason other than death or disability, the date that the Company delivers written notice of termination
of the Optionee&rsquo;s employment or consulting or service contract to the Optionee; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">in the case of the expiry of a fixed-term employment or consulting or service contract that is
not renewed or extended, the last day of the term.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(oo)</TD><TD STYLE="text-align: justify">&ldquo;<B>Transfer</B>&rdquo; includes any sale, exchange, assignment, gift, bequest, disposition,
mortgage, charge, pledge, encumbrance, grant of a security interest or other arrangement by which possession, legal title or beneficial
ownership passes from one Person to another, or to the same Person in a different capacity, whether or not voluntarily and whether
or not for value, and any agreement to effect any of the foregoing, including any sale or exchange pursuant to a plan of arrangement,
merger, consolidation, acquisition or similar transaction; and the words &ldquo;<B>Transferred</B>&rdquo;, &ldquo;<B>Transferring</B>&rdquo;
and similar words have corresponding meanings.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(pp)</TD><TD STYLE="text-align: justify">&ldquo;<B>TSXV</B>&rdquo; means the TSX Venture Exchange.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(qq)</TD><TD STYLE="text-align: justify">&ldquo;<B>U.S. Participant</B>&rdquo; has the meaning given to that term under Section 3.12.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">1.2</FONT></TD><TD STYLE="text-align: justify">Choice of Law</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Plan is established under, and the
provisions of the Plan will be subject to and interpreted and construed in accordance with, the laws of the Province of British
Columbia.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">1.3</FONT></TD><TD STYLE="text-align: justify">Headings</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The headings used herein are for convenience
only and are not to affect the interpretation of the Plan.</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;2<BR>
PURPOSE AND PARTICIPATION</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">2.1</FONT></TD><TD STYLE="text-align: justify">Purpose</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The purpose of the Plan is to provide
the Company with a share-related mechanism to attract, retain and motivate qualified Directors, Officers, Employees and Consultants,
to reward such of those Directors, Officers, Employees and Consultants as may be awarded Options under the Plan by the Board from
time to time for their contributions toward creating shareholder value through achievement of the short and long term goals of
the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Plan shall serve as the successor
to the Company&rsquo;s Amended and Restated Stock Option Plan approved by the board of directors of the Company on March 8, 2017
(the &ldquo;<B>Prior Plan</B>&rdquo;), and no further awards shall be made under the Prior Plan from and after the effective date
of the Plan. All outstanding awards under the Prior Plan immediately prior to the effective date of the Plan shall be included
in the maximum number of Common Shares and other limitations set forth in subsection 3.2 herein. However, each such award shall
continue to be governed solely by the terms and conditions of the instrument evidencing such grant and the Prior Plan, provided
such award was granted prior to February 28, 2017, and no provision of the Plan shall affect or otherwise modify the rights or
obligations of holders of such awards. For greater certainty, each award granted under the Prior Plan on or after February 28,
2017 will be governed solely by the terms and conditions of the Plan and the instrument evidencing such grant.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">2.2</FONT></TD><TD STYLE="text-align: justify">Eligibility</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Board will, from time to time and
in its sole discretion, determine those Directors, Officers, Employees and Consultants, if any, to whom Options are to be awarded.
Further:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Options may be granted to any Employee, Officer, Director or Consultant of the Company or any Affiliate.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding Section 4.1 hereof, grants of Options to Insiders shall be subject to the policies
of the TSXV so long as the Common Shares are listed on the TSXV.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">No Option shall be granted to any Optionee unless the Board has determined that the grant of such
Option and the exercise thereof by the Optionee will not violate the securities laws of the jurisdiction in which the Optionee
resides.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The number of grants which may be issuable under the Plan and all of the Company&rsquo;s other
security based compensation arrangements in existence from time to time on and after the effective date of the Plan, within any
one-year period:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">to any one Person, shall be no more than 5% of the issued and outstanding share capital of the
Company, with the exception of a Consultant who may not receive grants of more than 2% of the issued and outstanding share capital
of the Company; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">to Persons employed to conduct Investor Relations Activities, shall be no more than an aggregate
of 2% of the number of issued and outstanding Common Shares in the capital of the Company at any one time.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">2.3</FONT></TD><TD STYLE="text-align: justify">Notification of Award</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Following the approval by the Board
of the awarding of an Option, the Administrator will notify the Optionee in writing of the award and will enclose with such notice
the Option Certificate representing the Option so awarded.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">2.4</FONT></TD><TD STYLE="text-align: justify">Copy of Plan</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Each Optionee, concurrently with the
notice of the award of the Option, will be provided with a copy of the Plan. A copy of any amendment to the Plan will be promptly
provided by the Administrator to each Optionee.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">2.5</FONT></TD><TD STYLE="text-align: justify">Limitation</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Plan does not give any Optionee
that is a Director or Officer the right to serve or continue to serve as a Director or Officer of the Company nor does it give
any Optionee that is an Employee the right to be or to continue to be employed with the Company, nor does it give any Optionee
that is a Consultant the right to have a consulting relationship with the Company or provide services to the Company.</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;3<BR>
<FONT STYLE="text-transform: none">TERMS AND CONDITIONS OF OPTIONS</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.1</FONT></TD><TD STYLE="text-align: justify">Board to Issue Common Shares</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Common Shares to be issued to Optionees
upon the exercise of Options will be authorized and unissued Common Shares the issuance of which will have been authorized by the
Board. Upon the exercise of Options in accordance with the terms hereof, the Company will issue Common Shares to the applicable
Optionees; provided that for any Options granted on or after February 28, 2017, and prior to the approval of this Plan by the shareholders
of the Company, no Options shall be exercisable nor any Common Shares issuable upon the exercise thereof until the following has
been obtained:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the prior approval of this Plan by the shareholders of the Company; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Disinterested Shareholder Approval of the grants of such Options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.2</FONT></TD><TD STYLE="text-align: justify">Number of Common Shares</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in">Subject to adjustment
as provided for in Section&nbsp;3.10 hereof, the maximum number of Common Shares that will be available for Directors, Officers,
Employees and Consultants to acquire pursuant to Options granted under the Prior Plan, in combination with the aggregate number
of Common Shares which may be issuable under any and all of the Company&rsquo;s equity incentive plans in existence from time to
time on and after the effective date of the Plan, will be 23,104,377 Common Shares, of which no more than 20,000,000 will be available
for Employees to acquire pursuant to ISOs. If any Option expires, cancels or otherwise terminates for any reason without having
been exercised in full, the number of Common Shares in respect of which the Option was not exercised will again be available for
the purposes of the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.3</FONT></TD><TD STYLE="text-align: justify">Option Details</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">With respect to each Option to be granted
to an Optionee, the Board shall specify the following terms in the Option between the Company and the Optionee:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Award Date;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">subject to Section 3.9, the term of the Option, provided that the Exercise Period shall in no event
be greater than ten (10) years following the Award Date; however, if the Exercise Period is terminated during a Blackout Period,
the Exercise Period shall be extended to the date that is ten (10) business days following the end of such Blackout Period (the
&ldquo;Extension Period&rdquo;), provided that, if an additional Blackout Period is subsequently imposed by the Company during
the Extension Period, then such Extension Period shall be deemed to commence following the end of such additional Blackout Period
to enable the exercise of such Option within ten (10) business days following the end of the last imposed Blackout Period;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Exercise Price, provided that the Exercise Price shall not be less than the Market Price;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">any vesting schedule contained in the Option Certificate upon which the exercise of the Option
is contingent; provided that, subject to compliance with the rules and policies of all applicable Regulatory Authorities, the Board
shall have complete discretion with respect to the terms of any such vesting schedule, including, without limitation, discretion
to:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">permit partial vesting in stated percentage amounts based on the term of such Option; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">permit full vesting after a stated period of time has passed from the Award Date;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">if the Optionee in respect of an Option grant is an Employee, Consultant or Management Company
Employee a representation by the Company that the Optionee is a <I>bona fide</I> Employee, Consultant or Management Company Employee;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">such other terms and conditions as the Board deems advisable and are consistent with the purposes
of this Plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.4</FONT></TD><TD STYLE="text-align: justify">Term of Option</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">An Optionee may exercise an Option in
whole or in part at any time or from time to time during the Exercise Period. Any Option or part thereof not exercised within the
Exercise Period will terminate and become null, void and of no effect as of 5:00 p.m. local time in Vancouver, British Columbia
on the Expiry Date; provided that, if the Expiry Date occurs during a Blackout Period, the Expiry Date shall be extended to the
date that is ten (10) business days following the end of such Blackout Period, provided that, if an additional Blackout Period
is subsequently imposed by the Company during the Extension Period, then such Extension Period shall be deemed to commence following
the end of such additional Blackout Period to enable the exercise of such Option within ten (10) business days following the end
of the last imposed Blackout Period.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.5</FONT></TD><TD STYLE="text-align: justify">Termination of Options</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">To the extent not earlier exercised
or terminated in accordance with Section 3.9 hereof, an Option shall terminate at the earliest of the following dates:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the termination date specified for such Option in the Option Certificate; provided that, if the
termination date occurs during a Blackout Period, such termination date shall be extended to the date that is ten (10) business
days following the end of such Blackout Period, provided that, if an additional Blackout Period is subsequently imposed by the
Company during the Extension Period, then such Extension Period shall be deemed to commence following the end of such additional
Blackout Period to enable the exercise of such Option within ten (10) business days following the end of the last imposed Blackout
Period;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="letter-spacing: -0.15pt">(b)</FONT></TD><TD STYLE="text-align: justify">where the Optionee's position as an Employee, Consultant, Director or Officer of the Company or
any Affiliate is terminated for just cause, the date of such termination for just cause<FONT STYLE="letter-spacing: -0.15pt">;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">unless determined otherwise by the Board, where the Optionee's position as an Employee, Consultant,
Officer or Director of the Company or any Affiliate terminates for a reason other than the Optionee's Disability, death, or termination
for just cause, (i) on the Termination Date with respect to Options that have not vested as at such Termination Date, and (ii)
90 days after the Termination Date with respect to Options that have vested as at such Termination Date, provided that if an Optionee&rsquo;s
position with the Company changes from one of the said categories to another category, such change shall not constitute termination
for the purpose of this subsection 3.3(c); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the date of any sale, Transfer, assignment or hypothecation, or any attempted sale, Transfer, assignment
or hypothecation, of such Option in violation of Section 3.9 hereof.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.6</FONT></TD><TD STYLE="text-align: justify">Exercise Price</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The price at which an Optionee may purchase
a Common Share upon the exercise of an Option will be as set forth in the Option Certificate issued in respect of such Option and
in any event will not be less than the Market Price. An Option shall not establish a minimum Exercise Price until such Option has
been allocated to a Particular Person.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.7</FONT></TD><TD STYLE="text-align: justify">Reduction in Exercise Price</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 6pt 0"><FONT STYLE="font-weight: normal">Disinterested Shareholder
Approval will be obtained for any reduction in the Exercise Price of Options granted to Insiders, if the Optionee is an Insider
of the Company at the time of such proposed reduction in Exercise Price. </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.8</FONT></TD><TD STYLE="text-align: justify">Additional Terms</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Notwithstanding the foregoing sections
of this Article&nbsp;3, and subject to all applicable securities laws and regulations and the rules and policies of all applicable
Regulatory Authorities, the Board may attach other terms and conditions to the grant of a particular Option, such terms and conditions
to be referred to in a schedule attached to the Option Certificate. These terms and conditions may include, but are not necessarily
limited to, the following:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">providing that an Option expires on a date other than as provided for herein, provided that in
no case will an Option be exercisable later than the tenth anniversary of the Award Date of the Option; however, if the Expiry
Date occurs during a Blackout Period, the Expiry Date shall be extended to the date that is ten (10) business days following the
end of such Blackout Period, provided that, if an additional Blackout Period is subsequently imposed by the Company during the
Extension Period, then such Extension Period shall be deemed to commence following the end of such additional Blackout Period to
enable the exercise of such Option within ten (10) business days following the end of the last imposed Blackout Period;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">providing that a portion or portions of an Option vest after certain periods of time or upon the
occurrence of certain events, or expire after certain periods of time or upon the occurrence of certain events other than as provided
for herein; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">providing that an Option be exercisable immediately, in full, notwithstanding that it has vesting
provisions, upon the occurrence of certain events, such as a friendly or hostile takeover bid for the Company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.9</FONT></TD><TD STYLE="text-align: justify">Assignment of Options</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Subject to this Section 3.9, Options
are non-assignable and non-transferable.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><I><U>Death of Optionee</U></I> &ndash; If the employment of an Optionee as an Employee or Consultant
of the Company or any Affiliate, or the position of an Optionee as a Director or Officer of the Company or any Affiliate, terminates
as a result of his or her death, any Options held by such Optionee shall pass to the Qualified Successor of the Optionee, and shall
be exercisable by the Qualified Successor for a period of 1 year following such death, provided that in no case shall the Exercise
Period of the Option extend beyond ten years from the Award Date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><I><U>Disability of Optionee</U></I> - If the employment of an Optionee as an Employee or Consultant
of the Company or any Affiliate, or the position of an Optionee as a Director or Officer of the Company or any Affiliate, is terminated
by the Company or any Affiliate by reason of such Optionee's Disability, any Option held by such Optionee that could have been
exercised immediately prior to such termination of service shall be exercisable by such Optionee, or by his Guardian, for a period
of 1 year following the termination of service of such Optionee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><I><U>Disability and Death of Optionee</U></I> - If an Optionee who has ceased to be employed by
the Company or any Affiliate by reason of such Optionee's Disability dies within 30 days after the termination of such employment,
any Option held by such Optionee that could have been exercised immediately prior to his or her death shall pass to the Qualified
Successor of such Optionee, and shall be exercisable by the Qualified Successor for a period of 1 year following the death of such
Optionee, provided that in no case shall the Exercise Period of the Option extend beyond five years from the Award Date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><I><U>Vesting</U></I> - Options held by a Qualified Successor or exercisable by a Guardian shall,
during the period prior to their termination, continue to vest in accordance with any vesting schedule to which such Options are
subject.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><I><U>Deemed Non-Interruption of Employment</U></I> - Employment shall be deemed to continue intact
during any military or sick leave or other <I>bona fide</I> leave of absence if the period of such leave does not exceed 90 days
or, if longer, for so long as the Optionee's right to reemployment with the Company or any Affiliate is guaranteed either by statute
or by contract. If the period of such leave exceeds 90 days and the Optionee's reemployment is not so guaranteed, then his or her
employment shall be deemed to have terminated on the ninety-first day of such leave.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="letter-spacing: -0.15pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I><U>Retirement</U></I> - </FONT>In the event of the termination
of employment of an Optionee who is an Employee at any time during the term of an Option by reason of the deemed retirement of
such Employee, as may be determined by the Board, in its sole discretion, then the rights to purchase Common Shares under the Option
which have accrued to the Optionee and remain unexercised at, or which accrue subsequent to, the date of his retirement shall remain
exercisable by the Optionee (or by the Optionee's legal personal representative or representatives if the Optionee dies before
the last date of exercise of the Option) for a period of 1 year following the retirement of such Optionee in accordance with the
terms of the Option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.10</FONT></TD><TD STYLE="text-align: justify">Adjustment of Options</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 12pt; letter-spacing: 0.05pt"><I><U>Alteration in Capital Structure</U></I>
&ndash; </FONT>If there is any change in the Common Shares through or by means of a declaration of stock dividends of the Common
Shares or consolidations, subdivisions or reclassifications of the Common Shares, or otherwise, the number of Common Shares available
under the Plan, the Common Shares subject to any Option and the Exercise Price therefor shall be adjusted proportionately by the
Board and, if required, approved by the Regulatory Authorities having authority over the Company or the Plan, and such adjustment
shall be effective and binding for all purposes of the Plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 12pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="letter-spacing: 0.4pt"><I><U>Effect of Amalgamation, Merger or Arrangement</U></I>
&ndash; </FONT>If the Company amalgamates, merges or enters into a plan of arrangement with or into another corporation, any Common
Shares receivable on the exercise of an Option shall be converted into the securities, property or cash which the Optionee <FONT STYLE="font-size: 12pt">would
have received upon such amalgamation, merger or arrangement if the Optionee had exercised his Option immediately prior to the record
date applicable to such amalgamation, merger or arrangement, and the exercise price shall be adjusted proportionately by the Board
and such adjustment shall be binding for all purposes of the Plan.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 12pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 12pt"><I><U>Acceleration on Change of Control</U></I> &ndash; Upon a Change
of Control, all Options shall become immediately exercisable, notwithstanding any contingent vesting provisions to which such Options
<FONT STYLE="letter-spacing: -0.05pt">may have otherwise been subject. Any proposed acceleration of vesting provisions are </FONT></FONT>subject
to the necessary approvals of the applicable Regulatory Authorities<FONT STYLE="font-size: 12pt">.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><I><U>Acceleration of Date of Expiry or Vesting</U></I> &ndash; The Board shall have the right
to accelerate the date of expiry of any portion of any Option or the vesting of any portion of any Option which remains unvested,
subject to the necessary approvals of the applicable Regulatory Authorities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 12pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 12pt; letter-spacing: 0.1pt"><I><U>Determinations to be made by Board</U></I>
&ndash; Adjustments and determinations under this subsection (e)</FONT> <FONT STYLE="font-size: 12pt; letter-spacing: -0.1pt">shall
be made by the Board, whose decisions as to the adjustments or determination which shall be </FONT><FONT STYLE="font-size: 12pt">made,
and the extent thereof, shall be final, binding, and conclusive.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><I><U>Effect of a Take-over</U></I> - If a <I>bona fide</I> offer (the &ldquo;<B>Offer</B>&rdquo;)
for Common Shares is made to an Optionee or to shareholders generally or to a class of shareholders which includes the Optionee,
which Offer constitutes a take-over bid within the meaning of Section 92 of the British Columbia <I>Securities Act</I>, as amended
from time to time, the Company shall, immediately upon receipt of notice of the Offer, notify each Optionee of full particulars
of the Offer, whereupon any Option held by an Optionee may be exercised in whole or in part by the Optionee so as to permit the
Optionee to tender the Common Shares received upon such exercise (the &ldquo;<B>Optioned Shares</B>&rdquo;) to the Offer. If:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Offer is not completed within the time specified therein; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">all of the Optioned Shares tendered by the Optionee pursuant to the Offer are not taken up and
paid for by the offeror pursuant thereto;</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">the Optioned Shares
or, in the case of clause (b) above, the Optioned Shares that are not taken up and paid for, may be returned by the Optionee to
the Company and reinstated as authorized but unissued Common Shares and with respect to such returned Optioned Shares, the Option
shall be reinstated as if it had not been exercised. If any Optioned Shares are returned to the Company under this Section, the
Company shall refund the Exercise Price to the Optionee for such Optioned Shares.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">No fractional Common Shares will be issued upon the exercise of an Option. Accordingly, if, as
a result of a consolidation, subdivision, conversion, exchange or reclassification of Common Shares, an Optionee would become entitled
to a fractional Common Share, such Optionee will have the right to purchase only the next lowest whole number of Common Shares
and no payment or other adjustment will be made with respect to the fractional interest so disregarded.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.11</FONT></TD><TD STYLE="text-align: justify">Option Grant and Vesting Terms</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise determined by the Board in
accordance with the terms and conditions of this Plan, Options will be granted by the Board. The Board may determine and impose
terms upon which each Option shall become vested, provided that, if the Common Shares are listed on the TSXV, Options granted to
Persons employed to conduct Investor Relations Activities, must vest in stages over 12 months with no more than 25% of the Options
vesting in any three month period.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.12</FONT></TD><TD STYLE="text-align: justify">U.S. Participants</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Any Option granted under the Plan to
an Optionee who is a citizen or resident of the United States (including its territories, possessions and all areas subject to
the jurisdiction) (a &ldquo;<B>U.S. Participant</B>&rdquo;) may, at the sole discretion of the Company, be an incentive stock option
(an &ldquo;<B>ISO</B>&rdquo;) within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, of the United
States (the &ldquo;<B>Code</B>&rdquo;), but only if so designated by the Company in the Option Certificate evidencing such Option.
No provision of this Plan, as it may be applied to a U.S. Participant with respect to Options which are designated as ISOs, shall
be construed so as to be inconsistent with any provision of Section 422 of the Code or the Treasury Regulations thereunder. Grants
of Options to U.S. Participants which are not designated as or otherwise do not qualify as ISOs will be treated as nonstatutory
stock options for U.S. federal tax purposes. Notwithstanding anything in this Plan contained to the contrary, the following provisions
shall apply to ISOs granted to each U.S. Participant:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">ISOs shall only be granted to individual U.S. Participants who are, at the time of grant, employees
of the Company within the meaning of the Code;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the aggregate fair market value (determined as of the time an ISO is granted) of the Common Shares
subject to ISOs exercisable for the first time by a U.S. Participant during any calendar year under this Plan and all other stock
option plans, within the meaning of Section 422 of the Code, of the Company shall not exceed One Hundred Thousand Dollars in U.S.
funds (U.S.$100,000);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Exercise Price for Common Shares under each ISO granted to a U.S. Participant pursuant to this
Plan shall be not less than fair market value of such Common Shares at the time the Option is granted, as determined in good faith
by the Board at such time (unless such ISO is granted pursuant to an assumption or substitution for another option in a manner
satisfying the provisions of Section 424(a) of the Code);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">if any U.S. Participant to whom an ISO is to be granted under the Plan at the time of the grant
of such ISO is the owner of shares possessing more than ten percent (10%) of the total combined voting power of all classes of
shares of the Company, then the following special provisions shall be applicable to the ISO granted to such individual:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Exercise Price (per share) subject to such ISO shall not be less than one hundred ten percent
(110%) of the fair market value of one Common Share at the time of grant; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">for the purposes of this Section 3.12 only, the Exercise Period shall not exceed five (5) years
from the date of grant;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">no ISO may be granted hereunder to a U.S. Participant following the expiration of ten (10) years
after the date on which this Plan is adopted by the Company or the date on which the Plan is approved by the shareholders of the
Company, whichever is earlier; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">no ISO granted to a U.S. Participant under the Plan shall become exercisable unless and until the
Plan shall have been approved by the shareholders of the Company.</TD></TR></TABLE>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;4<BR>
<FONT STYLE="text-transform: none">EXERCISE OF OPTION</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.1</FONT></TD><TD STYLE="text-align: justify">Exercise of Option</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Except as provided pursuant to Sections
3.5, 3.9, and 3.10 hereof, no Option may be exercised unless the Optionee is, at the time of such exercise, a <I>bona fide</I>
Employee, Officer, Director or Consultant of the Company or any of its Affiliates or the Personal Representative of the Optionee,
and shall have been continuously such a <I>bona fide </I>Employee, Officer, Director or Consultant, as the case may be. An Optionee
or the Personal Representative of the Optionee may exercise the vested portion or portions of an Option in whole or in part at
any time or from time to time during the Exercise Period up to 5:00 p.m. local time in Vancouver, British Columbia on the Expiry
Date by delivering to the Administrator an Exercise Notice, the applicable Option Certificate and a certified cheque or bank draft
payable to &ldquo;<B>ESSA Pharma Inc.</B>&rdquo; in an amount equal to the aggregate Exercise Price of the Common Shares to be
purchased pursuant to the exercise of the Option.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.2</FONT></TD><TD STYLE="text-align: justify">Issue of Share Certificates</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As soon as practicable following the
receipt of the Exercise Notice, the Administrator will, in his sole discretion, either cause to be delivered to the Optionee a
certificate for the Common Shares purchased by the Optionee or cause to be delivered to the Optionee a copy of such certificate
and the original of such certificate will be placed in the minute book of the Company. If the number of Common Shares in respect
of which the Option was exercised is less than the number of Common Shares subject to the Option Certificate surrendered, the Administrator
will forward a new Option Certificate to the Optionee concurrently with delivery of the share certificate for the balance of the
Common Shares available under the Option.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.3</FONT></TD><TD STYLE="text-align: justify">Condition of Issue</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Options and the issue of Common
Shares by the Company pursuant to the exercise of Options are subject to the terms and conditions of the Plan and compliance with
the rules and policies of all applicable Regulatory Authorities with respect to the granting of such Options and the issuance and
distribution of such Common Shares, and to all applicable securities laws and regulations. The Optionee agrees to comply with all
such laws, regulations, rules and policies and agrees to furnish to the Company any information, reports or undertakings required
to comply with, and to fully cooperate with, the Company in complying with such laws, regulations, rules and policies.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.4</FONT></TD><TD STYLE="text-align: justify">Exchange Hold Period&rsquo;s and Resale Restrictions</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">If required by the policies of the Exchange,
the certificate representing the Option and any certificate representing Shares issued upon the exercise of such Option (if exercised
prior to the expiry of the Exchange Hold Period) will bear the following Exchange Hold Period legend:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify">&ldquo;Without prior written approval
of TSX Venture Exchange and compliance with all applicable securities legislation, the securities represented by this certificate
may not be sold, transferred, hypothecated or otherwise traded on or through the facilities of TSX Venture Exchange or otherwise
in Canada or to or for the benefit of a Canadian resident until [<I>insert date that is four months and a day after the distribution
date</I>].&rdquo;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.5</FONT></TD><TD STYLE="text-align: justify">Tax Withholding and Procedures</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Notwithstanding anything else contained
in this Plan, the Company may, from time to time, implement such procedures and conditions as it determines appropriate with respect
to the withholding and remittance of taxes imposed under applicable law, or the funding of related amounts for which liability
may arise under such applicable law. Without limiting the generality of the foregoing, an Optionee who wishes to exercise an Option
must, in addition to following the procedures set out in this Article&nbsp;4 and elsewhere in this Plan, and as a condition of
exercise:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">deliver a certified cheque, wire transfer or bank draft payable to the Company for the amount determined
by the Company to be the appropriate amount on account of such taxes or related amounts; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">otherwise ensure, in a manner acceptable to the Company (if at all) in its sole and unfettered
discretion, that the amount will be securely funded; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">direct a portion of the Common Shares acquired to be sold by a broker, the funds from such sale
paid to the Company and the Company directed to remit the funds received to the Canada Revenue Agency and/or such other applicable
provincial taxation authority in satisfaction of the applicable withholding requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 11pt">and must in all other respects follow any related procedures
and conditions imposed by the Company.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;5<BR>
ADMINISTRATION</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">5.1</FONT></TD><TD STYLE="text-align: justify">Administration</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Plan will be administered by the
Administrator on the instructions of the Board. The Board may make, amend and repeal at any time and from time to time such policies
not inconsistent with the Plan as it may deem necessary or advisable for the proper administration and operation of the Plan and
such policies will form part of the Plan. The Board may delegate to the Administrator or any director, officer or employee of the
Company such administrative duties and powers as it may see fit.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">5.2</FONT></TD><TD STYLE="text-align: justify">Interpretation</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The interpretation by the Board of any
of the provisions of the Plan and any determination by it pursuant thereto will be final and conclusive and will not be subject
to any dispute by any Optionee. No member of the Board or any person acting pursuant to authority delegated by it hereunder will
be liable for any action or determination in connection with the Plan made or taken in good faith and each member of the Board
and each such person will be entitled to indemnification with respect to any such action or determination in the manner provided
for by the Company.</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;6<BR>
AMENDMENT, TERMINATION AND NOTICE</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.1</FONT></TD><TD STYLE="text-align: justify">Termination and Amendment of Plan</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><I><U>Power of the Board to Terminate or Amend Plan</U></I> - Subject to the acceptance of the
TSXV and any other applicable Regulatory Authorities and the requirements of the policy manual of the TSXV and any other applicable
Regulatory Authority, the Board may terminate, suspend or amend the terms of the Plan; provided, however, that, except as provided
in Section 4.1 hereof, the Board may not do any of the following without obtaining, within 12 months either before or after the
Board&rsquo;s adoption of a resolution authorizing such action, approval by the affirmative votes of the holders of a majority
of the voting securities of the Company present, or represented, and entitled to vote at a meeting duly held in accordance with
the applicable corporate laws, and, where required, by way of Disinterested Shareholder Approval:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">increase the maximum number of Common Shares that may be reserved under the Plan for issuance pursuant
the exercise of Options (other than pursuant to Section 3.10);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">place limitations under the Plan on the number of Options that may be granted to any one Person
or any category of Persons;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">reduce the exercise price of Options (other than pursuant to Section 3.10);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">grant to Insiders, within a 12 month period, an aggregate number of options exceeding 10% of the
Company&rsquo;s issued Common Shares, calculated at the date the Option is granted to the Insider;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">issue to any one Optionee, within a 12 month period, a number of Common Shares exceeding 5% of
the Company&rsquo;s Common Shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">reserve for issuance Common Shares under the Plan and all of the Company&rsquo;s other security
based compensation arrangements in existence from time to time on and after the effective date of the Plan, where such reservation
could result in the aggregate number of Common Shares granted to Insiders exceeding 10% of the Company&rsquo;s issued Common Shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">materially modify the requirements as to eligibility for participation in the Plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">materially increase the benefits accruing to participants under the Plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ix)</TD><TD STYLE="text-align: justify">modify the method for determining the exercise price of the Options;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">modify the maximum term of the Options;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(xi)</TD><TD STYLE="text-align: justify">modify the expiry and termination provisions applicable to Options;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(xii)</TD><TD STYLE="text-align: justify">expand the types of awards which may be granted under the Plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(xiii)</TD><TD STYLE="text-align: justify">extend the duration of the Plan; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(xiv)</TD><TD STYLE="text-align: justify">modify the provisions of this Section 6.1</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">however, the Board
may, without shareholder approval:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">make any amendment of a typographical, grammatical, clerical or administrative nature or clarification
correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan
or any Option;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">make any addition to, deletion from or alteration of the provisions of this Plan or any Option
that are necessary to comply with applicable law or the requirements of any regulatory or governmental agency or applicable stock
exchange and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">make any amendments to clarify existing provisions of this Plan or any Option provided that such
changes do not have the effect of altering the scope, nature and intent of this Plan or any Option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><I><U>No Grant During Suspension of Plan</U></I> - No Option may be granted during any suspension,
or after termination, of the Plan. Amendment, suspension or termination of the Plan shall not, without the consent of the Optionee,
alter or impair any rights or obligations under any Option previously granted.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.2</FONT></TD><TD STYLE="text-align: justify">Approvals</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Plan and any amendments hereto are
subject to all necessary approvals of the applicable Regulatory Authorities.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.3</FONT></TD><TD STYLE="text-align: justify">Term of Plan</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Notwithstanding anything in the Plan
to the contrary, no Option may be granted under the Plan following February 21, 2028 unless the shareholders of the Company shall
have approved the extension of such date; provided that, in the event that the Plan terminates pursuant to this Section 6.3, such
termination will not alter the terms or conditions of any Option or impair any right of any Optionee pursuant to any Option awarded
prior to the date of such termination which will continue to be governed by the provisions of the Plan.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.4</FONT></TD><TD STYLE="text-align: justify">Termination</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Board may terminate the Plan at
any time provided that such termination will not alter the terms or conditions of any Option or impair any right of any Optionee
pursuant to any Option awarded prior to the date of such termination which will continue to be governed by the provisions of the
Plan.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.5</FONT></TD><TD STYLE="text-align: justify">Agreement</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company and every Option awarded
hereunder will be bound by and subject to the terms and conditions of the Plan. By accepting an Option granted hereunder, the Optionee
has expressly agreed with the Company to be bound by the terms and conditions of the Plan.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.6</FONT></TD><TD STYLE="text-align: justify">Notice</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Any notice or other communication contemplated
under the Plan to be given by the Company to an Optionee will be given by the Company delivering or faxing the notice to the Optionee
at the last address for the Optionee in the Company&rsquo;s records. Any such notice will be deemed to have been given on the date
on which it was delivered, or in the case of fax, the next business day after transmission. An Optionee may, at any time, advise
the Company of a change in the Optionee&rsquo;s address or fax number.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Schedule&nbsp;A<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>STOCK OPTION PLAN</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>OPTION CERTIFICATE</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">This Certificate is
issued pursuant to the provisions of the ESSA Pharma Inc. (the &ldquo;<B>Company</B>&rdquo;) stock option plan
(the &ldquo;<B>Plan</B>&rdquo;) and evidences that <FONT STYLE="font-family: Wingdings">&#108;</FONT> is the holder
(the &ldquo;<B>Optionee</B>&rdquo;) of an option (the &ldquo;<B>Option</B>&rdquo;) to purchase up to <FONT STYLE="font-family: Wingdings">&#108;</FONT>
Common Shares Without Par Value (the &ldquo;<B>Common Shares</B>&rdquo;) in the capital stock of the Company. The Exercise
Price of the Option is <FONT STYLE="font-family: Wingdings">&#108;</FONT> per Common Share.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Subject to the provisions of the Plan:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Award Date of the Option is <FONT STYLE="font-family: Wingdings">&#108;</FONT>, <FONT STYLE="font-family: Wingdings">&#108;</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Expiry Date of the Option is <FONT STYLE="font-family: Wingdings">&#108;</FONT>, <FONT STYLE="font-family: Wingdings">&#108;</FONT>; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Option shall vest in accordance with the following schedule:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings">&#108;</FONT>; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings">&#108;</FONT>.</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The vested portion or portions of the
Option may be exercised at any time and from time to time from and including the Award Date through to 5:00 p.m. local time in
Vancouver, British Columbia on the Expiry Date by delivering to the Administrator of the Plan an Exercise Notice, in the form provided
in the Plan, together with this Certificate and a certified cheque or bank draft payable to &ldquo;ESSA Pharma Inc.&rdquo; in an
amount equal to the aggregate of the Exercise Price of the Common Shares in respect of which the Option is being exercised.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">This Certificate and the Option evidenced
hereby are not assignable, transferable or negotiable and are subject to the detailed terms and conditions contained in the Plan,
the terms and conditions of which the Optionee hereby expressly agrees with the Company to be bound by. This Certificate is issued
for convenience only and in the case of any dispute with regard to any matter in respect hereof, the provisions of the Plan and
the records of the Company will prevail.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Option is also subject to the terms
and conditions contained in the schedules, if any, attached hereto. All terms not otherwise defined in this Certificate will have
the meanings given to them under the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Dated this <FONT STYLE="font-family: Wingdings">&#108;</FONT>
day of <FONT STYLE="font-family: Wingdings">&#108;</FONT>, <FONT STYLE="font-family: Wingdings">&#108;</FONT>.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 60%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 3pt 5.4pt"><FONT STYLE="font-size: 11pt"><B>ESSA PHARMA INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding: 3pt 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 88%; padding: 3pt 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 5.4pt"><FONT STYLE="font-size: 11pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 5.4pt">&nbsp;</TD>
    <TD STYLE="padding: 3pt 5.4pt"><FONT STYLE="font-size: 11pt">Administrator, Stock Option Plan</FONT><BR>
<FONT STYLE="font-size: 11pt">ESSA Pharma Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 86 -->
    <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR><TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-size: 10pt">A-1</FONT></TD></TR>
</TABLE>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>OPTION CERTIFICATE &ndash; SCHEDULE</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt">The additional terms and conditions attached to the Option
represented by this Certificate are as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD><FONT STYLE="font-size: 11pt"><B>&#9679;</B></FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding-top: 12pt; font: 12pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">Per:</FONT></TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-top: 12pt; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-top: 12pt; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Administrator, Stock Option
        Plan</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">ESSA Pharma Inc.</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-size: 10pt">A-2</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in">Schedule&nbsp;B<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ESSA
PHARMA INC.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>STOCK OPTION PLAN</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>NOTICE OF EXERCISE OF OPTION</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">TO:&#9;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrator, Stock
Option Plan<BR>
&#9;ESSA Pharma Inc.<BR>
&#9;999 West Broadway Suite 720</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in">Vancouver, British Columbia V5Z 1K5</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The undersigned hereby irrevocably gives
notice, pursuant to the ESSA Pharma Inc. stock option plan (the &ldquo;<B>Plan</B>&rdquo;), of the exercise of the Option to acquire
and hereby subscribes for (cross out inapplicable item):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">all of the Common Shares; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">___________________ of the Common Shares,</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">which are the subject of the Option Certificate attached
hereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">The undersigned tenders herewith a certified
cheque or bank draft (circle one) payable to &ldquo;<B>ESSA Pharma Inc.</B>&rdquo; in an amount equal to the aggregate Exercise
Price of the aforesaid Common Shares and directs the Company to issue the certificate evidencing said Common Shares in the name
of the undersigned to be mailed to the undersigned at the following address:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">___________________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">___________________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">___________________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">By executing this Notice of Exercise
of Option the undersigned hereby confirms that the undersigned has read the Plan and agrees to be bound by the provisions of the
Plan. All terms not otherwise defined in this Notice of Exercise of Option will have the meanings given to them under the Option
Certificate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">DATED the ________ day of ____________________, __________.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left">
Signature of Optionee</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">B-1</FONT></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-size: 11pt">SCHEDULE
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Restricted
Share Unit Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">(See attached)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"></FONT></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font: 9pt Arial, Helvetica, Sans-Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED SHARE UNIT PLAN</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EFFECTIVE February 21, 2018</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 1</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>General Provisions</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>1.1 Purpose </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Restricted Share Unit Plan is established
as a vehicle by which equity-based incentives may be awarded to the employees, consultants, directors and officers of the Company,
to recognize and reward their significant contributions to the long-term success of the Company including to align the employees&rsquo;,
consultants&rsquo; directors&rsquo; and officers&rsquo; interests more closely with the shareholders of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>1.2 Definitions </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in the Plan, the following terms have
the following meanings:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Affiliate</B>&rdquo; has the meaning given to such term
in Policy 1.1 of the TSXV Policies.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Associate</B> has the meaning given to such term in Policy
1.1 of the TSXV Policies.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Blackout Period</B>&rdquo; means a period of time imposed
by the Company, pursuant to the Company's policies, upon certain designated persons during which those persons may not trade in
any securities of the Company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Board</B>&rdquo; means the Board of Directors of the Company;
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Business Day</B>&rdquo; means any day that is not a Saturday,
Sunday or holiday (as defined in the <I>Interpretation Act </I>(Canada)) in Vancouver, British Columbia; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Cash Consideration</B>&rdquo; has the meaning ascribed
<FONT STYLE="color: windowtext">thereto</FONT> in Section 3.2(b);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Change of Control</B>&rdquo; means the occurrence of any
of the following events: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the direct or indirect acquisition or conversion of more than 50%
of the issued and outstanding shares of the Company by a person or group of persons acting in concert, other than through an employee
share purchase plan or employee share ownership plan and other than by persons who are or who are controlled by, the existing shareholders
of the Company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a merger, amalgamation or arrangement of the Company or of the voting
shares of the Company where the voting shares of the resulting merged, amalgamated or arranged company, as applicable, are owned
or controlled by shareholders of whom more than 50% are not the same as the shareholders of the Company immediately prior to the
merger, amalgamation or arrangement; or </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a sale by the Company of greater than 50% of the fair market value
of the assets of the Company, through one or a series of transactions, to an entity that is not controlled by either the shareholders
of the Company or by the Company; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Code</B>&rdquo; means the United States Internal Revenue
Code of 1986, as amended;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Committee</B>&rdquo; means the Compensation Committee of
the Board or such other persons designated by the Board to determine the grants of Restricted Share Units and administer this Plan;
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Common Share</B>&rdquo; means a common share in the capital
of the Company; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Company</B>&rdquo; means ESSA </FONT><FONT STYLE="font-size: 11pt">Pharma
<FONT STYLE="color: windowtext">Inc. and its successors and assigns;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Consultant</B>&rdquo; means an individual or Consultant
Company, other than an Employee, a Director or an Officer of the Company, that:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">is engaged to provide on a bona fide basis, consulting, technical,
management or other services to the Company or an Affiliate, other than services provided in relation to a distribution;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">provides the services under a written contract between the Company
or an Affiliate of the Company and the individual or the Consultant Company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">in the reasonable opinion of the Company, spends or will spend a
significant amount of time and attention to the affairs and business of the Company or an Affiliate; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD>has a relationship with the Company or an Affiliate that enables the individual to be knowledgeable about the business and
affairs of the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Consultant Company</B>&rdquo; means for an individual Consultant,
a company or partnership of which the individual is an employee, shareholder or partner;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Deferred Payment Date</B>&rdquo; means
the date for a Non-Canadian Eligible Person under the Plan after the Redemption Date and not later than the Non-Canadian Eligible
Person&rsquo;s Retirement Date which the Non-</FONT><FONT STYLE="font-size: 11pt">Canadian <FONT STYLE="color: windowtext">Eligible
Person has elected to defer receipt of Common Shares and/or Cash Consideration, as applicable;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(o)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Director</B>&rdquo; means a non-Employee
director of the Board of the Company and/or the board of directors of a Subsidiary of </FONT><FONT STYLE="font-size: 11pt">the
<FONT STYLE="color: windowtext">Company;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(p)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Disinterested Shareholder</B>&rdquo;
means a holder of Common Shares that is not an Insider nor an Associate of an I</FONT><FONT STYLE="font-size: 11pt">nsider<FONT STYLE="color: windowtext">;
</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(q)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Dividend</B>&rdquo; means a dividend
declared and payable on a Common Share in accordance with the Company&rsquo;s dividend policy as the same may be amended from time
to time (an &ldquo;<B>Ordinary Dividend</B>&rdquo;), and may, in the </FONT><FONT STYLE="font-size: 11pt">discretion <FONT STYLE="color: windowtext">of
the Board, include a special or stock dividend (a &ldquo;<B>Special Dividend</B>&rdquo;), and may, in the discretion of the Board,
include a Special Dividend declared and payable on a Common Share; </FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(r)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Eligible Person</B>&rdquo; means any
Employee, Consultant, Director or Officer who is designated as an Eligible Person </FONT><FONT STYLE="font-size: 11pt">pursuant
<FONT STYLE="color: windowtext">to </FONT>Section <FONT STYLE="color: windowtext">2.1;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(s)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Employee</B>&rdquo; means an employee of the Company and/or
of a Subsidiary of the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(t)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Exchange</B>&rdquo; means, collectively,
the </FONT><FONT STYLE="font-size: 11pt">TSX <FONT STYLE="color: windowtext">Venture Exchange, any successor thereto and any other
stock exchange or trading facilities through which the Common Shares trade or are quoted from time to time;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(u)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Fair Market Value</B>&rdquo; means the
closing price of the Common Shares on the Exchange on the Business Day immediately prior to the relevant date, or if the Common
Shares are not listed on the Exchange, then on such </FONT><FONT STYLE="font-size: 11pt">other <FONT STYLE="color: windowtext">stock
exchange or quotation system as may be selected by the Committee, provided that, if the Common Shares are not listed or quoted
on any other stock exchange or quotation system, then the Fair Market Value will be the value determined by the Committee in its
sole discretion acting in good faith;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Grant Date</B>&rdquo; means any date
determined from time to time by the Committee as a date on which a grant of Restricted Share Un</FONT><FONT STYLE="font-size: 11pt">i<FONT STYLE="color: windowtext">ts
will be made to one or more Eligible Persons under this Plan;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">&ldquo;<B>Investor Relations Activities</B>&rdquo; shall have the meaning ascribed to such term
in the TSXV Policies;</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&ldquo;<B>Insider</B>&rdquo; has the meaning given to such term in Policy 1.1 of the TSXV Policies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(y)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Non-Canadian Eligible Person</B>&rdquo; means an Eligible
Person who is not, or has not, been resident, or deemed to be resident, in Canada at any time, and has not received his or her
grant of Restricted Share Units as a result of employment carried on in whole or in part in Canada; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(z)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Officer</B>&rdquo; means an officer
of the Company </FONT><FONT STYLE="font-size: 11pt">that <FONT STYLE="color: windowtext">has been duly appointed by the Board and/or
an officer of a Subsidiary of the </FONT>Company <FONT STYLE="color: windowtext">that has been duly appointed by the board of directors
of such Subsidiary;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(aa)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Plan</B>&rdquo; means this Restricted
Share Unit </FONT><FONT STYLE="font-size: 11pt">P<FONT STYLE="color: windowtext">lan, as amended from time to time;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(bb)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Redemption Date</B>&rdquo; in respect
of any Restricted </FONT><FONT STYLE="font-size: 11pt">Share <FONT STYLE="color: windowtext">Unit means a date to be selected by
the Board following the date a Restricted Share Unit has become a Vested Restricted Share Unit, which shall be within thirty (30)
days of the Vesting Date, </FONT>unless <FONT STYLE="color: windowtext">(i) except with respect to a Vested Restricted Share Unit
held by a U.S. Taxpayer, an earlier date(s) has been approved by the Board as the Redemption Date in respect of such Vested Restricted
Share Unit, or (ii) Section 3.8, 4.1, 4.2, 6.2 is applicable, in which case the Redemption Date(s) in respect of such Vested Restricted
Share Unit shall be the date(s) established as such in accordance with the applicable Section. Such date shall, in all cases, be
in compliance with the requirements pertaining to the exception to the application of the salary deferral arrangement rules in
paragraph (k) of the definition of &ldquo;salary deferral arrangement&rdquo; in subsection 248(1) of the <I>Income Tax Act</I>
(Canada), as such subsection may be amended or enacted from time to time;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(cc)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Reorganization</B>&rdquo; means any
declaration of any stock dividend (other than a Special Dividend in respect of which the Board, in its discretion, determines that
Eligible Persons are to be paid pursuant to Section 3.7), stock split, co</FONT><FONT STYLE="font-size: 11pt">mbination or exchange
of shares, merger, consolidation, recapitalization, amalgamation, plan of <FONT STYLE="color: windowtext">arrangement, reorganization,
spin-off or other distribution (other than Ordinary Dividends) of the Company assets to shareholders or any other similar corporate
transaction or event which </FONT>the <FONT STYLE="color: windowtext">Board determines affects the Common Shares such that an adjustment
is appropriate to prevent dilution or enlargement of the rights of Eligible Persons under this Plan;</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(dd)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Restricted Share Unit</B>&rdquo; means
one </FONT><FONT STYLE="font-size: 11pt">notional <FONT STYLE="color: windowtext">Common Share (without any of the attendant rights
of a shareholder of such Common Share, including, without limitation, the right to vote such Common Share and the right to receive
dividends thereon, except to the extent otherwise specifically provided herein) credited by bookkeeping entry to a notional account
maintained by the Company in respect of an Eligible Person in accordance with this Plan;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ee)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Retirement</B>&rdquo; in respect of
an Eligible Person means the Eligible Person ceasing to be an Employee, Director, Contractor or Officer as a result of a resignation
by the Eligible Person where the Eligible Person is at least 55 years of age; has completed 5 years of service with Company or
an Affiliate and the Eligible Person has indicated that the Eligible Person intends to cease active full-time employment from any
employer;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(ff)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Retirement Date</B>&rdquo; means the
date </FONT><FONT STYLE="font-size: 11pt">an <FONT STYLE="color: windowtext">Eligible Person ceases to be an Employee, Consultant,
Director, or Officer due </FONT>to <FONT STYLE="color: windowtext">Retirement of the Eligible Person;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt">(gg)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">&ldquo;<B>Stock Option Plan</B>&rdquo; means the stock option plan
of the Company dated <B>[&#9679;]</B>, 2018, as amended from time to time;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(hh)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Subsidiary</B>&rdquo; has the meaning
set </FONT><FONT STYLE="font-size: 11pt">out <FONT STYLE="color: windowtext">in the <I>Securities Act</I> (British Columbia); </FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>TSXV Policies</B>&rdquo; means the policies
included in the TSX Venture Exchange Corporate Finance Manual and &ldquo;TSXV Policy&rdquo; </FONT><FONT STYLE="font-size: 11pt">means
<FONT STYLE="color: windowtext">any one of them; </FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(jj)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>U.S. Taxpayer</B>&rdquo; means an </FONT><FONT STYLE="font-size: 11pt">Eligible
<FONT STYLE="color: windowtext">Person who is at the relevant time subject to Section 409A of the Code;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(kk)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Vested Restricted Share Unit</B>&rdquo;
means any Restricted </FONT><FONT STYLE="font-size: 11pt">Share <FONT STYLE="color: windowtext">Unit which has vested in accordance
with the terms of this Plan and/or the terms of any applicable Grant Agreement; and</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 11pt; color: windowtext">(ll)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; color: windowtext">&ldquo;<B>Vesting Date</B>&rdquo; means, in respect
of any Restricted Share Unit, the date that the Restricted Share Unit becomes a Vested Restricted Share Unit and shall, in all
</FONT><FONT STYLE="font-size: 11pt">cases<FONT STYLE="color: windowtext">, be in compliance with the requirements pertaining to
the exception to the application of the salary deferral arrangement rules in paragraph (k) of the definition of &ldquo;salary deferral
arrangement&rdquo; in subsection 248(1) of the <I>Income Tax Act</I> (Canada), as such subsection may be amended or enacted from
time to time.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>1.3 Effective Date </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">The Plan shall
be effective February 21<B>, </B>2018; provided that no Common Shares and/or Cash Consideration, as </FONT>applicable<FONT STYLE="color: windowtext">,
may be issued and/or paid under the Plan until and unless all required Exchange, regulatory and shareholder approvals have been
obtained with respect to the issuance of Common Shares and/or payment of Cash Consideration, as applicable, hereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext"></FONT></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>1.4 Governing Law; Subject to Applicable Regulatory Rules </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">The Plan shall
be governed by and construed in accordance with the laws of the Province of British </FONT>Columbia <FONT STYLE="color: windowtext">and
the federal laws of Canada applicable therein. The provisions of the Plan shall be subject to the applicable by-laws, rules and
policies of the Exchange and applicable securities legislation. </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 2</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Eligibility and Participation</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.1 Eligibility </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">This Plan applies
to those Employees, Consultants, Directors and Officers whom the Committee designates as </FONT>eligible <FONT STYLE="color: windowtext">for
a grant of Restricted Share Units pursuant to Section 3.1. The Committee shall make such a designation prior to each Grant Date.
</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.2 Rights Under the Plan</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to Sections 4 and 5, an Eligible Person
who has been granted Restricted Share Units shall continue to have rights in respect of such Restricted Share Units until such
Restricted Share Units have been redeemed for Common Shares and/or Cash Consideration, as applicable, in accordance with this Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.3 Copy of the Plan</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">The Company
shall provide each Eligible Person with a copy of this Plan following the initial grant of Restricted </FONT>Share <FONT STYLE="color: windowtext">Units
to such Eligible Person and shall provide each Eligible Person with a copy of all amendments to this Plan. </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.4 Limitation on Rights</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">Nothing in
this Plan shall confer on any Employee, Consultant, Director or Officer any right to be designated as an Eligible Person or to
be granted any Restricted Share Units. There is no obligation for uniformity of treatment of Eligible Persons or any group of Employees,
Consultants, Directors, Officers or Eligible Persons, whether based on salary or compensation, grade or level or organizational
position or level or otherwise. A grant of Restricted Share Units to an Eligible Person on one or more Grant Dates shall not be
construed to create a right to a grant of Restricted Share Units on a </FONT>subsequent <FONT STYLE="color: windowtext">Grant Date.
</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.5 Grant Agreements </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">Each grant
of Restricted Share Units shall be evidenced by a written agreement (a &ldquo;<B>Grant Agreement</B>&rdquo;) executed by </FONT>the
<FONT STYLE="color: windowtext">Eligible Person in substantially the form appended as Schedule A hereto. An Eligible Person will
not be entitled to any grant of Restricted Share Units or any benefit of this Plan unless the Eligible Person agrees with the Company
to be bound by the provisions of this Plan. By entering into an </FONT>agreement <FONT STYLE="color: windowtext">described in this
Section 2.5, each Eligible Person shall be deemed conclusively to have accepted and consented to all terms of this Plan and all
bona fide actions or decisions made by the Committee. Such terms and consent shall also apply to and be binding on the legal representative,
beneficiaries, heirs and successors of each Eligible Person.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext"></FONT></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.6 Limits on Common Shares Issuable </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The number of Common Shares which may be reserved for issuance under
the Plan in combination with the aggregate number of Common Shares which may be issuable under any and all of the Company&rsquo;s
equity incentive plans in existence from time to time on and after the effective date of the Plan, including the Company&rsquo;s
Stock Option Plan, shall not exceed 23,104,377 Common Shares, or such greater number of Common Shares as shall have been duly approved
by the Board and, if required by the TSXV Policies or any other stock exchange on which the Common Shares of the Company may then
be listed, by the shareholders of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The number of Common Shares which may be issuable under the Plan
and all of the Company&rsquo;s other security based compensation arrangements in existence from time to time on and after the effective
date of the Plan, within any one-year period: </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to any one Eligible Person, shall not exceed 5% of the total number
of issued and outstanding Common Shares on the Grant Date on a non-diluted basis;</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">to Insiders as a group shall not exceed 10% of the total number of
issued and outstanding Common Shares on the Grant Date on a non-diluted basis; and</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">To any one Consultant shall not exceed 2% of the total number of
issued and outstanding Common Shares on the Grant Date on a non-diluted basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">To all Eligible Persons retained by the Company to provide Investor
Relations Activities as a group, shall not exceed 2% of the total number of issued and outstanding Common Shares on a non-diluted
basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>2.7 No Fractional Shares </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No fractional Common Shares may be issued under
the Plan. In the event the number of Common Shares to be issued upon the redemption of Restricted Share Units is a fraction, the
respective Eligible Person will receive the next lowest whole number of Common Shares and will not receive any other form of compensation
(cash or otherwise) for the fractional interest.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 3</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Restricted Share Units</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>3.1 Grant of Restricted Share Units </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On each Grant Date, the Committee shall designate
Eligible Persons and determine the number of Restricted Share Units to be granted to each Eligible Person in the Committee&rsquo;s
sole discretion.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3.2 Redemption of Restricted Share Units
</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless redeemed earlier in accordance with
this Plan, the Restricted Share Units of each Eligible Person will be redeemed on or about (but no later than 30 days following)
each applicable Vesting Date or, if applicable, at a later Deferred Payment Date(s), the Eligible Person will be entitled to receive
and the Company will issue and/or pay to the Eligible Person, as applicable:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a number of Common Shares equal to the number of Vested Restricted Share Units (net of any applicable
statutory withholdings) on the Redemption Date(s) or Deferred Payment Date(s), as the case may be;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a cash amount, payable by way of certified cheque, bank draft, wire transfer or such other means
as the Board may determine in its sole discretion, equal to the number of Common Shares set out in subsection (a) above multiplied
by the Fair Market Value on the applicable Vesting Date (the &ldquo;<B>Cash Consideration</B>&rdquo;) (net of any applicable statutory
withholdings) on the Redemption Date(s) or Deferred Payment Date(s), as the case may be; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a combination of (a) and (b),</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">as </FONT>determined
<FONT STYLE="color: windowtext">by the </FONT>Committee <FONT STYLE="color: windowtext">in its sole discretion.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3.3 Deferred Payment Date</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">Non-Canadian
Eligible Persons may elect to defer the receipt of all or any part of their entitlement to Common Shares and/or Cash Consideration,
as applicable, until a Deferred Payment Date. </FONT>Elections <FONT STYLE="color: windowtext">made by U.S. Taxpayers to defer
the receipt of all or any part of their entitlement to Common Shares and/or Cash Consideration, as applicable, until a Deferred
Payment Date shall comply with timing of election requirements and the timing and form of payment requirements of Section 409A
of the Code.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3.4 Prior Notice of Deferred Payment Date</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">Non-Canadian
Eligible Persons who elect to set a Deferred Payment Date must give the Company written notice of one or more Deferred Payment
Dates not later than thirty (30) days prior to the </FONT>applicable <FONT STYLE="color: windowtext">Redemption Date(s); provided
however, that in the case of a U.S. Taxpayer, such election must be made prior to the year of the Grant Date of the Restricted
Share Units to which the election relates. Non-Canadian Eligible </FONT>Persons <FONT STYLE="color: windowtext">may change a Deferred
Payment Date by providing written notice to the Company not later than thirty (30) days prior to the Deferred Payment Date.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>3.5 Blackout Period</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event the Redemption Date or, if applicable,
the Deferred Payment Date, determined in accordance with the Plan occurs during a Blackout Period applicable to the relevant Eligible
Person, then the Redemption Date or the Deferred Payment Date, as applicable, shall be the date that is the tenth Business day
after the expiry of the Blackout Period; provided, however, that in the case of a U.S. Taxpayer, the change in the Redemption Date
or the Deferred Payment Date does not violate Section 409A of the Code.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>3.6 Withholding Taxes</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may take such steps as are considered
necessary or appropriate for the withholding of any taxes which the Company is required by any law or regulation of any governmental
authority whatsoever to withhold in connection with any Common Share and/or Cash Consideration including, without limiting the
generality of the foregoing, the withholding of the issue of Common Shares and/or the withholding of all or any portion of any
payment of the Cash Consideration, as applicable, to be issued and/or paid under the Plan, until such time as the Eligible Person
has paid the Company for any amount which the Company is required to withhold with respect to such taxes or other amounts. Without
limitation to the foregoing, the Committee may, if applicable, adopt administrative rules under the Plan which provide for the
sale of Common Shares (or a portion thereof) in the market upon the issuance of such Common Shares under the provisions of the
Plan to satisfy withholding obligations under the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>3.7 Payment of Dividend Equivalents</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When Dividends are paid on Common Shares, an
Eligible Person shall be credited with Dividend equivalents in respect of the Restricted Share Units credited to the Eligible Person&rsquo;s
account as of the record date for payment of Dividends. Such Dividend equivalents shall be converted into additional Restricted
Share Units (including fractional Restricted Share Units) based on the Fair Market Value per Common Share on the date credited
and redeemed on the Redemption Date or Deferred Payment Date, as applicable, of the Restricted Share Unit with respect to which
the Dividend equivalent was granted.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>3.8 Adjustments </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any change occurs in the outstanding Common
Shares by reason of a Reorganization, the Committee, in its sole discretion, and without liability to any person, shall make such
equitable changes or adjustments, if any, as it considers appropriate, in such manner as the Committee may consider equitable,
to reflect such change or event including, without limitation, adjusting the number of Restricted Share Units credited to Eligible
Persons and outstanding under the Plan, provided that any such adjustment will not otherwise extend the Redemption Date otherwise
applicable. The Company shall give notice to each Eligible Person of any adjustment made pursuant to this section and, upon such
notice, such adjustment shall be conclusive and binding for all purposes. The existence of outstanding Restricted Share Units shall
not affect in any way the right or power and authority of the Company or its shareholders to make or authorize any alteration,
recapitalization, reorganization or any other change in the Company&rsquo;s capital structure or its business or any merger or
consolidation of the Company, any issue of bonds, debentures or preferred or preference shares (ranking ahead of the Common Shares
or otherwise) or any right thereto, or the dissolution or liquidation of the Company, any sale or transfer of all or any part of
its assets or business or any corporate act or proceeding whether of a similar character or otherwise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 4</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Events Affecting Entitlement</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>4.1 Termination of Employment or Election as a Director </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt"><B><U>Voluntary Termination or Termination for Cause.</U></B> If
an Eligible Person is terminated by the Company for cause (as determined by the Company), or if an Eligible Person, voluntarily
terminates employment for any reason or resigns as a Director, as applicable, prior to a Redemption Date, all of the Eligible Person&rsquo;s
Restricted Share Units shall be cancelled and no amount shall be paid by the Company to the Eligible Person in respect of the Restricted
Share Units so cancelled. Any Restricted Share Units outstanding after a Redemption Date for which an Eligible Person who is terminated
as set out in this Section 4.1(a) has elected a Deferred Payment Date will be redeemed for an equal number of Common Shares, Cash
Consideration in lieu thereof or a combination of both, as determined by the Board in its sole discretion, as soon as possible
but no later than 30 days following the date of termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt"><B><U>Involuntary Termination.</U></B> The Restricted Share Units
of an Eligible Person which are Vested Restricted Share Units on the applicable date, other than a Director, who is involuntarily
terminated by the Company, for reasons other than cause, shall be redeemed for an equal number of Common Shares, Cash Consideration
in lieu thereof or a combination of both, as determined by the Board in its sole discretion. For the purposes of this Section 4.1(b),
the Redemption Date shall be the date on which the employment of the Eligible Person, other than a Director, is terminated as stated
in a written notice of termination, irrespective of any entitlement of the Eligible Person to notice, pay in lieu of notice or
benefits beyond the termination date. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt"><B><U>Termination related to Directors.</U></B> The Restricted Share
Units of a Director, who is not re-elected at an annual or special meeting of shareholders shall be redeemed for such number of
Common Shares equal to the number of Vested Restricted Share Units on the Redemption Date or Cash Consideration in lieu thereof
or a combination of both, as determined by the Board in its sole discretion. For purposes of this Section 4.1(c), the Redemption
Date shall be the date on which the annual or special meeting is held. </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt"><B><U>Termination on Change of Control</U>.</B> Notwithstanding anything
else herein to the contrary, if an Eligible Person&rsquo;s employment is terminated, for reasons other than cause, at any time
within 12 months following a Change of Control, then the Corporation shall redeem 100% of the Restricted Share Units granted to
such Eligible Person and outstanding under the Plan as soon as reasonably practical following such termination, but no later than
thirty (30) days following the Redemption Date for an equal number of Common Shares, Cash Consideration in lieu thereof or a combination
of both, as determined by the Board in its sole discretion. For the purposes of this Section 4.1(d) the Redemption Date shall be
the last day such Eligible Person provides actual service to the Company pursuant to a written notice of termination and does not
include any subsequent common law or contractual notice period.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: windowtext">For purposes
of Section 4.1, a U.S. Taxpayer shall be treated as terminated when such person incurs a &ldquo;separation from service&rdquo;
within the meaning of Section 409A of the Code and United States Treasury Regulation Section 1.409A-1(h) (&quot;<B>Separation from
Service</B>&quot;). Solely to the extent required by Section 409A of the Code, any payment in respect of Restricted Share Units
which has become payable on or following a Separation from Service to any U.S. Taxpayer who is determined to be a &quot;specified
employee,&quot; under Section 409A(a)(2)(B)(i) of the Code and United States Treasury Regulation Section 1.409A-1(i), shall not
be paid before the date that is six months after such U.S. Taxpayer's Separation from Service (or, if earlier, the date of the
death of such U.S. Taxpayer).</FONT> Following any applicable six month delay of payment, all such delayed payments shall be made
to the U.S. Taxpayer in a single lump sum on <FONT STYLE="color: windowtext">the</FONT> earliest possible date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>4.2 Death </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Restricted Share Units of an Eligible
Person who dies shall be redeemed in accordance with Section 3.2. For the purposes of the foregoing, the Redemption Date shall
be the date of the Eligible Person&rsquo;s death.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>4.3 No Grants Following Last Day of Active Employment</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event of termination of any Eligible
Person&rsquo;s employment with the Company, such Eligible Person shall not be granted any Restricted Share Units pursuant to Section
3.1 after the last day of active employment of such Eligible Person. Without limiting the generality of the foregoing and of Section
2.4, notwithstanding any other provision hereof, and notwithstanding any provision of any employment agreement between any Eligible
Person and the Company, no Eligible Person will have any right to be awarded additional Restricted Share Units, and shall not be
awarded any Restricted Share Units, pursuant to Section 3.1 after the last day of active employment of such Eligible Person on
which such Eligible Person actually performs the duties of the Eligible Person&rsquo;s position, whether or not such Eligible Person
receives a lump sum payment of salary or other compensation in lieu of notice of termination, or continues to receive payment of
salary, benefits or other remuneration for any period following such last day of active employment. Notwithstanding any other provision
hereof, or any provision of any employment agreement between the Company and an Eligible Person, in no event will any Eligible
Person have any right to damages in respect of any loss of any right to be awarded Restricted Share Units pursuant to Section 3.1
after the last day of active employment of such Eligible Person and no severance allowance, or termination settlement of any kind
in respect of any Eligible Person will include or reflect any claim for such loss of right and no Eligible Person will have any
right to assert, claim, seek or obtain, and shall not assert, claim, seek or obtain, any judgment or award in respect of or which
includes or reflects any such right or claim for such loss of right.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 5</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Administration</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>5.1 Transferability</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Rights respecting Restricted Share Units shall not be transferable
or assignable other than by will or the laws of decent and distribution.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>5.2 Administration </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Committee shall, in its sole and absolute
discretion, but subject to applicable corporate, securities and tax law requirements: (i) interpret and administer the Plan; (ii)
establish, amend and rescind any rules and regulations relating to the Plan; and (iii) make any other determinations that the Committee
deems necessary or desirable for the administration and operation of the Plan. The Committee may delegate to any person any administrative
duties and powers under this Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in
the Plan in the manner and to the extent the Committee deems, in its sole and absolute discretion, necessary or desirable. Any
decision of the Committee with respect to the administration and interpretation of the Plan shall be conclusive and binding on
the Eligible Person and his or her legal representative. The Board may establish policies respecting minimum ownership of Common
Shares of the Company by Eligible Persons and the ability to elect Restricted Share Units to satisfy any such policy.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is intended that this Plan and Grant Agreements
will comply with Section 409A of the Code (and any regulations and guidelines issued thereunder), to the extent this Plan and such
agreements are subject thereto, and this Plan and such agreements shall be interpreted on a basis consistent with such intent.
Each amount to be paid under the Plan shall be construed as a separate identified payment for the purposes of Section 409A of the
Code. If an amendment of this Plan and such agreements is necessary in order for it to comply with Section 409A of the Code, the
Board will adopt any such amendment in a manner that preserves the original intent of the parties to the extent reasonably possible.
No action or failure to act by the Board shall subject the Company to any claim, liability, or expense, and the Company shall not
have any obligation to indemnify or otherwise protect any person from the obligation to pay any taxes, interest or penalties pursuant
to Section 409A of the Code.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>5.3 Records</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will maintain records indicating
the number of Restricted Share Units credited to an Eligible Person under the Plan from time to time and the Grant Dates of such
Restricted Share Units. Such records shall be conclusive as to all matters involved in the administration of this Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>5.4 Statements</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">The Company shall furnish annual statements to each Eligible Person
indicating the number of Restricted Share Units credited to the Eligible Person and the Grant Dates of the Restricted Share Units
and such other information that the Company considers relevant to the Eligible Person.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>5.5 Legal Compliance</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Without limiting the generality of the foregoing,
the Committee may take such steps and require such documentation from Eligible Persons as the Committee may determine are desirable
to ensure compliance with all applicable laws and legal requirements, including all applicable corporate and securities laws and
regulations of any country, and any political subdivisions thereof, and the by-laws, rules and regulations of any stock exchanges
or other organized market on which Common Shares may from time to time be listed or posted and any applicable provisions of the
<I>Income Tax Act</I> (Canada), as amended or income tax legislation or any other jurisdiction.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 6</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amendment and Termination</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>6.1 Amendment </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The Board reserves the right, in its sole discretion, to amend, suspend
or terminate the Plan or any portion thereof at any time, provided that no such amendment, suspension or termination may be (i)
made without obtaining any required regulatory or shareholder approvals, or (ii) adversely affect the rights of any Eligible Person
with respect to the Restricted Share Units to which the Eligible Person is then entitled under the Plan without the consent of
the Eligible Person. Notwithstanding the foregoing, the Company will be required to obtain the Disinterested Shareholder approval
for any amendment related to:</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">the number or percentage of issued and outstanding Common Shares
available for grant under the Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">a change in the method of calculation of redemption of Restricted
Share Units held by Eligible Persons; and</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">an extension to the term for redemption of Restricted Share Units
held by Eligible Persons.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Unless an Eligible Person otherwise agrees, any amendment to the
Plan or Restricted Share Unit shall apply only in respect of Restricted Share Units granted on or after the date of such amendment.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">Without limiting the generality of the foregoing, the Board may make
the following amendments to the Plan, without obtaining shareholder approval:</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments to the terms and conditions of the Plan necessary to ensure
that the Plan complies with the applicable regulatory requirements, including the rules of the Exchange, in place from time to
time;</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments to the provisions of the Plan respecting administration
of the Plan and eligibility for participation under the Plan; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments to the provisions of the Plan respecting the terms and
conditions on which Restricted Share Units may be granted pursuant to the Plan, including the provisions relating to the payment
of the Restricted Share Units; and </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">amendments to the Plan that are of a &ldquo;housekeeping&rdquo; nature.
</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>6.2 Termination of the Plan</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may from time to time amend or suspend
this Plan in whole or in part and may at any time terminate this Plan. No such amendment, suspension or termination shall adversely
affect the rights of any Eligible Person at the time of such amendment, suspension or termination with respect to outstanding and
unredeemed Restricted Share Units credited to such Eligible Person without the consent of the affected Eligible Person. If the
Board terminates the Plan, no new Restricted Share Units will be awarded to any Eligible Person, but outstanding and unredeemed
previously credited Restricted Share Units shall remain outstanding, be entitled to payments as provided under Section 3.7, and
be paid in accordance with the terms and conditions of this Plan existing at the time of termination. This Plan will finally cease
to operate for all purposes when the last remaining Eligible Person receives a payment in satisfaction of all outstanding and unredeemed
Restricted Share Units credited to such Eligible Person, or all outstanding and unredeemed Restricted Share Units credited to such
Eligible Person are cancelled pursuant to the provisions thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Article 7</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>General</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>7.1 Rights to Common Shares and/or Cash Consideration</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Plan shall not be interpreted to create
any entitlement of any Eligible Person to any Common Shares, or to the dividends payable pursuant thereto, or to any Cash Consideration,
as applicable, except as expressly provided herein. A holder of Restricted Share Units shall not have rights as a shareholder of
the Company with respect to any Common Shares which may be issuable pursuant to the Restricted Share Units so held, whether voting,
right on liquidation or otherwise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>7.2 No Right to Employment</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Plan shall not be interpreted as either
an employment or trust agreement. Nothing in this Plan nor any Committee guidelines or any agreement referred to in Section 2.5
nor any action taken hereunder shall be construed as giving any Eligible Person the right to be retained in the continued employ
or service of the Company or any of its subsidiaries, or giving any Eligible Person or any other person the right to receive any
benefits not specifically expressly provided in this Plan nor shall it interfere in any way with any other right of the Company
to terminate the employment or service of any Eligible Person at any time.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>7.3 Right to Funds </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither the establishment of this Plan nor
the granting of Restricted Share Units under this Plan shall be deemed to create a trust. Amounts payable to any Eligible Person
under the Plan shall be a general, unsecured obligation of the Company. The right of the Employees, Consultants, Directors or Officers
to receive payment pursuant to this Plan shall be no greater than the right of other unsecured creditors of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED SHARE UNIT GRANT AGREEMENT</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED SHARE UNIT PLAN OF ESSA PHARMA
INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Restricted Share Unit Grant
Agreement is made the _____ day of _____, 20___<U></U> between ___________________________________________, the undersigned
&ldquo;Eligible Person&rdquo; (the&nbsp;&ldquo;Eligible Person&rdquo;), being an employee, consultant, director or officer of
ESSA Pharma Inc. (the&nbsp;&ldquo;Company&rdquo;) or a subsidiary thereof, name or designated pursuant to the terms of the
Restricted Share Unit Plan of the Company (which Plan, as the same may from time to time be modified, supplemented or amended
and in effect, is herein referred to as the &ldquo;Plan&rdquo;), and the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration of the grant of Restricted
Share Units made to the Eligible Person pursuant to the Plan (the receipt and sufficiency of which are hereby acknowledged), the
Eligible Person hereby agrees and confirms that:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The Eligible Person has received a copy of the Plan and has read,
understands and agrees to be bound by the provisions of the Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The Eligible Person accepts and consents to and shall be deemed conclusively
to have accepted and consented to, and agreed to be bound by, the provisions and all terms of the Plan and all bona fide actions
or decisions made by the Board, the Committee, or any person to whom the Committee may delegate administrative duties and powers
in relation to the Plan, which terms and consent shall also apply to and be binding on the legal representatives, beneficiaries
and successors of the undersigned.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">On ____________, 20___, the Eligible Person was granted
                                                                                                    _______________________ Restricted Share Units, which grant is evidenced by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">The Redemption Date(s) for the Restricted Share Units is/are as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 6in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 11pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt">This Restricted Share Unit Grant Agreement shall be considered as
part of and an amendment to any employment agreement between the Eligible Person and the Company and the Eligible Person herby
agrees that the Eligible Person will not make any claim under that employment agreement for any rights or entitlement under the
Plan or damages in lieu thereof except as expressly provided in the Plan. </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Agreement shall be determined in accordance
with the laws of the province of British Columbia and the laws of Canada applicable therein. Words used herein which are defined
in the Plan shall have the respective meanings ascribed to them in the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ESSA PHARMA INC.</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Per: ____________________________</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Authorized Signatory</P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ELIGIBLE PERSON</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>____________________________</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Print Name:</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Eligible Person)</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"></FONT></P>


<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>SCHEDULE
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt"><B>Board
Mandate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 11pt">(See attached)</FONT></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 11pt Arial, Helvetica, Sans-Serif"><B></B>&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 11pt Arial, Helvetica, Sans-Serif"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>ESSA PHARMA INC.</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><BR>
<FONT STYLE="text-transform: uppercase"><B>Board Mandate</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Purpose</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in">The board of directors
(the &ldquo;<B>Board</B>&rdquo;) of ESSA Pharma Inc. (the &ldquo;<B>Corporation</B>&rdquo;) is responsible for the proper stewardship
of the Corporation. The Board is mandated to represent the shareholders to select the appropriate Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;)
of the Corporation, assess and approve the strategic direction of the Corporation, ensure that appropriate processes for risk assessment,
management and internal control are in place, monitor management performance against agreed bench marks, develop the Corporation&rsquo;s
approach to corporate governance, and assure the integrity of financial reports.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Membership and Reporting</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Board will be comprised of at least three &ldquo;independent&rdquo; directors within the meaning
of the applicable securities laws, and rules and policies of the stock exchange(s) on which the Corporation&rsquo;s securities
are listed. The Board will have the number of directors as may be determined in accordance with the <I>Business Corporations Act</I>
(British Columbia) and the Corporation&rsquo;s articles and bylaws.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Appointments to the Board will be reviewed on an annual basis. The Corporate Governance Committee
(the &ldquo;<B>CGC</B>&rdquo;), in consultation with the CEO, is responsible for identifying and recommending new nominees with
appropriate skills to the Board.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The chairman of the Board (the &ldquo;<B>Chairman</B>&rdquo;) will be an independent director,
unless the Board determines that it is inappropriate to require the Chairman to be independent. If the Board determines that it
would be inappropriate to require the Chairman to be independent, then the independent directors shall select from among their
number a director who will act as &ldquo;Lead Director&rdquo; and who will assume responsibility for providing leadership to enhance
the effectiveness and independence of the Board.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The Board will report to the shareholders of the Corporation and will develop, in its discretion,
a formal or informal communication policy for the Corporation that includes measures for receiving feedback from the Corporation&rsquo;s
shareholders.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Terms of Reference</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Meetings</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Board will meet as required, but at least once quarterly.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The independent directors will meet as required, without the non-independent directors and members
of management, but at least once quarterly.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-size: 10pt">-2-</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Meeting Preparation and Attendance</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">In connection with each meeting of the Board and each meeting of a committee of the Board of which
a director is a member, each director will:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">review thoroughly the materials provided to the directors in connection with the meeting and be
adequately prepared for the meeting; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">attend each meeting in person, by phone or by video-conference depending on the format of the meeting,
to the extent practicable.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Corporate Planning</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>The Board will:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">adopt a strategic planning process and approve a strategic plan each year which takes into account,
among other things, the opportunities and risks of the Corporation; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">approve and monitor the operational plans and budgets of the Corporation submitted by management
at the beginning of each fiscal year.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Risk Management and Ethics</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>The Board will:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">ensure that the business of the Corporation is conducted in compliance with applicable laws and
regulations and according to the highest ethical standards;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">identify and document the principal risks, including financial risks and other risks that the Corporation
must face in the course of its business and ensure the implementation of appropriate systems to manage these risks; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">adopt a disclosure policy.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Supervision of Management</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD>The Board will:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to the extent feasible, satisfy itself as to the integrity of the CEO and other executive officers
and that all such officers are creating a culture of integrity throughout the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">ensure that the CEO is appropriately managing the business of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">ensure appropriate succession planning is in place;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">establish corporate objectives for the CEO annually and evaluate the performance of the CEO against
these corporate objectives;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-size: 10pt">-3-</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">consider and approve major business initiatives and corporate transactions proposed by management;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">ensure the Corporation has internal control and management information systems in place.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Management of Board Affairs</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD>The Board will:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">develop a process for the orientation and education of new members of the Board;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">support continuing education opportunities for all members of the Board;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">in conjunction with the CGC, assess the participation, contributions and effectiveness of the Chairman
and individual board members on an annual basis;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">monitor the effectiveness of the Board and its committees and the actions of the Board as viewed
by the individual directors and senior management;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">establish the committees of the Board it deems necessary to assist it in the fulfillment of its
mandate; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">disclose on an annual basis the mandate and composition of the Board and its committees.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 12pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Approved by the Board: <B>_______________</B>,
2018</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 11pt Arial, Helvetica, Sans-Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "A @\# 2(  A$! Q$!_\0
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MXBGB8T^ZJ^SG)TY:/2<*325VK>\7**0,IY# CU!%+D'H0:X#UPHHHH ****
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M*>%P. PU7%8G$57:%.E2@Y2=DTY-OEC&$;SE.<8QC*4E%^(?\%#/^"F_P/\
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M_P"@+"?^$N%_^9#E_P#A$_#?_0NZ/_X*--_^1J/^$3\-_P#0NZ/_ ."C3?\
MY&KJ**.>?_/VO_X4XK_YJ#ZC@?\ H"PG_A+A?_F0Y?\ X1/PW_T+NC_^"C3?
M_D:C_A$_#?\ T+NC_P#@HTW_ .1JZBBCGG_S]K_^%.*_^:@^HX'_ * L)_X2
MX7_YD.6/A/PY_P!"]HWXZ/IQ'Z6W'/L:TM)TJPTE)(=.LH;&!V:0Q6\*01&1
MVR[B)$C56;C<0N6 7<3@8UZ*3G4DN656I.',I*$YSG%22MS?O*E5\VKM).+2
M]U:%4\+AJ,W4HX?#TIN/*YTZ%&G-QNGR\]*E1ERMJ[B^:+>MKI!1114G003D
M*%).WD\]NG<]LG YK^%O_@X&_:JO/C%^U;;_   T'49#X!_9PLX;"\M8I&6"
M^^*/BG3K'6_$>I[H_ED72-!O-"\+6T99FL+^S\3Q1B)KR9G_ +FM2E2.W9W;
M"JK,<<DA0#] !W8_*#C/6O\ +/\ CUX]U'XJ?''XO_$S5KF2ZU'Q]\3/'GC"
MZD9CM$OB+Q1J>JM&B!F5(HC<>7;QY;R;=8XD8QJH']&_1JX;P^:\7YEG6*I1
MK0R#*U/#0E9J&.S"NL/&N]VI4J%&?LDDK2G)_:N?RK]*SB7%97PIDF0X2O*A
M+/\ ,:];&<C:=3!9/2I5H4[K11JXO%Q52#TJ*C3OS."2\F4$9!]<]..?0]_R
M&*=_7@?7THIK8 +$@!0222...N#QQUSVQZ'-?W3)\JE)*[]Z;7=VE.3;Z749
MMMV2M>34;M?Y]Q4JDU%:RG))><I222\KRDE=V2O=M+4_3G_@F]_P3$^+'_!0
M;QA?WFGWLW@'X)>"[^WL_'WQ,N; W4YU*6VBO4\'^#=,E>.'6_%,UG-!=W;S
MSP:5X>T^YMKW4I+B[NM/TB__ +._V;_^"4O[#W[,>E6,'@KX%>&/$_B:T:.>
M;XA?$_3M/^('C6\O5$ EO8;W7=.GT_P_)/\ 9XQ+!X4TGP]8D[I(K.)Y)';U
MW]@SX Z!^S-^RE\$_A)H-E#:2:#X"\.WWB2=(ECFU?QKKUA'KGC#6KO$<;F7
M4-?O[UXHI%!M;1+:T0+##&H^R:_SJ\4?%?B'C+.L?A<+F&-RWAO!XJOA<NRW
M"5YX95Z.'K2IK&8V="<)8BOB94IU7&<Y4:5.I&E"FU%3?^FOA%X,<+\'Y%EV
M8YAEN$S7B;'X&AB,;CL93IXNG@I8B,<1]3P%#$4JU"A'#PJPHU:KHSK5*L:D
M_:04E%8=KI-C;1K!9V%K:PQ#;'##:K;PQANHBB2*&, X^8 -VZ<9AO- TN_B
M:"]TVRNX9/\ 617%E;W$;X'&Z.6"2,X[93')XZ8Z*BOR#GJ\_/[:K>Z=N>5V
MTMW-3C4NW[U^:]_+0_<'@L)*/(\-AW3LH^SEA\)*GRK9>SE@G3LNB]GH]=]3
MXC^+?_!.S]B/XY17:_$;]E[X/ZO>7L4D5UKUAX-T_P *>*7$@<;T\5^%;?0_
M$:2KYDACECU17A+,8V0NV[\5OVF/^#;?X4>)+2_UG]EGXH^(OAIKICGE@\#?
M$K[1XT\$WTL?-I8VOB>W2+QCX=A)8K->WQ\:LA_>0V<B$K7]0M,<$XP">O\
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M&^#WP,TB.5IOB9X[T/PW>W,"*SZ7X>ENEN_%VNAR"R+H'A*TUS6'VJP(LL.
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M)K51=TGIS1:U3MW3:=O/KM_6?_P;9?M1$Z5\9/V2=>O%\W3I_P#A<_PZ@GN
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M3VSR6TUY9VVIQVMS);.T$DT$DD>U6"#_ "R#_4?S%?Z:G_!/3_DQ#]C =_\
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MF0X["Y[/&93CJ^ Q,\-@\-5H2K8=P4I4JD\;2E*#YU9N"ZI.5KG[UP_]'3Q
MXER/*^(,M_L-8#-\%1Q^$^M9O'#U_85N?D]I1^I5E!_NY:.L[JS:B_=/X+J*
M_O._XA]/^">7_0M_%C_PZ&L__(E'_$/I_P $\O\ H6_BQ_X=#6?_ )$KRO\
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M#.<KS#+*R?*J6.P>)PTW)6YK.OAZ4)K=J5*=6+C9J36HM-;&6)17WX#!E#
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MF,CD7<HZ\'(P,D'!&>.>]>6_%3X-_#3XW^#]3\ ?%GP/X>^('@[6$V:CX?\
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M@VN?]G ?$3_TP>!:_?5>@^@_E7^8?B?_ ,G$XT_[*',/_2Z)_K'X-_\ )J^
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MBT_Q-X9UF%C!>V3-OMYXVQ/8W]M*$NM/U*T8>5>6%W%%<6LBXD0[D=OY;_\
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MA]V?\//O^"A/_1W'QL_\+&\H_P"'GW_!0G_H[CXV?^%C>5\)T5C_ *G<)_\
M1-9#_P"&;*O_ )WFW^N?%_\ T5/$7_A[S3_YN/NS_AY]_P %"?\ H[CXV?\
MA8WE'_#S[_@H3_T=Q\;/_"QO*^$Z*/\ 4[A/_HFLA_\ #-E7_P [P_USXO\
M^BIXB_\ #WFG_P W'W9_P\^_X*$_]'<?&S_PL;RC_AY]_P %"?\ H[CXV?\
MA8WE?"=%'^IW"?\ T360_P#AFRK_ .=X?ZY\7_\ 14\1?^'O-/\ YN/NL_\
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M)RE*H\$H.OEM:HYN[C.E4J8:,GK*>':UC%6EF_@_WJ_@6_X+$_L[_M">-O\
M@I%^TSXL\$_ ;XT>,?"^KZG\-/[)\2>%?A=XW\0^']4BLO@Q\.K"[DT[6-)T
M&\T^]6UU2VO].N6MKF18+RRN;27;<6TR+_?8X)Q@$]?Z51%K$7):'=P>7C)'
M)'0L"!GT4*.^.:^0\/>/L1X=YU7SG#9?0S*KB<OJY<J&(KXC#TXQJU:=9U55
MP\)R4XNDHJ,TH-2=WS<I]IXI^&U#Q.R3!9)B,UJY13PN8PS#V]'#4L54J3IX
M>MAU2]G6J4H*+55S<E-23BDKIL_R\/\ AE#]J_\ Z-@_:(_\,I\2?_F9H_X9
M0_:O_P"C8/VB/_#*?$G_ .9FO]1!K6$=+:,_]L@?Y#_/\F_9HO\ GUC_ ._7
M_P!:OV;_ (FDSK_HD\K_ /#OF'_S.?@O_$H.5?\ 1;YC_P"&; __ #>?Y>/_
M  RA^U?_ -&P?M$?^&4^)/\ \S-'_#*'[5__ $;!^T1_X93XD_\ S,U_J'?9
MHO\ GUC_ ._7_P!:C[-%_P ^L?\ WZ_^M1_Q-)G7_1)Y7_X=\?\ _,X?\2@Y
M5_T6^8_^&; __-Y_EX_\,H?M7_\ 1L'[1'_AE/B3_P#,S1_PRA^U?_T;!^T1
M_P"&4^)/_P S-?ZAWV:+_GUC_P"_7_UJ/LT7_/K'_P!^O_K4?\329U_T2>5_
M^'?'_P#S.'_$H.5?]%OF/_AFP/\ \WG^7C_PRA^U?_T;!^T1_P"&4^)/_P S
M-'_#*'[5_P#T;!^T1_X93XD__,S7^H=]FB_Y]8_^_7_UJ/LT7_/K'_WZ_P#K
M4?\ $TF=?]$GE?\ X=\?_P#,X?\ $H.5?]%OF/\ X9L#_P#-Y_EX_P##*'[5
M_P#T;!^T1_X93XD__,S1_P ,H?M7_P#1L'[1'_AE/B3_ /,S7^H=]FB_Y]8_
M^_7_ -:C[-%_SZQ_]^O_ *U'_$TF=?\ 1)Y7_P"'?'__ #.'_$H.5?\ 1;YC
M_P"&; __ #>?Y>8_9._:O96_XQ@_:(.,<?\ "E?B3D\]O^*9_P XK^W3_@@C
MX+\;^ /V"M-\-?$'P;XI\">(8/BM\2+AM!\8^'M7\,:TME/?6'V:[?2];L[&
M^%O/M?R9S (I=K;&.TU^S'V>('_CUC_[\Y'XX4__ *ZGMH1$6Q&J @\JH7(W
M9 VA5 Q],GJQ8\U\/X@^-&8>(614LEQ>0X++:=''T,?'$X;&XO$U)3H0KTU2
ME"O"%/DDJ[;E'WTXI:IL_1/#+P$P7AIQ)_K#A^(\;FLY8#&Y>L-7RW#8:CR8
MWZLYU?;4,35G&=-X6/+&2Y)<\N:S42W1117XJ?T(%%%% %"_LX[V(12QK(OS
M AE5AAQL=2KJZ,KH61U=65T9E((-?E'^TY_P1?\ V%OVEI]0UJ^^&#_"GQKJ
M*2F7QI\%YK7P5?->.3(M_>^'DT^]\%ZM?/+M^U7VI>&Y;^ZCSYU_N5&3]:Z*
M]+*LYSC(L4L;DN:8_*L2G%RJX+$UJ+GR[1J051T:E.V\)T))MM\R;9X>><,\
M/\38;ZGG^3Y?F^&U<:6.PM&MR2:MSTZG)#$4YK2SAB8Q32;A*UG_ !K_ !D_
MX-H?C'I,\]W\!_C]X'\8:>?,D@T;XG:%K7@K5;6,RMLMQK7AJ'QG8:O,L)&Z
M9]'\/QRR#B* /A?SG\=_\$3_ /@I)X#NIH?^&>KGQE9PD[=7\!^-? NOVET%
M*_-#8OX@M/$D1);A+C0H6;YBID"-M_T/RH;&<\4PQ(QR1R?3CI7[)E7TBO$C
M+U%8O%97G:C&,8SS/+H*O&,4HZ8C!5<+4NXKE<G%MK>[O)_A^<_1@\-LR<IX
M*.<9-.3<N3 X]5*"<G?W:&+I581BND>:2\UI;_,P\0?\$\_V\/#LBPW_ .QU
M^TG=.7V;]&^#WCGQ+"IX/^M\-Z'J\90YYE1F12#NZC'+6_[$/[:=W*8;;]CS
M]J:>19$C=(?V>_B_N1GW%1+O\&Q1Q*=K9DFD1$QSG/'^GH8%XZM_O*K8^F$X
MSW_"FK$#G<".F/E(]<GY53.>,YW#T YS]3_Q-+Q+RJ-3A3(INRYI/$YK*E)K
MKRRE.JK]O:M*6WN)1/D)?1%X=<FX\79Y&G?2$LORR4TNSG"I3I.SV?LHMK>\
MKR/\V3PU_P $N/\ @H;XM:,:/^R)\:(/-P57Q'X;_P"$.VYSCSY?%ESI"P<@
M_P"N5,C''(K[4^%7_!OE_P % ?'S6TWC73?AI\&M/8;IQXT\9VNO:W;J=P_<
M:9\/(?%FGW4IV@K%<:YIJ\J6E7)*_P!YBQ(,\ ].J[?7T S3O+7L,?2O(S#Z
M3''>*C..78'(<HA./+%T\+BL;.G=6E*'UW%1A&3=Y)^R]UM.TFM?;ROZ*7 6
M%<)9EFG$&;2C*_+[;!Y=3:YK\K^IT:E9IQT;]LGNTTK)?SA_LV?\&Y'[-/P\
MO++Q!^T%XY\7_'K6+7[/(/#-I:O\-_AV;@-'-+]ITW2;_5/%NHQ1S1(B>=XQ
MLK.XA#B\TF7S(O*_?CX>_"OX??"3PQI?@GX9^"O#G@'PAHL8BTKPWX/T;3]!
MT6S7:1(T6G:9;VUNLTS,TEQ<E#<W,[O//+),S.?1Z*_&N(N+^*.+*\,1Q%GN
M8YHZ;;HT<1B''"4&[J]'"4%0PT)6?+S2I59\NG/?WC]PX9X X.X/I^SX=R#+
M\N<E%5<1"BJN-KJ,;)5\=7]MB9J_O-1J44Y:RC+6\4:XW'!^;!Y&/7V'K4M%
M%?.'V+=WV_X&@4444""BBB@"*4$J ,_>YP"<C!ZXZ#OG\.]>-?%OX!?"#X\^
M&I_!WQB^&7@SXE^')S*W]G>,]!T_65MGF14:YTV>\MWN=*OD"(8+_39[2^MG
M198)XY41U]JHK2C6KX:O2Q.%KU<-B*+;IUZ%2M1K0NTWR5:->A.#NEK>6EU:
MTFGS8K!X3'4:F&QN'HXS"UK*MA<51HXG#5DDTHSHUZ56-K/7EY&VHOF32/YO
M_P!H7_@W#_9E\>7%YJWP%^(_CSX#ZE<EF30+^W;XH^!HI"?,5X+36[_2_&,+
M,O\ HSF3QW=VD<2P/#IXDMWBN/R(^*/_  ;O?MX^!TN[OP#=?"3XQV<:NUI!
MX>\6W7A;Q#<A"WR2Z3X[T?0=&M))%"LGE^*;M06V%CPU?W;$ C!INP>I_3_"
MOUC(O'+Q)R*-.E3SR.98>FE&-#.,)1Q]H+[,<1)T<5%VLE/V\YI*R>KO^+\0
M?1W\+\^E5JQR?$9)7K.4IU,BQE3!4Y2D[N4\+4ABL/*[U<;0@W9\L>5(_P W
M;Q-_P2>_X*/>$WE35OV1OBK=-"7#_P#"-1^'?&D1V%@QAE\):WJZ7!^4[%@W
MF4$,F05W>+ZC^PQ^VWI<DD=_^QY^U%;^7*(C*_[/WQ:DMF<AR$BNK7PC=6D[
M%49CY-PVT*WWAAJ_T[6B Y&XDGV/Z8IC0K@'&3GD>6/?_8;^7XU][0^E%Q=3
MIQC7X>R#$R5^><:V<493OTC36*JT8OM>$X[Z;6_.L1]$?A2523PG%6?4*;MR
MTJN$RRO*+UO><70E)=O=4M-6S_,FT7]@3]N;7)TM]/\ V.?VG2\JQ-'+=? S
MXDZ/:,DH5D?[?K?AO3;01L&!:0R"./(#OT-?0G@O_@C;_P %)O'=S;P67[,7
MBCP]%/*HDU#QOXC\">%+*SBRH:>[BU7Q1!K+H@8$QV>D74S_ #;(25('^BF(
MAW5B,="&Q^ VJ!^'3L,5.L*#D#!(Y_PZ5&*^E#QC6@XX/(.'\"VFG.K_ &AC
M9:]?95:]'#Z/57IMO[3;2:UPGT2N$J56,L;Q'Q!C(J2;C3I9;@E;M>,*]=_.
MJEK>*C9I_P 8_P $?^#:GX[>(KNSNOC_ /&WP'\/-'*"6ZTCX=Z=K'C[Q*Z[
MO^/62_UFW\(:%I4Y4X:X@/B2&&1,+#/'()$_?O\ 90_X)%_L6_LCS:9K_@SX
M<'QO\1].2WEA^)WQ2E@\8>*;2^MU&S4=#M9K.U\+>$[\.2WVOPMX<T>_D54C
MNKRY16#_ *@!0#D9IU?EG$WBKQ]Q91GA<TXAQ=/ 3<W++LMMEF!GS+E_>TL'
M*G5K6BW&U3%.$DW>ET?Z[PIX+^'7!]2.)RWA^AB\=!Q<,?G$Y9MB:4DU)O#K
M&*>&PUY)2O1PJJ)Z*KU*=M$L!,:J57&?N%5SD<+A50#T4=N@QG%RBBOSQ)))
M+9)):MO3NY-MONVVWU;/U3;;[M++9))1C!1BDDHQ44DE9!4<K;5S]<?7:W_Z
MA[XJ2HY!E1\I;GH!D]#S_P#7H]5?5.WHT_S2$[6=W9=;*_;IY[>C;Z'\E_\
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L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #U MH# 2(  A$! Q$!_\0
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MM$_\*"__ /F9K;HH Q/M'B/_ *!6B?\ A07_ /\ ,S1]H\1_] K1/_"@O_\
MYF:VZ* ,3[1XC_Z!6B?^%!?_ /S,T?:/$?\ T"M$_P#"@O\ _P"9FMNB@#$^
MT>(_^@5HG_A07_\ \S-'VCQ'_P! K1/_  H+_P#^9FMNB@#$^T>(_P#H%:)_
MX4%__P#,S1]H\1_] K1/_"@O_P#YF:VZ* ,3[1XC_P"@5HG_ (4%_P#_ #,T
M?:/$?_0*T3_PH+__ .9FMNB@#$^T>(_^@5HG_A07_P#\S-'VCQ'_ - K1/\
MPH+_ /\ F9K;HH Q/M'B/_H%:)_X4%__ /,S1]H\1_\ 0*T3_P *"_\ _F9K
M;HH Q/M'B/\ Z!6B?^%!?_\ S,T?:/$?_0*T3_PH+_\ ^9FMNB@#$^T>(_\
MH%:)_P"%!?\ _P S-'VCQ'_T"M$_\*"__P#F9K;HH Q/M'B/_H%:)_X4%_\
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MT3_PH+__ .9FMNB@#$^T>(_^@5HG_A07_P#\S-'VCQ'_ - K1/\ PH+_ /\
MF9K;HH Q/M'B/_H%:)_X4%__ /,S1]H\1_\ 0*T3_P *"_\ _F9K;HH Q/M'
MB/\ Z!6B?^%!?_\ S,T?:/$?_0*T3_PH+_\ ^9FMNB@#$^T>(_\ H%:)_P"%
M!?\ _P S-'VCQ'_T"M$_\*"__P#F9K;HH Q/M'B/_H%:)_X4%_\ _,S1]H\1
M_P#0*T3_ ,*"_P#_ )F:VZ* ,3[1XC_Z!6B?^%!?_P#S,T?:/$?_ $"M$_\
M"@O_ /YF:VZ* ,3[1XC_ .@5HG_A07__ ,S-'VCQ'_T"M$_\*"__ /F9K;HH
M Q/M'B/_ *!6B?\ A07_ /\ ,S1]H\1_] K1/_"@O_\ YF:VZ* ,3[1XC_Z!
M6B?^%!?_ /S,T?:/$?\ T"M$_P#"@O\ _P"9FMNB@#$^T>(_^@5HG_A07_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_P"(/PF^%?Q:L=.T
MOXJ_#3X?_$W3-(OCJ>DZ=\0?!OASQG8Z7J1A>W.H:=:>(]-U*WLKXV\DD!N[
M:.*X,+O$9-C,I[Y55%5$541%"HB@*JJH 554 !54        8IU%"T3BM(N;
MJ.*TBZCC&#J.*M%U'"$(.HXNHX0A!S<(1C$>K3>KC'DBWJXPYG+DBW=QAS-R
MY$U#F;ER\S<F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <3X*_YFW_L=M>_]M*[:N)\%
M?\S;_P!CMKW_ +:5VU '$_$7_D3=8_[A_P#Z=;&NVKB?B+_R)NL?]P__ -.M
MC7;4 ?%/[:OQ/\:^"M(^!?P]\!Z_=^"M7_:$_: \#?!J_P#B!8164FI^#?#6
MKV^KZ[XCO=!;4;>[L8/$VK:7H$_A_0+NYM;@6%WJC:C;Q_;+.V8>K>"_@=;_
M  O\3Z;XBT#XJ?%Z\\):;X:\1:?KW@SXD_$_QS\5M,U;5-2F\/W5OXQ/B'XD
M>)/$7B72-3T>WT*[M8].M=5;PM':ZSJ,EAH6E7DUS>774_&?X+> OCUX)E\"
M?$*POKC3$U;2/$6C:KHNJ7N@>)O"OBKP]>QZCX>\5^%/$.FRPZAH?B'1;Z-;
MBQO[63!4S6EW%=6%U=6L_E>J?LN7?B#P/XC\(^)OVC?VA?$6K:_H,OA.U^(M
M[?\ P?L?''A?PM??94US1_#4>@?!O1O!,%SXBMK;[%K/BO5?!>K^.I+.>:"S
M\4V0$!@F#G3HXA045B98FO5IUI^_"IAZV#PN&PV&G"]XQP5:.,K3I^Y"O'$2
MQ%*LL?"@J=24)U*"E*7U?ZO3HU:<8I3I5HXVK7KXJ$M/:3Q&&>'IPES*I0EA
M8X7E^I8G$U'\;_LK?M2:5\3?VKOB#X7'QWT;XE^$/VCOAC<_$WP%X,\/_$O3
MM>N/@Q>> O$>I>$KOP-!IGA[6)=2^'^K>)_AIJ7@SQSJ=C(-,U0>++/Q?=(R
M75E*T/$^#_A_XHE_9"^-?QS\-?'_ /:'\,?%OX1^.OVIM2\(^*/$?[17QF\=
M^$GTKX.?$GXAZ;X7\+^+O /Q)\;^+O &N^''\.^'K'0]1N+_ ,-OK<D:C5?[
M6_MA6O9/T%^*7[+=E\4+GX':L?C)\7O ?B?X RWMYX/\6> H/@Y9:SJ>J:EX
M;3PI?ZCXDM_$GP@\3Z!,E[HQO8+O0-#T30/"-TVHS-<>'95LM%32_*M._P""
M?_A5/!E_\+_$W[0'[1WCCX1Z[XI\3>,/%OPNUK5_@[X<\.>,]6\9>(]1\7>*
M+?Q+K7PR^"W@'X@76A:WXAU:^O[_ ,.67C2PT*:.;^S3IXTA$L%<X?N:E'#U
M98>O3P:RW!X^474E3CA<\^MX+,I4XQ<YU5EM6O2JT*L)U<1.%/"8JI/#XBK+
M#N%1>VI5J]&-6C4QU',<7@8RLI1J936PF/RR-67)#V=3%4\&Z=>E[&C34JN,
MHT:6)HQC5]I^'VKZW^TE^S=\(?%U_J^N?#R?XI> /A_XS\8)X1O=0T+7ELM?
M\/V.M:WX>\/>([&]M-;\)_VC<W(M%\1:1=1^(=/TEISHM]I>L2V>M:?\F^'_
M  ]^T=J'P4\=:%X,N?%OQ>\ :?\ M%^)V\%2:[\>_'?PV^-7C+]G/1+>V=-'
M\(_&JRM;GQ7?:P_Q%@U>Q\-:_P")/%GA^?Q9\.M/ABD\?+::Y8Z\_P!W_$KX
M60?$'X<77PSTGQEXO^%.DW-KI^F+JGPQ3P=9:Q::'8>4A\/V47C#PAXS\/V^
MC7MI"FFWUH-!9I=,,EC%+#;S3(_!6'P#\8:=H,>BVW[4O[0:7*ZC:33:XFG?
MLY6][)H%CIZZ?9^#;31;/]GNV\%:!H, ,UV;_P +>%-"\8SW,ZK=>*Y[.PTF
MTT_3$RA5Q.9U</26&HXBMS87#SY*M.,'CXXVA[2+YER8.%.CA524H*5"6-Y7
M55>E3>.'52EAL!3K3]O6H07MZJ<X3<HX2OAJD85+1G*>)>(E5E7=YJI0P,I1
MISIU:D/BNS\8?\+Y\3>#_AS\//'?QV^&GPQ\,_LE^)_C5I:W7Q)^(-I\57^*
M-UX_U3P/IMGX^\8ZOXMU;QOXM?X4:KX;\0P:UX4\0>*/$7A#7-4U"RM?$$&O
MZ):Z5;GN_$?Q^^)'C']A_P#9F\>V>KW/A/QY^T9JO[,W@;Q+XMT1+>QNO#:?
M%KQ#X:TGQMX@T-Y$%OI.H7>FW&KP>';F- ^F:GJFG36)6Y@MW'OOB[]C[X9^
M(M-\%Z=X?USQ]\,9?!?@SQ#\-4UCX>Z[IEOKOB7X<>,9[*\\8^#/%>J^*]!\
M67&HVWBC4]/MM:U'Q-:'3O'UKKAN]9T7Q=I6I:CJ-S=]?XC_ &=/!/B?X>ZG
M\)[_ %/Q';?#<Z/X#TKP3X3TIO#6EVWPHF^&[V=SX4UOX>ZM:>&H_$D6M:?J
MFEZ+K,=QXMUKQ;:P7^C62V5E::?+J-C?-RI\LU.G[6+QV#Q%2DVVL13PV;8G
M&8VTZLE.,<PRW$8;*J5"M./)2RRE3QDHPJRQ%9I24J3A-4Y1PN,HPJ<JO0G7
MROZE@[TXQ<)RP690><U:M.,E.KBJSPT95(0P\/SFL/&7CV__ &KKK]A*3XB?
M%6/X4Z5\4-<U\^+A\1O&D'Q/O/ EK\!/"?Q$L_A4?C(?$'_"T)E@\>>*9=9_
MMV/Q8?&$_AG3CX?EUC^Q8986^Z?V,/'OBKQ]\#X9O&FK7GB+Q!X,^(OQ>^%D
M_B;4EC&I^)K#X7?$[Q5X&T77=5:)$CFU>_T;1+!]7NE7-YJBWEVY\R=L4'_8
MT\!_V5!<6_CSXHV7Q4A^(MY\5W^/UOJ'@AOBU<^.=1\+_P#""ZCJ=PMUX"N?
MAG_9MYX%$?@\^%H/AO#X3M-'@MI-.T.SU:UM]3B]^^&'PU\)_"#P+H/P\\$V
MEQ:>'O#\-T+<WUY/J.I7]]J5_=:OK.LZOJ-RS3ZAK&N:S?W^L:M?2D-=:A>W
M,P2-76-2C+DP\J=67M:_U>A2J5N5_P"TXJ&+IU_KEY)2I^PP">4J,HPG7Y/K
M,H.-:<TJJ4ZL)TH>RI*O.I"ES?[O0^IU:%3#V3E&?UO'SAFEXRG&A;V'-&5.
M$'WU<Y>^)[2QNIK233?$<SPE5:6R\-:Y?6KED5P8;JUL9;>8 , S1R,%<,A(
M92!T=%9EG)?\)C8?] GQ;_X1_B/_ .5M'_"8V'_0)\6_^$?XC_\ E;76T4 <
ME_PF-A_T"?%O_A'^(_\ Y6T?\)C8?] GQ;_X1_B/_P"5M=;10!R7_"8V'_0)
M\6_^$?XC_P#E;1_PF-A_T"?%O_A'^(__ )6UUM% ')?\)C8?] GQ;_X1_B/_
M .5M'_"8V'_0)\6_^$?XC_\ E;76T4 <E_PF-A_T"?%O_A'^(_\ Y6T?\)C8
M?] GQ;_X1_B/_P"5M=;10!R7_"8V'_0)\6_^$?XC_P#E;1_PF-A_T"?%O_A'
M^(__ )6UUM% ')?\)C8?] GQ;_X1_B/_ .5M'_"8V'_0)\6_^$?XC_\ E;76
MT4 <E_PF-A_T"?%O_A'^(_\ Y6T?\)C8?] GQ;_X1_B/_P"5M=;10!R7_"8V
M'_0)\6_^$?XC_P#E;1_PF-A_T"?%O_A'^(__ )6UUM% ')?\)C8?] GQ;_X1
M_B/_ .5M'_"8V'_0)\6_^$?XC_\ E;76T4 <E_PF-A_T"?%O_A'^(_\ Y6T?
M\)C8?] GQ;_X1_B/_P"5M=;10!R7_"8V'_0)\6_^$?XC_P#E;1_PF-A_T"?%
MO_A'^(__ )6UUM% ')?\)C8?] GQ;_X1_B/_ .5M'_"8V'_0)\6_^$?XC_\
ME;76T4 <E_PF-A_T"?%O_A'^(_\ Y6T?\)C8?] GQ;_X1_B/_P"5M=;10!R7
M_"8V'_0)\6_^$?XC_P#E;1_PF-A_T"?%O_A'^(__ )6UUM% ')?\)C8?] GQ
M;_X1_B/_ .5M'_"8V'_0)\6_^$?XC_\ E;76T4 <E_PF-A_T"?%O_A'^(_\
MY6T?\)C8?] GQ;_X1_B/_P"5M=;10!R7_"8V'_0)\6_^$?XC_P#E;1_PF-A_
MT"?%O_A'^(__ )6UUM% ')?\)C8?] GQ;_X1_B/_ .5M'_"8V'_0)\6_^$?X
MC_\ E;76T4 <E_PF-A_T"?%O_A'^(_\ Y6T?\)C8?] GQ;_X1_B/_P"5M=;1
M0!R7_"8V'_0)\6_^$?XC_P#E;1_PF-A_T"?%O_A'^(__ )6UUM% ')?\)C8?
M] GQ;_X1_B/_ .5M'_"8V'_0)\6_^$?XC_\ E;76T4 <E_PF-A_T"?%O_A'^
M(_\ Y6T?\)C8?] GQ;_X1_B/_P"5M=;10!R7_"8V'_0)\6_^$?XC_P#E;1_P
MF-A_T"?%O_A'^(__ )6UUM% ')?\)C8?] GQ;_X1_B/_ .5M'_"8V'_0)\6_
M^$?XC_\ E;76T4 <E_PF-A_T"?%O_A'^(_\ Y6T?\)C8?] GQ;_X1_B/_P"5
MM=;10!R7_"8V'_0)\6_^$?XC_P#E;1_PF-A_T"?%O_A'^(__ )6UUM% ')?\
M)C8?] GQ;_X1_B/_ .5M'_"8V'_0)\6_^$?XC_\ E;76T4 <E_PF-A_T"?%O
M_A'^(_\ Y6T?\)C8?] GQ;_X1_B/_P"5M=;10!R7_"8V'_0)\6_^$?XC_P#E
M;1_PF-A_T"?%O_A'^(__ )6UUM% ')?\)C8?] GQ;_X1_B/_ .5M'_"8V'_0
M)\6_^$?XC_\ E;76T4 <E_PF-A_T"?%O_A'^(_\ Y6T?\)C8?] GQ;_X1_B/
M_P"5M=;10!R7_"8V'_0)\6_^$?XC_P#E;1_PF-A_T"?%O_A'^(__ )6UUM%
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MH_#[Q==:+=W$2^:+JZBUWXTRZQ96,4D]K<Z5:?#K0M:-V<S0V\T$EEX-;B3
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M?&I:9J%I*-T5U8W]GXLFM;NWD',<T$LD;CE6(K1_L[QI_P!#3HG_ (25Q_\
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M9M@<9EF8X.O#XJ.*P./PN#Q>'J+1\E;#P;BXRBYPE"I4Y+^SO&G_ $-.B?\
MA)7'_P T]']G>-/^AIT3_P )*X_^:>NMHJS@.2_L[QI_T-.B?^$E<?\ S3T?
MV=XT_P"AIT3_ ,)*X_\ FGKK:* .2_L[QI_T-.B?^$E<?_-/1_9WC3_H:=$_
M\)*X_P#FGKK:* .2_L[QI_T-.B?^$E<?_-/1_9WC3_H:=$_\)*X_^:>NMHH
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M_L[QI_T-.B?^$E<?_-/1_9WC3_H:=$_\)*X_^:>NMHH Y+^SO&G_ $-.B?\
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MEIEG=:CJ5Y:Z?I]E!+=7M]?7$-I9VEM"ADFN+JZN'C@MX(D4O+-*Z1QH"SL
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MT 6:*K?;;/\ Y^[;_O\ Q?\ Q='VVS_Y^[;_ +_Q?_%T 6:*K?;;/_G[MO\
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MOKB2[O?#VAWEU,0TUS=:387%Q*RJ$4R336[R2$(JJ"S$A5"C@ 5N45(SF_\
MA#?"'_0J^&__  1Z7_\ (M'_  AOA#_H5?#?_@CTO_Y%KI** .;_ .$-\(?]
M"KX;_P#!'I?_ ,BT?\(;X0_Z%7PW_P""/2__ )%KI** .;_X0WPA_P!"KX;_
M /!'I?\ \BT?\(;X0_Z%7PW_ ."/2_\ Y%KI** .;_X0WPA_T*OAO_P1Z7_\
MBT?\(;X0_P"A5\-_^"/2_P#Y%KI** .;_P"$-\(?]"KX;_\ !'I?_P BT?\
M"&^$/^A5\-_^"/2__D6NDHH YO\ X0WPA_T*OAO_ ,$>E_\ R+1_PAOA#_H5
M?#?_ ((]+_\ D6NDHH YO_A#?"'_ $*OAO\ \$>E_P#R+1_PAOA#_H5?#?\
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MT*OAO_P1Z7_\BT?\(;X0_P"A5\-_^"/2_P#Y%KI** .;_P"$-\(?]"KX;_\
M!'I?_P BT?\ "&^$/^A5\-_^"/2__D6NDHH YO\ X0WPA_T*OAO_ ,$>E_\
MR+1_PAOA#_H5?#?_ ((]+_\ D6NDHH YO_A#?"'_ $*OAO\ \$>E_P#R+1_P
MAOA#_H5?#?\ X(]+_P#D6NDHH YO_A#?"'_0J^&__!'I?_R+1_PAOA#_ *%7
MPW_X(]+_ /D6NDHH YO_ (0WPA_T*OAO_P $>E__ "+1_P (;X0_Z%7PW_X(
M]+_^1:Z2B@#X^_:#_8'_ &1_VGM+FL/BW\$O!VI:FT)BM/&/A_3X_"/CK32"
MC1-:>+?#8TW6)8H7C1UT_4;B^TF7#1W.GSPRRQO^)_C#_@C=^UM^R;K5U\0?
M^"=G[26H:S9Q3/?7/PF^)\FBV-YJ^V+RO*G^V:;=?";QS?RQQP11OXH\+^#4
MLXU:2UU 3Q0 _P!.-%>/CLBRW'S]M.B\/BT[PQN"G+"8N$OYO;4.3VC_ .OL
M:E]FVFT?NGAW]([Q9\-LNGP[EG$%+B/@?$)4\?X=<?9=A..> \?ATVY8>7#W
M$<,?2RZ+O)PJY'C,EK4*DE7H1IUXQJG\S?PZ_P""P/C'X!^)K+X4_P#!27]C
M:\^&'B16>U3XA>"_ <.G6VII:O%#+JC^#==,EAKFGQI/;SW_ (A\!>+M5T^:
M27.E^'DBFA@7]P/@)\=OV2_VGM 'B+X$^+OA;\0K5((KB^T[2[+3+;Q-HJS)
M&Z)X@\):G8V/B;09/WJ)MU;2;/=)N1"Y4X]M^(7PT^'GQ9\,WO@SXG^!_"GQ
M!\)Z@!]L\/>,=!TWQ#I$SK_JYOL6J6US!'<PGYH+F)4N(' DAEC<!A^'7QY_
MX(+?"F\U]/B9^QK\6/&W[+WQ*TJ634-"L(-8U[6_"5IJ)2Y4OHFO0:G:_$3P
M7<7*W3P3:A9^(/$5K:VBBVL?#\2/+OX?9\1Y9_"J4L_PD?\ EW7Y,'FD(KI"
MM%?5<3)+;VD:<Y-:N[N?HW]I?13\7KK.,JSSZ,7&N)WS3AJGC_$+P9QN+FOC
MQ?#>*K+CC@S#U:KYIO*,?G^ PD)2=/#>SI1@?NQ_PAOA#_H5?#?_ ((]+_\
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M+7244 <W_P (;X0_Z%7PW_X(]+_^1:/^$-\(?]"KX;_\$>E__(M=)10!S?\
MPAOA#_H5?#?_ ((]+_\ D6C_ (0WPA_T*OAO_P $>E__ "+7244 <W_PAOA#
M_H5?#?\ X(]+_P#D6C_A#?"'_0J^&_\ P1Z7_P#(M=)10!S?_"&^$/\ H5?#
M?_@CTO\ ^1:/^$-\(?\ 0J^&_P#P1Z7_ /(M=)10!S?_  AOA#_H5?#?_@CT
MO_Y%H_X0WPA_T*OAO_P1Z7_\BUTE% '-_P#"&^$/^A5\-_\ @CTO_P"1:/\
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M0_$G_@1H/_RWH_X2G6O^A#\2?^!&@_\ RWH [:BN)_X2G6O^A#\2?^!&@_\
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M 54QQLOZ?V'_  6I^ JQVL=W\)/BQ9(JQQRQ6"^#+N.VC7"[+59/$>G"98T
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M'_"4ZU_T(?B3_P "-!_^6] ';45Q/_"4ZU_T(?B3_P "-!_^6]'_  E.M?\
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M2=U"GQ1PFLHXPP.%4I<L:F89!CZE.FE*I*<N9P_HGHK^:$^,?^"^/[&L<?\
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M<E_8&O\ _0\ZW_X*O"O_ ,H:/[ U_P#Z'G6__!5X5_\ E#0!UM%<E_8&O_\
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M#]BMNL,T<?A?XG:?<R2),D21S;#>?T8?V!K_ /T/.M_^"KPK_P#*&C^P-?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_\ R+1_PAOA#_H5?#?_ ((]+_\ D6@ _P"$R\(?]#5X;_\ !YI?_P E4?\
M"9>$/^AJ\-_^#S2__DJC_A#?"'_0J^&__!'I?_R+1_PAOA#_ *%7PW_X(]+_
M /D6@ _X3+PA_P!#5X;_ /!YI?\ \E4?\)EX0_Z&KPW_ .#S2_\ Y*H_X0WP
MA_T*OAO_ ,$>E_\ R+1_PAOA#_H5?#?_ ((]+_\ D6@ _P"$R\(?]#5X;_\
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ME_\ R+0 ?\)EX0_Z&KPW_P"#S2__ )*H_P"$R\(?]#5X;_\ !YI?_P E4?\
M"&^$/^A5\-_^"/2__D6C_A#?"'_0J^&__!'I?_R+0 ?\)EX0_P"AJ\-_^#S2
M_P#Y*H_X3+PA_P!#5X;_ /!YI?\ \E4?\(;X0_Z%7PW_ ."/2_\ Y%H_X0WP
MA_T*OAO_ ,$>E_\ R+0 ?\)EX0_Z&KPW_P"#S2__ )*H_P"$R\(?]#5X;_\
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M&_\ P>:7_P#)5'_"9>$/^AJ\-_\ @\TO_P"2J/\ A#?"'_0J^&__  1Z7_\
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MH_B;PO?:;/97]ZUZE];S7&FW?] O_"9>$/\ H:O#?_@\TO\ ^2J/^$-\(?\
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M-_@?\-1X273+WP=XB^)QUY-6?Q/XO;Q)J4?C/3/"UGXK\3:5\/K"Q\+^#Y=
MTO5WAUB]\37=I97L#HR4IPG7CRPG*K5E3BE&="C5KXJIB\$HQE*]6IAY82&
MK.K5>'Q,L3&C7PF'P]&=3.M%JG5A3G*=2-*%-579*O7AAU##8M/EA&,:>,E4
MJ8RE"GAX5L-2I.I2Q-2I["'EW@7]I[XE?#K]GG]IGXD?&'5;3XO>-?A#\?\
MQ[\*?"-EX7\*VO@2U\6ZG#JWA/PG\/?"FDZ':7>OW.FQZUXI\16EFUSJ>L^(
M]2MDOYI[O5;N&VC6+U?]DCXG^,_'-Y\5?#?Q9\4^/F^,W@?5?"\/C_X8^+_!
M7PS\&^'?AZ/$&CS:KHEU\,O^%?7_ (PO?$'@;Q1;_:6L=;\5_%+QYK$MQH\\
M$Z>&;N*^TBN:T#]C/Q)=?"K]H#X7?$[XLZ#XHB^-?Q1U/XR:/XC\#_"Z]\ Z
MI\//'M_K>F>)[/4;.#7OB;\2K/7[3P]XC\/>&]1T*TN(],D1-/O;35[K6$U)
M7LO</@O\%-:^'WB3XC?$CQ_XQT?X@_%CXIMX3M?%7B?PYX*E^'OAU-!\":5<
MZ5X4T31O"MUXL\=7]G':C4-7U/4;N_\ %FJS:AJVKWDD"Z=IT=AI=F4-%)UW
M%S>5Y=1]U6C'$4\GRF-?V247%XB><T<R_M"I.-IX1X2MA,3S5,33KE=:*-)O
MW<TS"JW>ZJ4*F:XR5!R<N64<+3RJK1>"IP:E'%\U#$X7V-.A*A]"4445)044
M44 %%%% !1110 4444 %?G3^TC\8_BC!\4OBCX \ _%B'X+S?!?]FB+]H;29
M+_PWX,UO3/BKJIU_Q59WNB>)IO&&C:M<VGP^\/6WA.ST[Q"_@N\\,>+%OO&-
MK>0>)+.+38K6_P#T6KY5^/7[,&D?M%^)/#D?Q$;X<ZC\-M"LF670[OX0:+KG
MQ1N+NZN6.M:?I/Q>\1ZYJ\?@_P (>)=,2WTG7]+\)> M(\775LMT;3Q_8K<I
M#;95(5)RI*G55%OV\?;.//'#U*F&G3P^,=)\T<0\#B''%PP=6$Z&.G#ZI74(
M5HUJ.U*=."J2JT_;12HR]DFE*O"GBL/5KX2,FX^R^O8:%;!2Q,:E.KA(5Y8J
ME/VE'EGC:;\0?BC\<H?AQ#\.M?\ ^%5PZ[\%O!WQ'^(M[-HVDZQKWAF7XIK9
M7/AVR\.VWB#1]9TF3Q-H^GZ!XU2"'6K2?2+2\O=$UC7-+UVQM1X?U?YKT[XY
M?'A9_"'P5\3?%*_TF3QA^UO\3/@1X>_:>M/"/P\AU_Q#X+\"^ =0\9:<+/1K
MOPQJ'PJA^(6I^,K'4OA5<:A_P@[>'KF[\*^(I;+PS9ZV8(+?[2\2_"'QVOA3
MXEZ?\+_B5HGP_P#&OQ#\2V6I1>+]2\ 7OBBP\,>&M.T;1/#5CX7T;P[I?C[P
M5=0-:>'M#2VM=7M?$MB;+4]1U36K'3K6[N(%MO-M9_9M^)OC#X71_"GQUX\_
M9]\0>&WU32XY-&;]E*+4_"&D>%M(M#]DC\*>$/B'\9_B+96WCX:N[ZJ?&OC6
M[^(&AH8K6.'P!%>+?ZGJ714G3G7Q%2EA^3#U*L*BPE2K)7A7S"MC71IXF+G.
MBLNPM7#9?"I'DA5EAL1/$0Q6%JP4N6E&I##T*=6MSXBG1]D\53IQDXSH9>L&
M\1.A-0C7ECL6Z^.E&?-*%/ZJJ3PV,3=+A_@[\<OC#\1_ 'ACPG9Z]X=UCXLZ
M7\7/C?\ #_5_'+:7:6/ACQMX8^ >M:YHK>-Y--T^UOK73]-\8ZZW@'PUXH'A
MZW0Z9=^(]>?PR;"6ST\6_GOQ.^.'[07[-NJ?M!Z;>^.C\<].T'X._#?Q=X-U
M_P 6>$/"6@CP'\8?B?\ $:?X9Z!X&OX?AWH_AB'5O!>HW4]OXKTNPU>.\\8:
M;H^F75IJ?BO61>VNI'["^'O[/FC?".S-E\-;^PT:VT3X;6_@+P#:ZKX?_M2T
M\-ZA-K.N^)?%'BS68=/U?09/$E_XX\2ZEI&L>*;6SG\-"\FT"%8+RV>Z,UMY
M#;?LJ_$WQ7\/OB%\+_C;\:/!?C/PS\1-"U>/7-6^'WP6U;X<>.]4\=7\^ESZ
M5\0=?\4>)OC+\6K:^U#PF^D63>%]%T+0O"VC:2EEI6FVT*>'M'TW0X)DX^TB
MWS58JC!XQJ,:/UWF>5X?%4\/"+4<'6J4,OS''T/91H.EC<VPU&&(HTHXOV&D
M?A=E&E?$+ZM!\U?ZK%5,;B:-2NV^;%4:,\7@L#5A.=55<'@<8Y4Z[>!E4\R\
M0_%']H/P)9?M<_!^+XOV?B/XA?!WX&^#OCQX"^+GC'X<^%K^_P#[/U^Q\:GQ
M)X6UKPEX-3X>>%+IK35?A[J<7A'4EL?,TS3?$-@WB.'Q?=Z)<'5_;K_5?&GB
M?]F_X:_%W7/C]XT^$.G:-\$=,^)OQ,\0^ ?"GPCO-?\ $5XW@;1_$6HWL\WQ
M+^'_ (_\*Z1I-LJ:W>3Z5HGA#3[N[OKNP^S:SINGZ?-INHY4G[*_CS4?!_Q^
MFU_XQ>'M9^-OQ^\":/\ ##5_B6_PIO+7P=X9\#:#IFL:-IVEZ!\,HOB<VIF\
M^R^)_%6L7E]>?$J:&Z\6ZT-6-A'HMC;^&#V-]^SOX@\0_LS^$/V=?%7Q"TF\
MCTC3OA]X6\7^)M!\"WFB67C'P%X*UO19=3\,1>&=0\=>(Y]#F\9>$]%7PKK>
MIR>)=;AB;4=3U2UTH0S0:1;*<'4HUZ7M80KS630AB8TVX4ZG-GM#&8JC2]Q2
MIX+"8W**]?#S4(8S%Y="\<3/VM:HJ;4*]"I*%25"+S+VE!58NK.E]7R"K3I3
MK.#@JF,QN"SFEA,3&$GA*68.?)A:$HX>GV?[,\WQ,O/@/\,M3^,.N7WB'XBZ
MYX;A\0^(-0U33O#VE:K"OB&XN-:TC1]7L_">A^&O#BZQX?T._P!-T+5I](T+
M2[.\U'3KJ[BM(Q.<^Z4BJJ*J* JJ JJH 5548  '     ' '%+6M><:E:K4I
MP]E3G4DZ=._-[.G=1IP<E&'/*-.%-3J<D'5J^VK2A&5><8Q1A.%*G"I-3J*"
M]I.*E&,JDN:=1PC*=24*?M*E14J;G-TJ,:%+GG['GF4445D:!1110 4444 <
M3X*_YFW_ +';7O\ VTKMJXGP5_S-O_8[:]_[:5VU '$_$7_D3=8_[A__ *=;
M&NVKQ/\ :*^)UG\'/@WXR^(^H?"CXN_&^S\/+H*3_"_X#^"W^(7Q7\3KK7B?
M1?#Z_P#"*>$(]5T1]6.BOJJ^(=;9-4M6TWPYI.KZL#*;'R)?S _X>?>&?^D6
MG_!8?_Q$+6O_ )[=8U,11I24:D^637,ER59:-M7O3HU%NGHY)^5K-_:<.>'?
M&?%N"JYCP[DG]I8*CBIX*K7_ +9X4R[DQ-.E2K3I>QSWC3AS%RY:5>E+VM/!
M5<.^?EABIU(5:5+]JZ*_%3_AY]X9_P"D6G_!8?\ \1"UK_Y[='_#S[PS_P!(
MM/\ @L/_ .(A:U_\]NL_KN%_Y^_^4L1_\RGO_P#$$_%'_HE/_-H\.O\ Z:A^
MU=%?BI_P\^\,_P#2+3_@L/\ ^(A:U_\ /;H_X>?>&?\ I%I_P6'_ /$0M:_^
M>W1]=PO_ #]_\I8C_P"90_X@GXH_]$I_YM'AU_\ 34/VKHK\5/\ AY]X9_Z1
M:?\ !8?_ ,1"UK_Y[='_  \^\,_](M/^"P__ (B%K7_SVZ/KN%_Y^_\ E+$?
M_,H?\03\4?\ HE/_ #:/#K_Z:A^U=%?BI_P\^\,_](M/^"P__B(6M?\ SVZ/
M^'GWAG_I%I_P6'_\1"UK_P">W1]=PO\ S]_\I8C_ .90_P"()^*/_1*?^;1X
M=?\ TU#]JZ*_%3_AY]X9_P"D6G_!8?\ \1"UK_Y[='_#S[PS_P!(M/\ @L/_
M .(A:U_\]NCZ[A?^?O\ Y2Q'_P RA_Q!/Q1_Z)3_ ,VCPZ_^FH?M717XJ?\
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M_B"?BC_T2G_FT>'7_P!-0_:NBOQ4_P"'GWAG_I%I_P %A_\ Q$+6O_GMT?\
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MH\.O_IJ'[5T5^*G_  \^\,_](M/^"P__ (B%K7_SVZ/^'GWAG_I%I_P6'_\
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M=PO_ #]_\I8C_P"90_X@GXH_]$I_YM'AU_\ 34/VKHK\5/\ AY]X9_Z1:?\
M!8?_ ,1"UK_Y[='_  \^\,_](M/^"P__ (B%K7_SVZ/KN%_Y^_\ E+$?_,H?
M\03\4?\ HE/_ #:/#K_Z:A^U=%?BI_P\^\,_](M/^"P__B(6M?\ SVZ/^'GW
MAG_I%I_P6'_\1"UK_P">W1]=PO\ S]_\I8C_ .90_P"()^*/_1*?^;1X=?\
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M/_XB%K7_ ,]NC_AY]X9_Z1:?\%A__$0M:_\ GMT?7<+_ ,_?_*6(_P#F4/\
MB"?BC_T2G_FT>'7_ --0_77P5_S-O_8[:]_[:5VU?G]^R7^VGIW[0?C;6OAO
MIG[&'[=W[.,&F>%M4\<2>,OVH/V?IOA9X#U>>UUKP[HLGAW3/%$_C/Q)+J'C
M/4!KJZK8Z,]LAN=$T/7[T7,8TP0S?H#6].I"K'GIRYHW:ORSCJM])PIRTO\
MRV?1L^&S_AW.N%LQGE&?X+^S\QA0P^)EAOKF4X^U#%0G/#U/K&2YUG^ ?M(4
MYODCF4ZU/EM6H8>4H0F44459XH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
